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The positron emitting isotope 68Ga is gaining increasing interest in the radionuclide 
imaging community, due to its favourable decay properties and availability from a 
generator. Incorporation of 68Ga into biomolecules requires conjugation to a 
bifunctional chelator. The tris(hydroxypyridinone) ligand THPMe is a valuable chelator 
for 68Ga, being able to coordinate Ga(III) effectively in extremely mild conditions. 
These outstanding radiolabelling properties prompted further investigation of THPMe, 
as a prototype to develop improved tris(hydroxypyridinone) chelators, and as a tool 
to explore new strategies for cancer imaging with 68Ga. 
In the first part of this project, a new tris(hydroxypyridinone) chelator, THPH, was 
developed, where the N1-methyl group in the hydroxypyridinone ring was replaced by 
hydrogen. A new synthetic strategy was developed to achieve this. Quantitative 68Ga 
labelling of THPH was achieved in mild conditions and in vivo stability of the 
radiolabelled complex demonstrated. Spectrophotometric titration and competition 
experiments revealed preference for Ga(III) over Fe(III) for both THPMe and THPH, with 
the latter possessing higher Ga(III) selectivity. A library of THP derivatives is potentially 
available from an intermediate in THPH synthesis as a result of the new strategy. 
In a second part of this work, the ability of THPMe to interfere with 68Ga trafficking in 
biological systems was investigated. THPMe (24 nmol) was found able to chelate 68Ga in 
vivo, significantly accelerating its renal excretion in mice. We therefore explored use 
of THPMe as a blood clearance agent, to increase the tumour-to-blood activity ratio in 
the context of cancer imaging with 68Ga salts. Initial evaluation of THPMe in a melanoma 
model lead to inconclusive results, due to inconsistency of 68Ga-acetate 
biodistribution. However, successive evaluation in a colon cancer xenograft showed a 
three-fold increase in tumour-to-blood ratio for mice treated with THPMe compared to 
a control group, demonstrating THPMe potential as a blood clearance agent in this 
model. 
Finally, a new pretargeting strategy for 68Ga imaging with antibodies was investigated, 
based on the in vivo chelation of 68Ga(III) by a pretargeted THPMe-antibody conjugate. 
Two THPMe-antibody conjugates were prepared by attachment of THPMe derivatives to 
non-internalising antibodies and their favourable 68Ga labelling properties and affinity 
for their target antigen verified. However, in vitro/in vivo evaluation, showed no 
pretargeting ability for either of these compounds, likely due to a low availability of 
THPMe-antibody conjugates at the antigen site and to competitive binding of 68Ga by 
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1 Chemistry of gallium and its interaction with 
biological systems: a radiochemistry 
perspective. 
The chemistry of gallium, including the properties of its most important radioactive 
isotopes, is briefly reviewed in this chapter, and the interactions of this exogenous 
element with biological systems are described. It is beyond the scope of this review to 
comprehensively discuss gallium chemistry and biology. Owing to the nature of this 
research work, and to the paramount importance of gallium in nuclear medicine, a 
radiochemistry perspective is adopted throughout the chapter. 
 Radioactive isotopes of gallium 
Natural gallium exists in two stable isotopes: 69Ga and 71Ga, which represent 60.1 % 
and 39.9 % of natural gallium, respectively. Several radioactive isotopes can be 
obtained synthetically. The most common radioisotopes are summarised in the table 
below. 
Table 1.1. Main radioisotopes of gallium. 




66Ga 9.5 hours 
43 % EC 




67Ga 78 hours EC 
93, 184, 300 (γ) 
84, 92 (IC e-) 
7.4, 8.4, 9.5 
(Auger e-) 
67Zn [1,2] 
68Ga 68 min 
10 % EC 




72Ga 14.3 hours 100 % β 
640, 960, 1480 (β) 





67Ga is a cyclotron-produced isotope, obtained by proton irradiation (beam energy: 20 
MeV) of enriched zinc, according to the nuclear reaction 68Zn(p, 2n)67Ga [4]. 
Alternatively, it can also be produced by irradiation with deuteron (8 MeV) or α-
particles, according to the reactions 66Zn(d, n)67Ga and 64Zn(α, p)67Ga, respectively [4]. 
67Ga decays to stable 67Zn by electron capture (EC) with a half-life of 78.26 hours. The 
decay is accompanied by an emission of de-excitation gamma-rays in the energy range 
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91-393 keV that can be useful for imaging studies with gamma camera imaging or 
single-photon emission computed tomography (SPECT) [1]. However, the resolution 
and contrast achievable for 67Ga SPECT images is limited by the presence of different 
photopeak energies, combined with the down-scatter from high energy photons into 
lower energy windows [5]. Auger electrons of relatively high energy (7-9 keV) and long 
range (up to 2.4 μm in water) are also produced following electron capture, making 
gallium-67 worth investigating as a therapeutic radionuclide [2,6]. 
1.1.2 Gallium-68 
68Ga decays to stable 68Zn by positron emission (β+ yield: 89 %, Emax = 1.89 MeV, 
maximum positron range in water Rmax = 9.2 mm [7]) with a half-life of 68 min. 
Annihilation of the emitted positron by an electron, results in the generation of two 
511 keV photons with an angle of approximately 180° that are detected in Positron 
Emission Tomography (PET) scans. Owing to its short half-life, gallium-68 is commonly 
used to radiolabel receptor-targeting peptides through a bifunctional chelator (BFC). 
The most prominent clinical applications of this isotope are described in Chapter 2. 
68Ga generator 
Gallium-68 is most commonly obtained from germanium-68/gallium-68 generators, 
which allow steady, and relatively inexpensive, availability of 68Ga in centres without 
access to a cyclotron. In these long shelf-life, bench-top generators, the parent isotope 
68Ge4+ (t1/2 = 271 days) is immobilised on a lead shielded glass column containing an 
organic/inorganic matrix, and decays over time to the daughter radionuclide 68Ga by 
electron capture. Separation of the two radioisotopes exploits the different chemical 
properties of the two radiometals [1,8] and consists of selective elution of 68Ga3+ using 
an appropriate mobile phase.  
The first generators used Al2O3 as a solid phase and 
68Ga was selectively eluted with 
ethylenediaminetetraacetic acid (EDTA). The [68Ga(EDTA)] complex produced by these 
generators could be used directly as a radiotracer (see Chapter 2), but transchelation 
to other ligands was challenging due to the thermodynamic stability of the EDTA 
complex [9]. Modern generators use several different combinations of solid/mobile 
phase, but they all produce gallium in an unchelated ionic form [8]. In the 
pharmaceutical grade Eckert & Ziegler generator that has been used in this thesis, 
germanium-68 is adsorbed on a TiO2 bed contained in a borosilicate glass column. 
68Ga 
is eluted with ultrapure 0.1 M hydrochloric acid to yield Ga3+ as a chloride salt [10].68Ga 
elution yield for a new generator, ranges between 70-80 % and decreases with the 
increase of the generator age. Daily elution of the generator minimises the level of co-
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eluted 68Zn. Because gallium-68 is continuously produced in the generator, multiple 
elutions can be performed in a day, with half of the maximum achievable activity 
already accumulated at one-hour post-elution.  
Although extremely convenient, generator-production of gallium-68 still presents 
several drawbacks, which decrease the radiolabelling efficiency and specific activity 
achievable. Trace metal contamination from natural elements (aluminium, iron, 
titanium, lead etc.) as well as from 68Zn and 68Ge, is a major issue since those metals 
can compete with 68Ga for chelator binding [10]. The use of large mobile phase volume 
for 68Ga elution is another issue, resulting in low 68Ga3+ concentration, which also can 
hamper radiolabelling. Several processing procedures have been developed to address 
these issues, mainly based on anion/cation exchange chromatography to concentrate 
and purify the eluate [10,11]. On the other hand, these techniques add complexity to 
the radiolabelling procedure and increase the time required for radiolabelling. 
1.1.3 Other gallium isotopes 
The positron emitting isotope gallium-66 has a convenient half-life of 9.5 hours. 
Nonetheless, the low positron yield and the very high energy associated with its decay, 
which impairs spatial resolution, are not ideal for radionuclide imaging. Therefore, 
66Ga has received little attention by the radiochemistry community [12]. 
Gallium-72 was used in many of the early nuclear medicine experiments. However, its 
production, by neutron irradiation of 71Ga, resulted in the presence of large amount of 
stable gallium (carrier-added radioisotope) in the final product, thus limiting the 
specific activity achievable for this isotope [13]. With the advent of gallium-67 the use 




 Coordination chemistry of gallium 
Gallium (Ga) has an atomic number of 31 and electronic configuration of [Ar] 3d10 4s2 
4p1; it belongs to the 13th group and 4th period of the periodic table. Gallium is mainly 
found in its Ga(III) oxidation state, which dominates its aqueous chemistry. Ga(III) is 
an amphoteric ion and, similarly to Al(III), its aqua ion [Ga(H2O)6]
3+ is present in acidic 
conditions. Hydrolysis of this species occurs when raising the pH according to equations 
below.  
[𝐺𝑎(𝐻2𝑂)6]








+ + 𝐻2𝑂 ⇄ [𝐺𝑎(𝑂𝐻)3](𝑠) + 𝐻3𝑂




When the pH is raised above 3 poorly soluble hydroxide species dominate, while at 
higher pH these species re-dissolve as gallate [Ga(OH)4]
- [14], which represents 98 % of 
gallium in aqueous solution at pH > 7.4 [15]. At this pH, the maximum gallate 
concentration achievable without exceeding the solubility of [Ga(OH)3] was calculated 
to be 2.5 μM [16]. The predisposition of gallium towards extensive hydrolysis in aqueous 
solutions and in the mid pH range can hamper its ability to form complexes with 
multidentate ligands, whose complexation kinetics are often too slow to prevent 
formation of gallium hydroxide species. Therefore, for radiopharmaceutical 
applications, addition of stabilising ligands is usually required and complex formation 
occurs via ligand exchange reactions [17]. 
The ionic radius of Ga(III) as an hexacoordinated ion in solution is 62 pm (Shannon 
effective ionic radius) [18]. This value is larger than that found for Al in the same 
conditions (53.5 pm), but similar to that of Fe(III) in hexadentate high-spin complexes 
of this ion (64.5 pm). This resemblance to high-spin Fe(III) is not limited to oxidation 
state and ionic radius, but is also reflected in gallium coordination chemistry, which 
mainly consists of hexacoordinate complexes with ligands containing hard Lewis bases 
as donor atoms, such as oxygen and nitrogen.  
Over the past three decades many different chelators have been explored for Ga(III) 
coordination and have been described in detail in several reviews [19-22]. Far from 
being exhaustive, this section aims to review the most important Ga(III) chelators for 
radiopharmaceutical applications. Ideally, the perfect chelator for radiotracer 
development (i) possesses fast complexation kinetics, (ii) forms a single species upon 
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radiolabelling and (iii) does not dissociate in vivo. Quick complex formation under mild 
reaction conditions is important to match the short half-life of 68Ga and to allow 
radiolabelling of sensitive biomolecules. Stability and sufficient kinetic inertness of 
the resulting complex are required to avoid transchelation to serum proteins and to 
prevent dissociation in vivo. Finally, ligands leading to a single geometric isomer upon 
gallium complexation are preferred and more easily translatable into clinics. 
The molecular structures of Ga(III) complexes presented in the following paragraphs 
were obtained from published crystal structures using the software Mercury 3.9 [23]. 
Gallium atoms are labelled and coloured in green, the other elements are coloured as 
follows: carbon = grey, nitrogen = light-blue, oxygen = red, phosphorous = orange. 
Hydrogen atoms are omitted for clarity. Gallium hexacoordinated complexes of 
bidentate, tridentate and hexadentate ligands can all exhibit two enantiomers, 
depending on the absolute configuration of the ligand about the metal centre. For 
clarity reasons only one of the enantiomers is represented for each complex structure. 
The different complexes will be described using a [M(L)n] notation. For ease of 
nomenclature, protonation states and charges will not be included in the ligands and 
complexes formulas. 
When available, stability constant for the Ga(III) complexes are also reported. 
Generally, these are determined by spectrophotometric or potentiometric titration of 
the gallium complexes, assessing the competition between the investigated complex 
and [Ga(H2O)6]
3+ (titration with HCl), [Ga(OH)4]
- (titration with NaOH or KOH), or 
another complex for which stability constants are known (frequently [Ga(EDTA)]). 
However, these methods allow only a short equilibration period for the system which 
may not be sufficient to achieve thermodynamic equilibrium for the Ga(III) complex. 
Therefore, some authors prefer to use out-of-cell titration experiments (also referred 
to as “batch” titrations), where several separate samples, representing different 
points in the titration curve, are prepared and kept under an inert atmosphere until 
equilibrium is reached before measurement is performed [24]. Whenever, an out-of-




1.2.1 Polyaza macrocycles 
Macrocycles containing multiple nitrogen atoms are among the most widely used 
ligands for metal-based radiotracers and lanthanide-based contrast agents for 
Magnetic Resonance Imaging (MRI) [21]. They represent the most prominent class of 
chelators for gallium and have been used in several 68Ga-based radiotracers. Owing to 
the constrained geometries and pre-organised structures of macrocyclic ligands, their 
metal complexation increases the entropy of the system more than metal coordination 
by an acyclic chelator. This phenomenon, referred to as the “macrocycle effect” adds 
a thermodynamic drive to complex formation for these chelators. Macrocyclic ligands 
also present an increased kinetic inertness compared to acyclic chelators, which, on 
one hand, enhances the in vivo stability of their metal complexes, but on the other 
hand, it often results in slower complexation kinetics. The most common macrocyclic 
chelators for Ga(III) complexation are described below and their structure presented 
in Figure 1.1. 
 
Figure 1.1. Common macrocyclic chelators for Ga(III). 
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DOTA is a cyclen type (1,4,7,10 tetra-azacyclododecane) chelator where each nitrogen 
atom has a pendant acetic acid group attached. It can coordinate Ga(III) in a distorted 
octahedral fashion through the four nitrogen atoms and two oxygen atoms from trans 
carboxylate groups, with Ga(III) being puckered from the N4-plane by 0.84 Å, rather 
than sitting in the macrocycle cavity (Figure 1.2) [25]. Conveniently, one of the non-
bonding carboxylate groups can be used to conjugate the chelator to a biomolecule 
either directly via amide bond formation or through functionalisation with an 
alternative reactive motif. Functionalisation can also be achieved by replacing one of 
the acetic acid arms with a glutaric acid (DOTAGA, Figure 1.2) or by modifying the 
cyclen scaffold of the chelator (e.g. p-SCN-Bn-DOTA, Figure 1.2) [22]. 
 
Figure 1.2. Representation of the molecular structure of [Ga(DOTA)] as determined by 
X-ray crystallography (left) [25], and schematic structure of some DOTA-based 
bifunctional chelators.  
The thermodynamic affinity of this chelator for gallium (LogK = 21.3) is lower than for 
other M3+ ions (and notably lower than for Cu2+) [19,26], although a more recent out-
of-cell measurement revealed a higher stability constant for this complex (LogK = 
26.05) [27]. Owing to a slow complexation kinetics for [Ga(DOTA)], quantitative 68/67Ga 
radiolabelling of DOTA derivatives for clinical imaging use requires harsh conditions 
(heating 80-90 °C, pH < 5) and subsequent purification to remove unreacted 68Ga and 
physiologically incompatible buffer component. This is not ideal for simple daily 
production of 68Ga radiopharmaceuticals and precludes the possibility of 68Ga labelling 
of sensitive biomolecules [19,28]. On the other hand, DOTA still represents one of the 
most popular chelators for 68Ga, owing to the kinetic inertness of its Ga(III) complexes, 
but mainly to the widespread application of this chelator in radiochemistry and the 
subsequent availability of several bifunctional DOTA derivatives [19]. 
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The macrocycle chelator PCTA (Figure 1.1) displays a similar structure, but 
incorporates a pyridine ring in the macrocycle [29,30]. Its bifunctional version p-NO2-
Bn-PCTA exploits a p-NO2-benzyl attached to the scaffold to allow for 
functionalisation. Compared to DOTA this chelator possesses a lower stability constant 
for Ga(III) [29], but faster radiolabelling kinetics, with quantitative 68Ga radiolabelling 
quickly achieved at room temperature and low concentration in the 3-5 pH range [31]. 
Preliminary preclinical studies showed sufficient stability in vivo and favourable 
biodistribution [32]; however, this chelator has only received limited attention due to 
the concomitant development of novel ligands, more specific for Ga(III). 
1,4,7-Triazacyclononane (TACN) chelators display lower energies of activation to 
Ga(III) complexation than their cyclen analogues and possess an increased 
thermodynamic affinity for Ga(III) due to their smaller cavity size, which results in 
complexes with lower ring strain [33]. Accordingly, their use as 68Ga chelators have 
rapidly increased over the past decade. The gold standard TACN chelator for gallium 
is NOTA (Figure 1.1, N,N’,N″-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid), 
which coordinates the Ga(III) ion through its N3O3 motif in a distorted octahedral 
fashion (Figure 1.3), as confirmed by crystal structure [34], and possesses high 
thermodynamic affinity (LogK = 31.0) for the metal [33]. Gallium-68 radiolabelling of 
NOTA is fast at room temperature and acidic pH (< 5.5) [35]. Derivatisation at one of 
the acetic acid arms to include an additional carboxylic moiety results in the 
bifunctional chelators NODAGA and NODASA, where one of the acetic acid arms has 
been replaced by glutaric and succinic acid, respectively [36,37] (Figure 1.3). 
Derivatisation at the TACN scaffold to include a benzyl isothiocyanate arm led to p-
SCN-Bn-NOTA, one of the most widely employed bifunctional chelators for 68Ga [22] 
(Figure 1.3). 
 
Figure 1.3. Representation of the [Ga(NOTA)] complex as determined by X-ray 
crystallography (left) [34], and structures of bifunctional chelators based on NOTA. 
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Modification of the NOTA structure to include pendant phosphinic in place of carboxylic 
acids resulted in a new family of TACN ligands, collectively known as TRAP (Figure 
1.1). As a consequence of the lower pKa of phosphinic acids (<1) these ligands can 
coordinate gallium at lower pH compared to NOTA, thus expanding the range of useful 
pH for radiolabelling. The first TRAP chelator, TRAP-Pr (LogK = 35.65, LogK = 26.24 by 
out-of-cell titration), possesses additional distal carboxylate groups attached to the 
phosphinic moieties, which are supposed to help the coordination of the metal, in the 
low concentrations typical of radiochemistry, by acting as “pre-coordination” sites 
[38,39]. These three distal carboxylate groups also open the way to multimeric 
functionalisation of TRAP-Pr. A crystal structure of the gallium complex showed how 
the metal is coordinated in a trigonally distorted octahedral fashion (Figure 1.4) 
through the three nitrogen atoms of the ring and three oxygen atoms from the 
phosphinic acid moieties. 
 
Figure 1.4. Representation of the molecular structure of [Ga(TRAP-Pr)] as determined 
by X-ray crystallography [38]. 
The second-generation derivative NOPO, designed for single functionalisation of the 
chelator, replaces two of the carboxylic acids with alcohol groups [40]. Interestingly, 
TRAP ligands possess increased selectivity for Ga3+ over competitor metal ions (e.g. 
Fe3+, Zn2+, Cu2+) with respect to DOTA and NOTA type chelators. This has been proved 
by comparing the thermodynamic constants of these chelators for different metals [38] 
as well as by competition studies [41] and transchelation studies [42]. 
The macrobicyclic hexamine ligand, 1,8-diamino-3,6,10,13,16,19-
hexaazabicyclo[6.6.6]icosane, better known as sarcophagine (Figure 1.1), famously 
forms particularly stable metal complexes, often referred to as cage complexes, 
because of the encapsulation of the metal into the byciclic structure. The two primary 
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amine groups at each cage extremity provide convenient access to bifunctional 
derivatives of this chelator. Although the main application of this ligand is 
radiolabelling with 64Cu, sarcophagine complexes of 68Ga, with the metal coordinated 
by the six secondary amine groups of the cage system (Figure 1.5), were found to be 
remarkably stable in vivo and resistant to transchelation in competition experiments 
with apotransferrin. On the other hand, the radiolabelling conditions for this ligand 
are far from ideal, requiring 35 min at high temperature and in non-aqueous solution 
for quantitative radiolabelling [43]. 
 
Figure 1.5. Molecular representation of the [Ga(sarcophagine)] complex as determined 
by X-ray crystallography [43]. 
Another promising gallium-68 chelator is the 6-amino-6-methylperhydro-1,4- 
diazepinetetraacetic acid AAZTA and its derivatives, collectively known as DATA 
chelators (Figure 1.1). AAZTA was initially developed as a Gd(III) chelator for 
application as a MRI contrast agent [44], but was also found to coordinate Ga(III) 
resulting in a stable [Ga(AAZTA)OH]2- complex at physiological pH [45]. Quantitative 
radiolabelling of AAZTA is performed under mild conditions (10 min, room 
temperature), but results in multiple species likely related to different conformers of 
the ligand [46], as illustrated in Scheme 1.1. Furthermore, preliminary in vivo studies 
of 68Ga AAZTA peptide derivatives showed some instability in human plasma [47].  
 
Scheme 1.1. Proposed equilibrium between conformers for the AAZTA ligands [46]. 
Equilibrium is shifted to the right to minimise repulsion. 
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Hexadentate derivatives of these chelators, possessing only three carboxylate 
moieties, were synthesised as part of the DATA family. These ligands coordinate the 
Ga(III) ion in a distorted octahedral fashion through the N3O3 donor atoms, forming 
neutral complexes (the [Ga(DATAm)] complex is reported in Figure 1.6). 
 
Figure 1.6. Molecular structure of [Ga(DATAm)] as determined by X-ray crystallography 
[46]. 
Some of the DATA ligands were specifically designed to possess a pre-organised 
conformation for metal coordination, thus favouring the formation of a single and 
stable 68Ga-labelled species [46]. This was achieved through the introduction of a bulky 
substituent in position C6, shifting the equilibrium in Scheme 1.1 towards the left, 
with the C6-amino group taking up the axial position and resulting in a facing-capping 
array of nitrogen atoms [48]. The DATA chelators quantitatively bind gallium-68 at 
room temperature in the pH range 4-7 and competition studies showed how the 
radiolabelling tolerated the presence of Fe(III) (up to 4 equivalents compared to the 
ligand) while it was more susceptible to the presence of Cu(II) [49]. As expected the 
DATA chelators possessing a bulky substituent in C6 formed a single radiolabelled 
species, while a minority species was also identified for the DATAm chelator, which 
only possesses a methyl group in position 6 [46]. Surprisingly, DATAm was the chelator 
chosen for further functionalisation and preclinical studies [50], likely due to the 




1.2.2 Acyclic chelators based on ethylenediamine 
Ethylenediamine tetracetic acid (EDTA) is a common chelator for metals and forms 
stable complexes with Ga(III) [14,34], and it was the first chelator to be used in 68Ga 
preparations [22]. Different acyclic ligands based on the EDTA scaffold, or more 
broadly on ethylenediamine, were found to be more selective for Ga(III) and were 
developed as 68Ga chelators (Figure 1.7). 
 
Figure 1.7. Chelators based on the ethylendiamine structure. 
HBED (N,N’-bis(2-hydroxybenzyl)ethylenediamin-N,N’-diacetic acid) maintains an 
EDTA-based scaffold, but has two of the pendant acetic acids replaced by phenol 
groups. Since its first reported synthesis in 1967 [51], the outstanding thermodynamic 
stability of its iron(III) complex was noticed (LogK = 39.01 [52]) and, hardly surprisingly, 
further studies revealed a similarly high affinity for Ga(III) (LogK = 37.73 [53], 38.51 
[52]). However, it was only recently, with the constantly increasing popularity of 68Ga, 
that radiolabelling of HBED derivatives with this isotope was attempted. In particular, 
the bifunctional derivative HBED-CC (Figure 1.8), possessing two carboxyethyl groups 
para to the hydroxyl group of the phenols, was successfully used to radiolabel an 
antibody targeting the epidermal growth factor receptor (EGFR) under extremely mild 
conditions (5 min, pH 4.5, 40 °C) [54]. More recently, the use of HBED-CC as a chelator 
in the prostate membrane targeting radiotracer 68Ga-PSMA has hugely increased the 
utility of this chelator [55]. Despite the many advantages of this chelator, a major 
disadvantage is represented by the multiple radiolabelled species obtained upon 
radiolabelling with 68Ga due to the different coordination modes that this chelator can 
adopt [56] (Figure 1.8). Incomplete hexadentate coordination of Ga(III) by HBED has 
also been observed by our group [57] and suggests that similar species could possibly 




Figure 1.8. Structure of the bifunctional chelator HBED-CC and representation of the 
different modes in which HBED can coordinate Ga(III), giving rise to 3 geometric isomers.  
A different type of chelators is the “pa” family, which uses two picolinic acid moieties 
attached to an ethylenediamine scaffold, to fulfil the coordination sphere of Ga(III). 
H2dedpa, the progenitor of this family (Figure 1.7, [58]), coordinates Ga(III) through 
the N4O2 motif, forming a [Ga(dedpa)] complex of high thermodynamic stability (LogK 
= 28.1) and distorted octahedral structure, as confirmed by X-ray crystallography 
(Figure 1.9, [59]). Notably H2dedpa can be radiolabelled quantitatively with 
68Ga at 
ligand concentration as low as 0.1 μM without the need of pre-processing of the eluate 
or purification of the radiolabelling mixture [59], and the resulting complex 
[Ga(dedpa)] proved to be stable to transchelation to apotransferrin. Functionalisation 
of the H2dedpa structure is feasible via modification of the ethylenediamine scaffold. 
This was exploited to yield isothiocyanate derivatives (Figure 1.9) that were 
conjugated to RGD peptides for a first preclinical imaging study [60]. 
 
Figure 1.9. Representation of the [Ga(dedpa)] complex as determined by X-ray 
crystallography (left) [34], and structure of the bifunctional derivative p-SCN-H2dedpa 




Siderophores (Figure 1.10) are iron chelating compounds secreted by microorganisms 
to acquire Fe(III) from the environment. Unsurprisingly, in light of the high similarity 
between Fe(III) and Ga(III) ions, siderophores are excellent gallium chelators and have 
been explored for 67Ga and 68Ga radiolabelling.  
 
Figure 1.10. Structures of siderophores-based chelators. 
Deferoxamine (also known as desferrioxamine, DFO-B and DFO Figure 1.10) is a 
hydroxamate-based bacterial siderophore used clinically for the treatment of iron 
overload [61]. This hexadentate chelator binds M(III) metals through the three 
hydroxamate groups, leaving a free amino group available for conjugation. Its Ga(III) 
complex proved to have high thermodynamic stability (LogK = 28.17 [62], LogK = 27.56 
[63]) and NMR studies showed how only two of the eight possible geometric isomers of 
the [Ga(DFO)] complex are present in the pH range 2-9 (the likely structures of the 
two isomers are depicted in Figure 1.11) [63]. Conjugation of DFO-B to several 
proteins and peptides, subsequent radiolabelling with 67Ga and in serum and in vivo 
stability was evaluated in several papers with promising results [64-66]. However, 
further evaluation of the chelator showed that dilution to low concentrations results 
in Ga(III) dissociation from the complex [67] and more recent studies with antibody 
conjugates of DFO-B revealed how the 67Ga complex is unstable when left in 
physiological conditions (cell culture medium or phosphate buffered saline with human 
serum albumin) for more than 24 hours [68]. While these results clearly undermine the 
feasibility of gallium-67 in vivo studies with DFO-B, this may be not an issue for 68Ga 




Figure 1.11. structure of the two geometric isomers which are believed to be present in 
[Ga(DFO)] solution. Numbers define the different chelate rings starting from the N-
terminus. N and C refers to the relative position of carbonyl and nitrogen in ring 1 (N = 
nitrogen in equatorial position, C= carbonyl in equatorial position), cis and trans refer to 
the relative orientation of ring 2 and 3 with respect to ring 1 (cis: same orientation, trans: 
opposite orientation). 
Desferri-triacetylfusarinine C (TAFC, Figure 1.10) is a different hydroxamate 
siderophore produced by the fungus Aspergillus fumigatus. TAFC radiolabelling with 
68Ga was first investigated as a way to detect fungal infections [69], but the facility of 
gallium-68 labelling prompted the further exploration of this siderophore as a 
bifunctional chelator for 68Ga. As a proof of principle, its deacetylated version 
Fusarinine C (FSC) was conjugated to three RGD peptides via their lysine sidechains 
and radiolabelled with 68Ga, achieving excellent radiolabelling over a wide (3-8) pH 
range [70,71]. Preclinical evaluation of the bioconjugate demonstrated specific 




1.2.4 3-Hydroxy-4-pyridinone based chelators 
Hydroxypyridinone ligands (HP) are based on a six-membered aromatic N-heterocyclic 
ring, containing a carbonyl and a hydroxyl function on adjacent atoms. Three classes 
of hydroxypyridinone, namely 3,4-hydroxypyridinone, 1,2-hydroxypyridinone and 3,2-
hydroxypyridinone, exist depending on the relative position of the carbonyl and 
hydroxyl function with respect to the pyridinone nitrogen (Figure 1.12). 
 
Figure 1.12. General structures of hydroxypyridinone ligands. 
Upon deprotonation of the hydroxyl function, hydroxypyridinones can bind metals in a 
bidentate O2 fashion, yielding stable 5-membered chelate rings [72]. Owing to their 
high affinity for hard Lewis acid metal ions, hydroxypyridinones have been widely 
investigated as Fe(III) chelators. In particular, 3,4-hydroxypyridinones possess the 
highest stability constants for iron coordination compared to 1,2-hydroxypyridinones 
and 3,2-hydroxypyridinones due to an increased electron delocalisation over the 
pyridinone ring that results in more electron-rich oxygen donors [72]. The 1-methyl-3-
hydroxy-4-pyridinone chelator deferiprone (also known as CP20 and marketed as 
ferriprox, Figure 1.13) is an in vivo, orally available iron chelator employed in clinics 
to treat iron overload diseases, alongside deferoxamine and the tridentate chelator 
Deferasirox [73].  
Similar to other 3,4-hydroxypyridinones, deferiprone possesses two pKa values of 3.56 
and 9.64 for the carbonyl and hydroxyl function, respectively [73]. It complexes Fe(III) 
in a 3:1 ratio to yield the neutral complex [Fe(deferiprone)3], which crystallises as a 
slightly distorted octahedron with the 3-hydroxy ligands in a facial (fac) arrangement 
[74] and displays high cumulative stability constant (Logβ3 = 37.2, [73]). The same 
crystalline arrangement and very similar thermodynamic affinity constant was found 
for the Ga(III) complex reported in Figure 1.13 (Logβ3 = 38,42 [75], Logβ3 = 38,42 [76]). 
Preliminary studies using 67Ga demonstrated facile radiolabelling of deferiprone at pH 
7.4 and a ligand concentration of 80 mM. The radiolabelled complex 




Figure 1.13. Structure of the 3,4-hydroxypyridinone chelator deferiprone (left), and 
molecular representation of its gallium complex as determined by X-ray crystallography 
(right) [77]. 
Incorporation of three 3,4-HP units onto a tripodal backbone provides an 
hexacoordinate environment ideal for M(III) coordination. The resulting complexes 
present higher kinetic stability compared to their bidentate counterparts and, 
importantly, first order dependence on the concentration of the ligand. Given the same 
stability constant, a first order dependence results in less unchelated metal present in 
solution (at a defined pH and total concentration of ligand and metal), in agreement 
with the equations below. 








pM values are conventionally calculated at pH 7.4, [L]tot =10
-5 M and [M]tot= 10
-6 M. and 
are particularly useful to compare ligands intended for in vivo use [78]. 
Different examples of tris(hydroxypyridinone) chelators are reported in Figure 1.14. 
Notably, the geometry of the tripodal structure is of fundamental importance in 
determining the metal affinity of the chelator and its ability to form 1:1 metal:ligand 
complexes. In particular, attachment of the 3,4-HP unit to the tripodal framework at 
the ortho and meta positions with respect to the coordinating oxygen atoms is crucial 
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to minimise the loss of entropy associated with metal coordination, owing to a shorter 
linking chain [79,80], thus favouring the formation of 1:1 complexes. 
 
Figure 1.14. Examples of tris(hydroxypyridinone) chelators [81-86]. 
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Santos and coworkers developed several hydroxypyridinone-based hexadentate ligands 
to be used as M(III) scavenging agents (Figure 1.14, top panel). These chelators 
comprise three 3,4-HP units connected via the pyridinone nitrogen to a tripodal 
framework, either acyclic like the nitrilopropionic acid NTP, or based on the cis-cis-
1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid KEMP. Fe(III), Al(III) and Ga(III) 
complexes of these chelators were found to be remarkably stable [81,82,87]. 
Radiolabelling with 67Ga was achieved in mild conditions and the resulting compounds 
displayed favourable in vivo biodistribution and pharmacokinetics [81,82]. 
A similar chelator (CP262) was developed by Hider’s group (Figure 1.14, [86]), 
possessing three 3,4-HP units attached to a tris(2-aminoethyl)amine framework in 
position C2 and thus less likely to form labile dinuclear species upon metal 
complexation [79]. This chelator differs from other tris(hydroxypyridinone) ligands 
since it utilises 3,4-HP units where the N1-methyl group has been substituted with 
hydrogen. This chelator possesses very high thermodynamic affinity for iron (LogK = 
30.7) and its pFe value is the highest reported for hexadentate HP ligand (pFe = 30.5) 
[86]. In subsequent studies, structurally related chelators with different N-R groups 
were also synthesised and tested as iron chelators [83], however, no studies with Ga(III) 
were performed. Despite their good M(III) binding capability, the structure of these 
tris(hydroxypyridinone) ligands does not allow straightforward modification to obtain 
bifunctional derivatives, thus preventing simple conjugation to biomolecules and 
accordingly, any sort of targeted imaging. 
On the contrary, the tris(hydroxypyridinone) chelator THPMe (previously known as 
CP256 [84], Figure 1.14) and its free amine derivative THPMe-NH2, also synthesised by 
Hider and co-workers [85], allows modification to obtain bifunctional derivatives and, 
consequently, its use as gallium chelator has been widely explored by our group. THPMe 
possesses three 1,6-methyl-3-hydroxy-4-pyridinone units connected in the C2 position 
to a tripodal scaffold via amide linkages. THPMe coordinates Fe(III) in a 1:1 mode with 
high thermodynamic affinity (LogK = 32.52) [85]. Investigation of this chelator for 68Ga 
labelling by our group revealed fast radiolabelling in extremely mild conditions (< 5 
min, room temperature, pH 6.5), achieving quantitative radiochemical yield at lower 
concentration compared to DOTA, NOTA and HBED [84]. [67Ga(THPMe)] proved to be 
stable in serum and in the presence of an excess of apotransferrin, and preliminary in 
vivo experiment showed quick blood clearance of the [68Ga(THPMe)] complex (blood 
half-life <3 min) [84]. Bifunctional derivatives of this chelator can be obtained via the 
free amine derivative THPMe-NH2 [85] and include a maleimide derivative [84], two 
isothiocyanate derivatives [88] and a glutaric acid derivative [89] (Figure 1.15), which 
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have been conveniently conjugated to several peptides and tested in vivo with 
promising results. 
 
Figure 1.15. Structures of bifunctional THPMe derivatives 
A different tris(hydroxypyridinone) chelator amenable for further functionalisation, 
CP254 (Figure 1.14), was synthesised by Hider and co-workers [90]. Similar to CP262, 
this chelator also contains hydroxypyridinone units where the N1-methyl moiety is 
replaced by N1-H and attachment to the tripodal structure is provided in position C5. 
However, unlike CP262 the tripodal scaffold provides an easy functionalisation route 
via the α,β-unsaturated carbonyl in the apical position. Intriguingly, this compound 
was developed for incorporation into polymers and, despite its high affinity for Fe(III) 




1.2.5 Weak chelators for Ga(III) 
Citrate and acetate (Figure 1.16) are weak chelators for Ga(III), not suitable in the 
context of 68Ga radiopharmaceuticals design. They do, however, deserve a mention 
owing to their role as stabilising ligands in radiolabelling reactions, preventing the 
formation of insoluble hydroxide species [91]. Furthermore, 67Ga-citrate has been 
extensively investigated clinically in the past, as will be discussed in the following 
section.  
 
Figure 1.16. Structure of acetic and citric acid. 
Citrate can coordinate Ga(III) yielding 2:1 or polymeric 1:1 = ligand: metal species, 
depending on citrate concentration and pH [92,93]. Martell measured a stability 
constant LogK = 10.0 for the formation of the polymeric (Ga3(OH)4citrate3)
4-
n species 
[92]. However, these complexes are easily hydrolysed to [Ga(OH)4]
- as the pH increases 
and gallate is the predominant species at pH > 6.3 in diluted aqueous solution of 
gallium citrate ([Ga] = 1 nM, [citrate] = 40 µM) [94]. Acetate can also coordinate Ga(III) 
in aqueous solution forming both 1:1 and 1:2 = ligand to metal species. However, the 
stability of these complexes is very low with LogK = -2.1 for [Ga(acetate)]2+ and 





 Gallium in biological systems 
In the 1970s and 1980s, interaction of gallium with biological systems was of great 
interest due to the use of gallium-67 salts and complexes in nuclear medicine [96,97]. 
More recently the topic has gained renewed attention with the development of 
gallium-based anticancer drugs [98]. 
Gallium is not an endogenous metal; however, due to the striking similarity between 
the Ga(III) and Fe(III) ions, its interactions with proteins and biological systems 
resemble those of iron and its biological effects are at least partly due to disruption in 
iron-related biochemical pathways. Nevertheless, despite the similarity, some 
remarkable differences between gallium and iron exist and are responsible for the 
dissimilarities found in the biological pathways of these ions. The most remarkable 
difference is that Fe(III) can be reduced to Fe(II) and vice versa, while Ga(III) does not 
display any redox chemistry in solution under physiological conditions. Furthermore, 
the existence at physiological pH of a soluble gallate species, although in equilibrium 
with insoluble Ga(OH)3, opens new possibilities for gallium behaviour in biological 
systems. In contrast, Fe(III) can only exist bound to proteins or chelators because of 
the comparative insolubility of iron hydroxide species. 
1.3.1 Interaction with transferrin and other biomolecules 
To understand in vivo biodistribution of gallium upon intravenous (IV) administration, 
and the mechanisms involved in gallium accumulation in specific tissues, it is crucial 
to analyse the interactions of this metal with proteins and other relevant biomolecules. 
The most prominent among these interactions involve the serum protein transferrin. 
Transferrin (Tf) is a monomeric glycoprotein of 80 kDa responsible for iron transport in 
vertebrates. It displays two metal binding sites located in the N-terminus and C-
terminus domains that can sequentially bind iron upon synergistic coordination of a 
carboxy anion, which is typically carbonate in vivo (serum bicarbonate concentration 
≈ 27-35 mM [16,99]). Stability constants for Tf-Fe(III) binding at serum bicarbonate 
concentration were measured to be LogK1 = 22.8 and LogK2 = 21.5 [16]. In normal 
physiological conditions, only one third of transferrin binding sites are occupied by 
iron. At this level of iron saturation, diferric transferrin (holotransferrin) constitutes 
30 % of the total plasma iron pool, while monoferric transferrins with iron bound at 
the N-terminus or at the C-terminus site represent the 41 % and 29 % of the plasma 
iron pool, respectively [100]. Transferrin delivers its iron load into cells through 
interaction with the transmembrane glycoproteins, transferrin receptors (TfR) 1 and 
2. This interaction is regulated by TfR binding to the hereditary hemochromatosis 
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protein HFE, which competes with holotransferrin for TfR binding [101]. Transferrin 
receptor 1 is expressed on highly proliferating tissue, including neoplastic cells, and is 
therefore particularly interesting for our purposes. TfR1 exhibits greater affinity for 
holotransferrin compared to monoferric transferrin and apotransferrin [102], with a 
dissociation constant Kd = 2.3 nM [103]. Holotransferrin binds to transferrin receptors 
on cell surfaces inducing endocytosis and is internalised in membrane bound 
endosomes. Lowering of the pH in these vesicles results in release of Fe(III), which is 
reduced to Fe(II) by a ferrireductase and transported out of the endosome in the 
cytoplasm via a divalent metal transporter [104]. Membrane bound apotransferrin is 
recycled to the surface of the cells, where it is finally released due to its low affinity 
for the receptor at physiological pH. The greater importance of holotransferrin in iron 
delivery, compared to any of the monoferric forms, is such that most of the literature 
around this protein deliberately considers only the diferric version or uses the term 
FeTf to include any Fe-Transferrin species [100]. In this work, the term FeTf and GaTf 
will be used to indicate any transferrin species containing iron and gallium, 
irrespective of metal ion occupancy of Tf’s binding sites. Intriguingly, the existence of 
mixed FeGaTf species is also possible, but will not be considered here. 
Owing to the previously discussed similarity between Fe(III) and Ga(III), gallium 
represents an excellent candidate to bind unoccupied transferrin metal binding sites. 
The Ga(III) stability constants for binding to transferrin (LogK1 = 20.3, LogK2 = 19.3 at 
serum bicarbonate concentration, LogK1 = 19.53, LogK2 = 18.58 at 5 mM bicarbonate 
concentration) are remarkably high, although lower than the stability constants 
reported for Fe(III) [16]. Furthermore, modelling studies by Byrne [94] suggest that at 
a gallium concentration lower than 50 μM (the metal ion concentration needed to 
occupy all of the vacant metal binding sites in transferrin) and bicarbonate level above 
2 mM, more than 99 % of gallium in plasma is bound to transferrin at equilibrium. At 
concentrations higher than this, the gallate form becomes progressively more 
important. 
Early in vitro studies using 67Ga support these calculations, highlighting that upon 
serum/blood incubation of gallium citrate, the majority of activity is associated with 
serum proteins [105], notably transferrin [106,107]. As for iron, transferrin binding to 
gallium is strongly dependent on bicarbonate levels. The lower threshold of 
bicarbonate concentration for quantitative binding of gallium to transferrin was 
experimentally determined to be 13 mM [108], higher than the 2 mM concentration 
threshold predicted in the above-mentioned modelling studies by Byrne [94]. The Ga-
Tf binding is less stable than the original Fe-Tf binding and easily disrupted, either by 
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a slightly acidic environment (less than 50 % of gallium bound at pH 6.1) or increased 
citrate concentration (less than 80 % of gallium bound at a citrate concentration of 10 
mM) [109]. Although these conditions are unlikely to be significant under normal 
physiological conditions, they could potentially be reached by injection of gallium 
salts, and weak chelates such as 67Ga-citrate, especially in animal studies. Notably, 
neither low pH (down to pH 4.7), nor high citrate concentration (up to 0.1 M) had an 
effect on the Fe-Tf binding [109]. More recent studies have investigated the kinetics 
of GaTf formation and the mechanisms for GaTf interaction with transferrin receptors. 
While the overall affinity of GaTf towards TfR was substantially decreased (Kd = 1.1 
μM) compared to that of FeTf (Kd = 2.3 nM), GaTf exhibited sufficient affinity for the 
helical domain of the receptor [103,110], allowing the same endocytosis-mediated 
pathway to internalise Ga(III) in TfR1 expressing cells.  
In addition to transferrin, gallium was found to avidly bind the homologous iron binding 
protein lactoferrin, which is found in many epithelial secretions (milk, seminal fluid, 
tears) as apolactoferrin and possesses antimicrobial properties [111]. Gallium has 
higher thermodynamic affinity for lactoferrin than for transferrin. Stability constants 
for gallium binding to lactoferrin at 5 mM bicarbonate concentration were found to be 
LogK1 = 21.43, LogK2 = 20.57, approximately 90-fold higher than those for transferrin 
in the same conditions [112]. 
Finally, some evidence suggests that gallium may also bind to the iron storage protein 
ferritin upon dissociation from transferrin and lactoferrin, mediated by phosphate-
containing compounds such as ATP [113-115]. However, rather than playing a role in 
uptake mechanisms of gallium, binding to ferritin appears only related to intracellular 
storage of this metal [116]. Furthermore, there is no evidence that gallium is actually 
incorporated into the ferritin core and not simply loosely bound to an external site 
[104]. If gallium incorporation in ferritin occurs, the mechanisms are likely to be 
different from that shown for iron, which is more easily incorporated as Fe(II) and then 
oxidised by ferroxidase centres in the protein [117].  
Importantly, Ga(III) cannot be incorporated in Fe(II)-bearing proteins such as 
haemoglobin or cytochromes and is therefore not involved in oxygen transport 
mechanisms. 
Ga(III) affinity for microbially-produced siderophores is well established, as discussed 
in the previous section, and could potentially play an important role in 
imaging/treatment of infections with radioactive isotopes. Importantly, Ga(III) is able 
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to displace Fe from siderophores in the presence of a reducing environment, with 
concomitant production of Fe(II) species [118].  
1.3.2 Pharmacokinetics and biodistribution 
The mechanisms by which gallium is distributed to tissues, and the pharmacokinetics 
of these processes, are important in order to evaluate the use of gallium/radioactive 
gallium salts for medical applications. Although the availability of gallium 
radioisotopes has enabled studies of Ga(III) biodistribution in vivo, some of the 
mechanisms underlying localisation in different tissues are not completely understood. 
Although gallium and iron are both bound to transferrin in plasma, they present 
important differences in their pharmacokinetics and biodistribution. By measuring 
plasma concentration of the radioactive species after intravenous injections in 
humans, Logan found that 59Fe-citrate was cleared from plasma 50 times more quickly 
than 67Ga-citrate. 67Ga-transferrin showed the same overall elimination rate constant 
as 67Ga-citrate [119]. The biodistributions of 67Ga- and 59Fe-citrate were also found to 
be markedly different in preclinical studies. 59Fe-citrate biodistribution changed over 
time, reflecting the progressive incorporation of radioactive iron into haemoglobin 
with 59Fe accumulation in spleen, bone marrow and blood and no preferential tumour 
uptake in tumour bearing mice [120]. On the contrary, 67Ga-citrate distribution in 
tissues was found to be largely established one hour after injection, although the 
amount of tissue-associated activity kept increasing over time as a result of its slow 
blood clearance. High concentration of 67Ga was found in bone (but not in the marrow), 
as well as in the liver, spleen, kidneys, intestine and, where applicable, tumours.  
Similar preclinical biodistribution data for 67Ga-citrate were reported by several groups 
in the past decades [121,122]. Another study in mice showed that the concentration 
of citrate in the injected 67Ga did not influence 67Ga biodistribution, which did not 
differ from that of gallium chloride [123]. The same study claimed that distribution 
profile was the same also for 67Ga-labelled serum/transferrin. However, this finding 
relies on the assumption that administered 67Ga citrate binds to transferrin in serum: 
verification of transferrin radiolabelling was not undertaken and the radiolabelled 
serum was simply obtained by exsanguination of a mouse previously injected with 67Ga-
citrate. More recently, data on the biodistribution of 68Ga-citrate, 68Ga-acetate [124] 
and 68Ga-chloride upon either neutralisation with NaOH [125,126] or buffered with PBS 
[127] also showed a similar biodistribution for Ga(III).  
In a recent study, 68Ga obtained from a generator used without pre-elution (> 24 hours 
from previous elution) was mixed with NaOH, with the aim of generating gallium 
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colloids. The 68Ga-containing solution was then administered to mice via a retroorbital 
injection, followed by PET scanning and ex vivo biodistribution. In a side-by-side 
comparison, the biodistribution of 68Ga-colloids, significantly differed from that of 
68Ga-citrate and 68Ga-acetate, with 68Ga-colloids predominantly found in the liver 
[124]. In light of the speciation of Ga(III), where an alkaline solution of Ga(III) should 
contain soluble [Ga(OH)4]
-, any formation of colloids containing 68Ga is likely due to the 
presence of other metal contaminants, whose concentration is higher in the eluate of 
generators used without pre-elution. Production of colloids containing 68Ga by addition 
of an excess of FeCl3 has previously been reported in the literature [128]. 
A first attempt to measure gallium biodistribution in humans was performed in the 
1970s when a post-mortem study was performed on 26 cancer patients, who died at 
different times during the month following a 67Ga-citrate scan. The biodistribution 
compared organ distribution of 67Ga between patients, and attempted to correlate 
differences in 67Ga biodistribution with patients’ age, sex, nutrition and time of death 
after 67Ga scan [129]. While the data were generally similar to preclinical findings, 
they also emphasised the high variability in tissue biodistribution of gallium-67. The 
most important factor found to influence biodistribution was the interval between 
67Ga-citrate injection and time of death, highlighting the slow pharmacokinetics of the 
tracer. Interestingly, higher accumulation in bones was measured for adolescent 
patients. Recently the whole-body biodistribution of 68Ga-citrate has been evaluated 
by PET imaging within a clinical study for bone infections. Results were similar to those 
obtained for 67Ga-citrate [130]. 
While providing useful information on the behaviour of 67Ga/68Ga in biological systems, 
all clinical and preclinical 68/67Ga biodistribution data were obtained using trace 
amounts of gallium, which is typical of modern radionuclide imaging where carrier-
free formulations are used. Pharmacokinetics and biodistribution of gallium become 
different for chemotherapeutic doses of gallium, or carrier-added 
radiopharmaceuticals, as demonstrated by different clinical and preclinical 
observations comparing the biodistribution of carrier-added and carrier-free 
radioactive gallium. An early 67Ga-citrate study in rats found significantly different 
biodistribution of this carrier-free tracer compared to 72Ga-citrate that contained high 
amounts (in the mg/Kg range) of natural gallium [131]. Particularly, a carrier 
concentration above a 0.25 mg/Kg resulted in a modification of the excretion and 
distribution of radioactivity, with increased urinary excretion and accumulation in 
bones and decreased accumulation in soft tissues [131]. The same behaviour was 
exploited in a very early study using 68Ga-citrate as a bone scanning agent, where 
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bone/soft tissue ratio was increased by co-administration of non-radioactive gallium 
salts. This study also demonstrated how the increased amount of citrate that 
accompanies the carrier-added administration could not, alone, produce the same 
effect [132].  
Other studies have demonstrated that modified 67Ga biodistribution, with increased 
bone uptake and renal clearance, was not exclusive to carrier-added 67Ga, but could 
also be achieved by administration of with iron(III), scandium(III) or by treatments 
(irradiation or drugs) that resulted in increased concentration of iron in the blood 
(hyperferremia) [133-135], prior or concomitant to the 67Ga injection. 
These observations are at least partially explained by considering that transferrin can 
be saturated by high doses of Ga(III) or other competing metals such as Fe(III) or Sc(III). 
Formation of gallate will start to compete with Ga-transferrin even before reaching 
the saturation threshold (50 μM of gallium at physiological concentration of transferrin) 
and, as a small anion, gallate is expected to be rapidly cleared renally and accumulate 
less in tissues. The increased bone uptake observed in these conditions suggests that 
gallium accumulation in bones follows a different mechanism in comparison to soft 
tissues [111].  
Effects of transferrin saturation on tumour uptake of 67Ga were conflicting, thus casting 
doubts on whether tumour uptake of gallium actually follows a route similar to other 
tissues. Hayes found that 67Ga uptake in 5123c hepatoma xenografts in rats was 
unaltered by saturation of transferrin with scandium or iron, while it was decreased 
by reduction in serum iron and consequent increase in available Tf binding sites 
[135,136]. In a later comprehensive study, Schomacker evaluated the effect of co-
administration of natural (non-radioactive) gallium and iron citrate on the 
biodistribution of 67Ga and 59Fe in xenograft bearing mice. Notably, co-administration 
of natural gallium or iron was able to decrease the amount of activity associated with 
blood and tumours for both 67Ga and 59Fe and to increase the amount of activity 
excreted in urine [137]. This study elegantly pointed out some other dissimilarities 
between iron and gallium and how they affect each other’s biological pathways. For 
67Ga the amount of activity associated with liver, spleen and muscle was decreased 
when natural gallium/iron was co-administered with the tracer, while deposition in 
bones (but not in bone marrow) increased. Conversely, gallium and iron addition 
increased the percentage of 59Fe associated with liver and spleen while accumulation 
in muscle, bone and bone marrow was decreased by co-administration of iron and 
unaffected by gallium [137].  
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1.3.3 Mechanism for gallium uptake in tumours 
Accumulation of gallium-67 in tumours was first described in 1969 by Hayes, who 
observed uptake of activity in a non-osseous tumour during the evaluation of 67Ga-
citrate as a bone-scanning agent in a Hodgkin lymphoma patient [138,139]. Since this 
serendipitous discovery, gallium-67 tumour scanning has been employed clinically for 
diagnosis of lymphomas, leukaemia, lung cancers, head and neck cancers and 
melanoma [140], although this technique has now largely been abandoned in favour of 
[18F]-FDG PET. Several animal models, were also established to better study and 
characterise accumulation of 67Ga in malignancies [141]. Nonetheless, the mechanisms 
underlying uptake of gallium in tumours are among the most controversial aspect of 
gallium biology, with the main point of contention being the role of transferrin in this 
process [142].  
Larson was the first to introduce the concept of gallium as an iron analogue to explain 
its interaction with biological systems, and to hypothesise transferrin-mediated 
gallium accumulation in tumours and soft tissues. According to this hypothesis, as it 
was formulated at first, circulating gallium is quantitatively bound to transferrin and 
carried to the tumour proximity where GaTf binds to the transferrin receptor and is 
internalised by endocytosis. Once internalised, GaTf migrates to lysosomes and then 
associates with unknown acceptor macromolecules [143]. Although this hypothesis has 
been modified in the following 40 years to account for the increasing knowledge of 
iron uptake and trafficking in cells (for example, it is now established that metals are 
released from transferrin into the endosome following acidification of the 
environment), the fundamental core of this hypothesis has remained unchanged. 
Larson’s hypothesis was supported by Harris and Sephton’s observations that human 
serum or transferrin promoted tumour uptake of gallium in vitro in both human and 
mouse cancer cell lines [144,145]. Intriguingly, addition of serum from different animal 
species had different effects on gallium tumour uptake, suggesting different affinities 
of species-specific transferrin protein for species-specific transferrin receptors. While 
human, horse and rabbit serum proved to be very effective in enhancing the uptake in 
mouse-derived tumour cells, mouse serum had an intermediate efficacy, and the foetal 
calf serum used in normal cell culture did not have any effect [145]. Other studies 
further validating Larson’s hypothesis have observed accumulation of gallium in 
lysosomes of viable tumour cells [146] and shown that in vitro [141,147] and in vivo 
[133] tumour uptake of gallium-67 is decreased, when 67Ga binding to transferrin is 
inhibited. Importantly, Larson’s hypothesis also provides a rationale for increased 
gallium accumulation in tumour cells relative to healthy cells: as highly proliferating 
43 
 
tissues require an increased amount of iron [148], cell-surface transferrin receptor 
expression is upregulated, increasing GaTf cell uptake.  
On the other hand, Larson’s hypothesis presented some critical issues. The 
experimental observation that, unlike 67Ga, 59Fe does not show any preferential 
accumulation in tumours in vivo [120], despite evidence of accumulation in cultured 
cells [143], clearly suggested that the analogy with iron was incorrect when considering 
tumour uptake, or at least incomplete. Furthermore, Larson’s hypothesis failed to 
explain some other experimental observations by Hayes: iron saturation of transferrin 
generally decreased 67Ga uptake in normal soft tissues but increased uptake in tumours 
[136]. Larson’s hypothesis was also unable to explain clinical data showing how 
patients presenting transfusion-induced iron overload had inferior 67Ga uptake in soft 
tissues but unaffected tumour uptake of the radiotracer [149]. To interpret these 
phenomena, Hayes hypothesised a different mechanism for gallium uptake in tumours, 
involving an unbound/loosely bound form of gallium (likely gallate), which could 
accumulate in the tumours owing to a hypothesised enhanced permeability of the 
tumour cell membrane [136]. This hypothesis was able to explain the lack of tumour 
uptake for 59Fe, since soluble, unchelated iron species do not exist in physiological 
conditions. It also explained those experiments where tumour uptake of 67Ga was 
increased by iron loading; in fact, this would result in a displacement of 67Ga from 
transferrin to its unbound form, which could then accumulate in tumours. On the other 
hand, the rational of this theory, the hyperpermeability of tumour plasma membrane, 
was somewhat lacking, as no evidence of this phenomenon or of its potential causes 
was presented [150]. 
To explain these conflicting results, Sephton hypothesised that the actual species 
responsible for tumour uptake of gallium was extravascular transferrin (ETf) in contact 
with the tumor tissue [151]. In order to reach these transferrin molecules, gallium has 
to exit the circulation and penetrate the endothelium either in the form of GaTf or as 
unbound gallate. Extravasation of a large macromolecular complex, such as GaTf, is 
necessarily a slow process and can only be responsible for tumour uptake at late time 
points after gallium injection. On the contrary, the gallate ion can cross the 
endothelium, bind to extravascular transferrin molecules and consequently to 
transferrin receptors on tumour cell surfaces, thus accounting for the majority of 
tumour uptake at early time points. Although the percentage of unbound Ga(III) in 
plasma is extremely low compared to GaTf, this is only true once the thermodynamic 
equilibrium is reached. In their computational studies, Jackson and Byrne analysed the 
speciation of Ga-citrate in aqueous solution at pH 7.4, with a total Ga(III) concentration 
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of 90 nM and a concentration of citrate equal to 4 x 10-5 M, typical for a 185 MBq 
injection of 67Ga-citrate [94]. Their studies showed how Ga-citrate initially exists 
mainly (>90%) as [Ga(OH)4]
- while, once thermodynamic equilibrium with Tf has been 
established >99% of Ga(III) is then associated with this protein, while the rest persists 
as [Ga(OH)4]
 [94]. Even when the equilibrium has been achieved, this involves a 
continuous re-equilibration between the two forms of gallium, so that removal of 
unbound Ga(III) from the circulation (e.g. by its diffusion into the extravascular space), 
would result in transferrin release of further Ga(III). The same reasoning applies to the 
extravascular space with opposite results: here the increase of unbound gallium would 
prompt binding to ETf to re-establish the equilibrium ratio and GaETf would then 
deliver gallium to the tumour tissue. 
This elegant hypothesis can easily explain the differences observed in vivo between 
gallium and iron, since a soluble unbound form of iron does not exist under 
physiological conditions and thus extravasation of iron has to rely only on FeTf. 
Furthermore, this could explain why a faster and higher tumour uptake of 67Ga could 
be achieved by iron loading of transferrin. In fact, decrease in the available transferrin 
binding sites would result in an increased release of gallium in its gallate form, which 
could rapidly penetrate the endothelium, bind ETf and be taken up by the tumour 
[151]. While this enhanced tumour uptake due to transferrin saturation would be very 
prominent at early time points, it would level off once extravasation as GaTf has also 
reached its equilibrium and can actively contribute to gallium delivery to tumour 
tissues. Interestingly, according to this hypothesis, the variability in the time points at 
which tumour uptake was measured in different studies could potentially explain the 
conflicting results obtained for tumour uptake in transferrin saturation experiments.  
Notably, although Sephton’s hypothesis can also be applied to 67Ga uptake in normal 
tissues, its effects are amplified in malignant tumour lesions. This is likely due to their 
increased capillary permeability and expanded extracellular space, which facilitates 
67Ga delivery to the ETf and, ultimately, to the tumour [152].  
While this revised theory could account for many experimental data, it still failed to 
explain some in vitro and in vivo observations, in which gallium uptake was measured 
in either mice congenitally lacking transferrin [153] or in a pair of matched cell-lines, 
one lacking Tf expression, and the other transfected to restore Tf expression [154]. 
These experiments demonstrated that although reduced, tumour uptake of gallium 
persisted when transferrin or transferrin receptor was absent, thus supporting the 
existence of transferrin-independent uptake mechanisms for gallium accumulation in 
tumours. In addition, in experiments where an anti-TfR monoclonal antibody was used 
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to block transferrin receptors prior to 67Ga-citrate injection, a 75 % reduction in 
gallium uptake was observed, thus demonstrating the key role of GaTf interaction with 
TfR in gallium uptake, but also highlighting that the transferrin-mediated uptake 
mechanism cannot account for the totality of the uptake [155]. Similarly, 67Ga uptake 
was inhibited but not eliminated in HeLa cells transfected to express the wild type 
Hemochromatosis protein HFE, which binds to TfR and inhibits TfR-mediated metal 
uptake pathways.  
The existence of transferrin-independent mechanisms of uptake is also in agreement 
with Chitambar’s findings that uptake of gallium in HL60 cells was still present, 
although to a lesser extent, in transferrin-free media and increased at higher gallium 
citrate concentration [116]. Whether these transferrin-independent mechanisms are 
related to those hypothesised for iron is still uncertain, but unlikely since Fe(III) 
reduction to Fe(II) and subsequent production of free radicals seems to be involved in 
its transferrin-independent cellular uptake [104]. 
1.3.4 Intracellular distribution of gallium 
Little is known about the fate of gallium upon internalisation in both tumour and 
normal cells [104]. Similar to FeTf, GaTf is initially internalised in an endosome and 
gallium released from transferrin upon lowering of the pH. While in the case of iron, 
transfer to the cytoplasm is then mediated by divalent metal transporters, these 
biomolecules are not able to bind Ga(III), whose cellular trafficking remains elusive 
[156].  
Intracellular distribution is also not completely understood. Both light and electron 
microscopy autoradiography showed accumulation of gallium granules in lysosome-like 
organelles [157]. However, the form in which gallium is stored in these organelles is 
debated, with some evidence suggesting binding to a macromolecule of 45 kDa 
[158,159]. Some other studies highlighted binding of gallium to ferritin, possibly 
mediated by phosphate molecules [115,116]. However, a more recent study showed 
that gallium binds to ferritin to a lesser extent compared to iron [160].  
1.3.5 Mechanism for gallium uptake in bone  
The ability of gallium to accumulate in bones, with particular affinity for growing and 
remodelling sites, has been documented [129,161]. Uptake of radioactive gallium in 
bones increases in the presence of carrier-added Ga(III) or Fe(III) above the threshold 
of transferrin saturation [132], and remains unaltered whenever transferrin dependent 
transport mechanisms are suppressed by different experimental procedures [153]. 
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While these studies demonstrate that transferrin is not involved in bone accumulation 
of gallium [162], the mechanisms responsible for this accumulation remain largely 
unknown, although they are likely to involve the free gallate anion. Like many trivalent 
ions, gallium is known to adsorb to synthetic hydroxyapatite in vitro [163]. In vivo this 
adsorption could be directly mediated by the small concentration of gallate present in 
serum at physiological pH, or released by transferrin in situ in the presence of local 
acidic conditions or high concentrations of phosphates [115]. In fact, it has been shown 
in vitro that both ATP and pyrophosphate decrease binding of transferrin to 67Ga, thus 
facilitating gallium transfer to other macromolecules. It is beyond the scope of this 
chapter to describe gallium interaction with bone cells function and the resulting 
pharmacological activity. Extensive description of these phaenomena can be found in 
a comprehensive review by Bernstein [111].  
1.3.6 Mechanism for gallium uptake in infections and inflammation 
Beside its accumulation in bones and cancer, gallium was also observed to localise in 
sites of inflammation and infection as demonstrated by several preclinical and clinical 
studies with 67Ga [111]. Gallium localisation in inflammation and infections is linked to 
increased blood flow and vascular permeability in these lesions and has not been 
observed in the absence of an adequate blood supply [164]. Through this increased 
blood flow, gallium is delivered to the lesion in either its unbound or GaTf form. Here 
it can transchelate to lactoferrin, which is excreted by leukocytes (mainly neutrophils) 
as part of the inflammation process. Lactoferrin possesses higher affinity for gallium 
compared to transferrin (at 5 mM bicarbonate concentration LogK1 = 21.43, 
LogK2 = 20.57 vs LogK1 = 19.53, LogK2 = 18.58 for transferrin [112]). Once bound to 
lactoferrin, gallium can be incorporated in leukocytes as well as in macrophages [111] 
and these cells can then migrate to different sites of infection, transporting their 
intracellular gallium to new infection foci [165]. Direct 67Ga labelling of leukocytes 
followed by their migration to sites of inflammation/infection has also been shown 
[166]. Where bacteria are present, they can bind gallium via siderophores, released at 
the infection site with the aim of acquiring iron from the environment [111]. Additional 
mechanisms for bacterial uptake of 67Ga involve facilitated diffusion of the metal ion 
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2 Clinical application of gallium compounds. 
Radionuclide imaging with 68Ga (and previously with 67Ga), represents the main clinical 
application of gallium compounds and will be the focus of the chapter. In particular, 
targeted imaging of receptors, using 68Ga-labelled peptides provides the principal 
driver for 68Ga tracers development and will be described extensively in the first 
section. Different strategies for imaging with 68Ga, including pretargeted and non-
targeted imaging will also be described. Alongside the development of new 
radiotracers, research on gallium compounds as chemotherapeutics has also produced 
some compounds of clinical interest for the treatment of cancer and related 
pathologies that will also be briefly discussed. 
 68Ga as a game-changer in PET imaging 
The interest of nuclear medicine researchers in gallium isotopes dates back in the 
1950s, first with the use of 72Ga [1] and then 67Ga as a bone scanning agent [2] and, 
later, to detect several types of soft tumour exploiting its similarity with iron [3]. 
Gallium-68 itself had been considered for clinical use in the 1960s, when carrier added 
68Ga-citrate was exploited for bone scanning [4] and [68Ga]Ga-EDTA used for the 
detection of brain tumours in association with the newly developed positron camera 
[5]. However, the following decades saw clinical application of these isotopes side-
tracked in favour of targeted imaging using γ-emitting radiometals such as indium and 
technetium, performed using a planar γ-camera or, more recently, a SPECT scanner. 
While the sub-optimal imaging properties of 67Ga account for the progressive 
abandonment of its clinical use, the delay in gallium-68 tracer development is 
attributable to the lack of a generator eluting 68Ga in a convenient form (instead of as 
an EDTA complex [6]), and to the slow proliferation of positron cameras. 
In the past three decades, the field of PET imaging has seen burgeoning development, 
mainly due to the success of [18F]-fluorodeoxyglucose ([18F]-FDG) scans, which has 
prompted the diffusion in hospitals of PET scanners and cyclotrons dedicated to the 
production of medical radioisotopes. While SPECT still represents the work-horse of 
nuclear medicine, due to higher availability and lower cost, PET presents several 
advantages compared to SPECT including higher sensitivity, better quantification and 
possibility of dynamic image reconstruction [7,8]. Furthermore, although PET 
resolution is intrinsically limited by the travelling distance of the positron before 
annihilation, current human PET systems provide higher resolution than SPECT [8,9].  
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In these new contexts, the advantageous emission properties of gallium-68, including 
an almost quantitative positron yield of 89 % and a half-life of 68 min, made it an ideal 
PET isotope for imaging with small biomolecules and prompted the development of 
novel generators systems as well as of 68Ga-based tracers. Compared to fluorine-18, 
gallium-68 has the disadvantage of a higher positron energy (Emax = 1.9 MeV [10]), which 
results in a longer positron range (Rmean = 3.5 mm vs Rmean = 0.6 mm for 
18F [10]) and, 
consequently, in lower spatial resolution for 68Ga images. On the other hand, gallium-
68 presents distinct advantages over traditional PET isotopes such as 18F and 11C. For 
example, as a radiometal, gallium-68 can be used to radiolabel biological molecules 
exploiting suitable bifunctional chelators, such as those described in the previous 
chapter, without the need for complex radiosynthetic procedures. More importantly, 
the recent availability of gallium-68 via a pharmaceutical grade generator could play 
for PET the same role that the 99Mo/99mTc generator has played for SPECT, thus 
enormously increasing the utility of PET beyond the centres possessing cyclotrons [11]. 
A description of 68Ge/68Ga generator development and of the techniques for pre-
concentration and purification of the generator eluate, is beyond the scope of this 
chapter, readers are referred to other comprehensive reviews and books [12,13].  
 Targeted imaging of receptors with 68Ga-labelled 
peptides 
These attractive features, unique among the pool of PET radioisotopes, have 
contributed to the increasing clinical interest for gallium-68. The principal application 
of 68Ga has been imaging the expression of receptors upregulated in cancer cells or in 
other pathological conditions, by radiolabelling molecules able to bind to these 
antigens with high selectivity. This is accomplished by means of a bifunctional 
chelator, which can be attached to the targeting molecule to allow its 68Ga labelling. 
So far, targeted imaging with gallium-68 has mainly focused on 68Ga-radiolabelled 
peptides, whose pharmacokinetic properties match the short half-life of the isotope 
[14]. In addition, the use of a short-lived isotope for imaging with radiolabelled 
peptides is advantageous owing to the improved dosimetry and to the possibility of 
performing repeat imaging of a patient on the same day. Finally, the possibility of 
using the same peptide-chelator conjugate for both gallium-68 imaging and targeted 
radiotherapy with lutetium-177 and yttrium-90 (especially when DOTA-based chelators 
are used) makes these systems a close to ideal theranostic pair for peptide receptor 
radionuclide therapy (PRRT). A review of the receptors investigated for imaging 
with68Ga and of the tracers developed to selectively target them is provided in the 
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paragraphs below, mainly focussing on their clinical translation. A brief description of 
interesting radiotracers in preclinical development is also presented. 
2.2.1 Somatostatin Receptors 
Imaging of somatostatin receptors with 68Ga-based somatostatin analogues has led to 
the clinical success of 68Ga PET and provided an enormous drive for the development 
of other gallium-68 radiotracers. Somatostatin receptors (SSTRs) are a family of G-
protein-coupled membrane glycoproteins, which regulate exocrine and endocrine 
secretion. SSTRs are highly expressed in 70-90 % of neuroendocrine tumours (NETs), 
such as pituitary adenoma, pancreatic islet cell tumour, carcinoid, 
pheochromocytoma, paraganglioma, medullary thyroid cancer and small cell lung 
carcinoma and in other types of cancer such as renal cell carcinoma, small cell lung, 
breast and prostate cancer and malignant lymphoma [15,16]. Five different receptor 
types exist (SSTR1-SSTR5), with SSTR2 being the most widely expressed in 
malignancies. The traditional gold standard for radionuclide imaging of these receptor 
was [111In]In-DTPA-octreotide (Octreoscan, Figure 2.1) which consisted of a SSTR 
agonist molecule (with sequence H2N-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol) 
attached to a DTPA chelator at the amino terminus and radiolabelled with indium-111. 
Despite the success of Octreoscan and its widespread use in clinics, this radiotracer 
also showed some limitations, especially concerning the detection of small lesions, 
which proved to be difficult owing to the limited spatial resolution achievable with 
SPECT. On the other hand, since [18F]FDG is not recommended for imaging of NETs, 
due to their low metabolic rate, which hinders [18F]FDG uptake, another PET tracer 
able to specifically target SSTR receptor had been actively sought [16]. Three different 
DOTA derivatives of octreotide have been extensively evaluated in clinics for labelling 
with 68Ga: namely [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-NOC, [68Ga]Ga-DOTA-TOC, 
which are all conjugated to DOTA at the N-terminus and differ only in the amino acid 
sequence (Figure 2.1); compared to octreotide, TOC and TATE have a tyrosine in 
position 3 and TATE also has the alcohol function at the C-terminus replaced by a 
carboxylic function; finally NOC displays a naphthalenyl-L-alanine in position 3 and 
maintains the alcohol group at the C-terminus. Despite a higher affinity of [68Ga]Ga-
DOTA-TATE for SSTR2 compared to [68Ga]Ga-DOTA-TOC, their tumour uptake and in 
vivo biodistribution were found to be very similar [17]. On the contrary, [68Ga]Ga-
DOTA-NOC, which possesses even greater affinity for SSTR2 as well as SSTR3 and SSTR5 
in vitro [18], displays an increased liver uptake, due to the presence of the lipophilic 




Figure 2.1. Chemical structures of the more common somatostatin analogues ligands. 
For DOTA-TOC, DOTA-TATE and DOTA-NOC differences in the amino acid sequence 
compared to the prototype compound DTPA-octreotide are highlighted [14]. 
While the three tracers have shared the interest of the nuclear medicine community 
so far, the FDA approval in June 2016 of [68Ga]Ga-DOTA-TATE (NETSPOT®) and the 
following approval of [68Ga]Ga-DOTA-TOC (SOMAKIT TOC®) by the EMA is likely to 
increase the prevalence of clinical studies using these radiotracers [19,20]. The 
analogous tracer [68Ga]Ga-DOTA-lanreotide ([68Ga]Ga-DOTA-2-Nal, Tyr3, ThrNH2
8-
octreotide) has also been investigated in clinics, but was found inferior to [68Ga]Ga-
DOTA-TOC in detecting NET lesions [21].  
Overall, 68Ga tracers based on SSTR agonist proved to be extremely successful in the 
diagnosis of NETs and able to influence patient stratification and treatment [14]. 
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Furthermore, they can be used in combination with PRRT exploiting DOTA’s ability to 
coordinate some M3+ therapeutic isotopes such as lutetium-177 or yttrium-90 [22].  
During the last two decades, a different class of SSTR imaging agents has been 
developed, mainly by Maecke and coworkers, based on antagonists of these receptors. 
Unexpectedly, in preliminary preclinical studies these compounds proved to be 
superior to SSTR agonists with comparable binding affinity [23], thus challenging the 
belief that internalisation of the radiotracer, which only occurs for agonist compounds, 
is important to obtain high tumour uptake [24]. Clinical evaluation of one of these 
compounds ([68Ga]Ga-NODAGA-JR11 (Figure 2.2), also known as [68Ga]Ga-OPS202) and 
its 177Lu counterpart is still ongoing, but has already produced promising results 
[25,26].  
 
Figure 2.2. Structure of the NODAGA-JR11 antagonist [23,24]. 
 
2.2.2 Prostate Specific Membrane Antigen 
More recently, the prostate specific membrane antigen (PSMA) has gained enormous 
attention within the nuclear medicine community as an imaging target. This receptor 
is overexpressed in the majority of prostate cancer (95 % of primary tumours, 80 % of 
metastasis [17]) as well as in some bladder cancers, schwannoma and in the 
neovasculature of many solid tumours [27]. PSMA is also expressed in kidneys, liver, 
salivary glands, lachrymal glands, colon, duodenal brush border, and the nervous 
system, where it is known as carboxypeptidase II because of its ability to cleave C-
terminal glutamate residues from its substrates [27]. The recent development of 
several 68Ga radiotracers based on the low molecular weight unit Glutamate-Urea-
Lysine (Glu-NH-CO-NH-Lys), which is a known inhibitor of PSMA, yielded impressive 
results in clinical trials providing target specific imaging with favourable 
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biodistribution [28]. A brief description of the different 68Ga radiotracers based on the 
Glu-NH-CO-NH-Lys pharmacophore is provided in the following paragraphs. 
The first 68Ga-based PSMA imaging agents were DOTA derivatives, with the chelators 
connected to the pharmacophore units via different linkers; their ability to detect 
PSMA expressing tumours in vivo, and their target specificity, was demonstrated in 
preclinical models [29]. More recently an HBED-CC derivative, connected to the 
peptidic unit via an aminohexanoic (Ahx) acid: Glu-NH-CO-NH-Lys-Ahx-[[68Ga]Ga(HBED-
CC)] (also known as [68Ga]Ga-PSMA11 and [68Ga]Ga-HBED-CC-Ahx-KuE, ligand shown in 
Figure 2.3) was found superior to its DOTA-based counterpart both in terms of its in 
vitro properties (reduced non-specific binding and increased internalisation) and in its 
ability to specifically delineate PSMA-expressing tumours in animal models [30]. These 
advantageous features have been ascribed to the increased lipophilic nature of the 
tracer, which would result in stronger interaction with a lipophilic pocket present in 
the active binding site of the receptor [30]. Furthermore, the facility of HBED 
radiolabelling compared to DOTA represents an additional advantage for this 
compound. Clinical evaluation of this radiotracer demonstrated its ability to visualise 
prostate cancer lesions with high detection rate [31] and superiority to traditional 
radioactive choline imaging of prostate cancer [32]. Optimisation of this ligand led to 
the development of a dimerised version with increased affinity for PSMA and prolonged 
tumour retention in preclinical models, which warrants further investigation [33]. As 
for the SSTR tracers, theranostic agents have been developed for PSMA, based on a 
DOTA scaffold, which is more suitable for radiolabelling with 177Lu. PSMA-617 (Figure 
2.3) is a DOTA-based peptidomimetic compound with optimised targeting properties 
[34], which has been used for theranostic application with 68Ga and 177Lu [35]. A 
modified version of one of the original DOTA tracers, PSMA I&T (Figure 2.3), was 
produced by switching to DOTAGA and performing a light modification of the 
hydrophobic substituents, to present higher in vivo stability and affinity for the target 
receptor and was investigated in first-in-man trials with promising results [36,37]. A 
different type of 68Ga-PSMA tracer has been developed by our group, exploiting a THPMe 
chelator connected to the PSMA moiety via a glutaric acid linker ([68Ga]Ga-THPMe-PSMA) 
[38]. Despite lower affinity for the target receptor, preclinical evaluation of this 
radiotracer produced results comparable to its HBED-CC counterpart. Furthermore, 
radiolabelling of this ligand is based on a single-step kit without need for further 
purification of the radiotracer, thus providing a great advantage over HBED and DOTA-
based tracers. Phase I clinical evaluation of this imaging agent produced encouraging 
results [39] and the compound is now undergoing a phase II multicentre clinical trial 




Figure 2.3. Chemical structure of different PSMA-chelator conjugates in clinical 
evaluation [30,34,36,38]. The chemical diversity of these agent, beyond the common 
PSMA targeting moiety, does not affect significantly their capability to delineate lesions 
in vivo.  
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2.2.3 αVβ3 integrins 
Owing to their major role in tumour angiogenesis and metastasis, integrins have been 
extensively investigated as a target for radionuclide imaging of cancer and other 
pathologies [40,41]. In particular, peptides based on the Arg-Gly-Asp (RGD) sequence 
have been used as the targeting moiety to visualise the αVβ3 integrin, overexpressed 
on activated endothelial cells such as those involved in angiogenesis [40]. The first 
68Ga-labelled RGD peptide to enter clinical trials was [68Ga]Ga-NOTA-RGD (Figure 2.4), 
consisting of a cyclic RGD peptide c(RGDyK) conjugated to the chelator p-SCN-Bn-NOTA 
via a thiourea linkage with the lysine side-chain [42]. Comparison of this tracer with 
[18F]FDG was performed in patients with hepatic metastasis of colorectal cancer about 
to start an antiangiogenic therapy. Notably, although this tracer was able to delineate 
fewer metastatic lesions than [18F]FDG, those patients with positive [68Ga]Ga-NOTA-
RGD uptake were found to respond to the subsequent antiangiogenic chemotherapy, 
thus highlighting the potential role of αVβ3 imaging as a patient stratification tool [41]. 
On the other hand, since the αVβ3 receptor is overexpressed also in several types of 
tumours it is always important to use histopathology techniques to verify whether the 
radiolabelled peptides are actually imaging angiogenesis or a simple upregulation of 
the receptor on tumour cell surfaces [43]. A similar radiotracer, where p-SCN-Bn-NOTA 
had been replaced by NODAGA in order to improve pharmacokinetic properties, was 
evaluated in patients with hepatocellular carcinoma showing outstanding in vivo 
stability, but insufficient uptake in metastatic lesion in order to image them [44]. 
Multimeric RGD peptides can enhance affinity for the integrin receptor through the 
covalency effect, thus resulting in increased tumour uptake and retention [45]. Among 
the several multimeric RGD peptides investigated preclinically, many see the 
incorporation of a PEG linker in their structure to improve their pharmacokinetic 
properties [46]. [68Ga]Ga-NOTA-PRGD2 (also known as [68Ga]Ga-NOTA-PEG4-
E[c(RGDfK)]2) ligand, shown in Figure 2.4, was compared to [
18F]FDG in patients 
suffering from lung cancer [47] and glioblastoma multiforme [48]; it showed higher 
specificity than [18F]FDG in both cases. In the glioblastoma study, 68Ga-NOTA-PRGD2 
was able to differentiate between low and high-grade glioma with improved accuracy 
compared to [18F]FDG and displayed higher sensitivity due to lack of integrin receptor 
in normal brain tissues. The same radiotracer has been evaluated with encouraging 
results in non-oncologic diseases involving angiogenic mechanisms, such as stroke, 
myocardial infarction and rheumatoid arthritis [49,50]. 
A different αVβ3-targeting tracer is based on a peptidomimetic antagonist, which was 
found to possess increased binding affinity for the integrin receptor [51]. A NODAGA 
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derivative of this tracer (NODAGA-THERANOST, Figure 2.4) was radiolabelled with 68Ga 
and first in human evaluation of this radiotracer showed increased sensitivity and 
specificity of this tracer compared to [18F]FDG [52]. In particular, [68Ga]Ga-NODAGA-
THERANOST, but not [18F]FDG, was able to identify areas of neovasculature in both 
primary tumours and metastases and a strong positive correlation was found between 
[68Ga]Ga-NODAGA-THERANOST uptake and cancer proliferation [52]. 
 
Figure 2.4. Structures of αVβ3-targeting ligands evaluated in clinical trials, including the 




2.2.4 Gastrin-releasing peptide receptors 
Bombesin analogues, both agonists and antagonists, have also been proposed for the 
imaging of prostate cancer and other malignancies that express their target receptor: 
gastrin-releasing peptide receptor (GRPR), including breast, gastro-intestinal and 
small-cell lung cancers. In a first study, a GRPR agonist DOTA-PEG2-[D-Tyr
6, β-
Ala11,Thi13,Nle14] Bombesin (BZH3) was radiolabelled with gallium-68 and, after 
encouraging preclinical results [53], evaluated in comparison with [18F]FDG in patients 
with gastrointestinal stromal tumours. Despite the high affinity for the target receptor, 
[68Ga]Ga-BZH3 was found inferior to [18F]FDG in visualising tumour lesions in the same 
patient cohort [54]. Similar to somatostatin receptors antagonists, GRPR antagonists 
showed higher tumour accumulation and longer washout time compared to agonist 
compounds. The synthetic antagonist [68Ga]Ga-BAY86-7548 (Figure 2.5, also known as 
[68Ga]Ga-RM2)) was evaluated in prostate cancer patients and showed 83 % accuracy 
in the detection of organ-confined primary tumours [55]. A recent comparison between 
this tracer and [68Ga]Ga-PSMA-11 in patients with biochemically recurrent prostate 
cancer showed similar ability to detect prostate cancer lesions for both radiotracers. 
However, the two radiotracers presented a different uptake in non-target organs 
(higher in the pancreas and blood for [68Ga]Ga-RM2, and in small intestine, kidneys, 
lacrimal, parotid and submandibular glands, for [68Ga]Ga-PSMA-11). This different 
biodistribution suggests that choice between the two radiotracers should depend on 
the type/position of the tumour in each individual patient. 
 
Figure 2.5. Chemical structure of the GRPR antagonist [68Ga]Ga-RM2 [55]. 
In a different study a similar GRPR antagonist [68Ga]GaSB3, an analogue of a 99mTc 
based antagonist which had showed promising imaging properties, was evaluated in 
patients with metastasised breast and prostate cancer and was able to visualise about 
50 % of the lesions [56]. Although those values are inferior to those previously reported 
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for [68Ga]Ga-RM2 [55], GRPR expression is known to decline in metastatic tissues and 
therefore a lower number of positive scans was expected [56]. 
2.2.5 Chemokine receptor CXCR4 
The chemokine receptor CXCR4 plays a key role in the proliferation migration and 
survival of cancer cells. Overexpression of CXCR4 is common in numerous malignancies 
including breast, pancreatic, ovarian, lung, prostate, colorectal and skin cancers, 
leukaemia, and lymphoma [17] and generally correlates with poor prognosis and 
increased probability of recurrence [57]. Development of CXCR4-targeting imaging 
agents focussed on three classes of antagonists: cyclam-based tracers, 
tetradecapeptides and cyclopentapeptides. This last class of compounds was 
developed to improve pharmacokinetic and in vivo stability compared to the heavier 
counterparts tetradecapeptides [58]. Cyclam-based tracers were evaluated in mice for 
imaging with copper-64, but revealed extremely high uptake in liver and lymphoid 
organs, which prevented clinical evaluation of these tracers [59]. On the contrary, 
peptide-based imaging of CXCR4 produced the first two clinical studies in 2015 
employing the pentacyclopeptide [68Ga]Ga-pentixafor (Figure 2.6, also known as 
CPCR4-2) [60] and the tetradecapeptide [68Ga]Ga-NOTA-NFB [61], respectively. 
[68Ga]Ga-pentixafor has been by far the most widely investigated PET radiotracer for 
CXCR4 and has shown a favourable dosimetry [62], good specificity and uptake for 
CXCR4-expressing lesions, with results comparable or superior to [18F]FDG for several 
haematological malignancies [60,63-65]. On the contrary, significantly lower 68Ga-
pentixafor uptake compared to [18F]FDG was recently reported for solid tumours [66]. 
Unexpectedly, 68Ga-pentixafor uptake in glioblastoma, small cell lung cancer and some 
neuroendocrine tumours [67] did not correlate with histological receptor expression 
probably due to receptor kinetics and internalisation mechanisms [68,69]. Based on 
the promising results in the diagnosis of haematological malignancies, radiotherapy 
with the 68Ga-pentixafor analogue 177Lu- and 90Y-pentixather is now being investigated 





Figure 2.6. Chemical structure of the pentixafor ligand [60]. 
Interestingly, replacing the DOTA chelator in 68Ga-pentixafor with NOTA was shown to 
markedly reduce tumour uptake in preclinical models, which was ascribed by the 
authors to decreased internalisation of this tracer [71]. This observation is at odds with 
the excellent tumour uptake observed for non-internalising SSTR radiotracers, and if 
confirmed it would be another indication on how imaging of different receptors may 
benefit from radiotracers with different properties. 
The tetradecapeptide [68Ga]Ga-NOTA-NFB is a derivative of the 18F radiotracer 4-[18F]F-
T140, where the N-terminal 4-fluoro-benzoyl group (NFB) was substituted with the 
chelating agent NOTA [72]. In a preliminary clinical study a favourable dosimetry was 
measured for [68Ga]Ga-NOTA-NFB in healthy volunteers and improved contrast 
compared to [18F]FDG scan was demonstrated in glioma patients [61].  
2.2.6 Glucagon-like peptide-1 receptor 
Glucagon-like peptide-1 receptor (GLP-1R) represents an important target for 
quantifying the beta cells mass in diabetic patients and to image insulinomas, a NET 
tumour where SSTR expression is relatively low, but GLP-1R is upregulated [73]. 
Imaging of this receptor is based on the substrate analogue exendin, whose half-life in 
vivo exceeds that of the native ligand GLP-1 [17]. While 111In-based tracers were 
initially evaluated, in the last few years the focus shifted towards 68Ga-labelled tracers 
[74]. In 2014, a first case report described the use of [68Ga]Ga-DO3A-VS-Cys40-Exendin-
4 for the detection of a metastatic insulinoma in a hypoglycaemic patient [75]. 
Interestingly, this study used the unusual chelator DO3A-VS, in which one of the acetic 
arms of DOTA has been replaced by a vinylsulfonic group to provide attachment of the 
peptide through a cysteine residue. More recently, other exendin derivatives have 
been clinically investigated with encouraging results. [Nle14,Lys40(Ahx-DOTA-
[68Ga]Ga)NH2]exendin-4 was evaluated in a small patient cohort for the detection of 
suspected benign insulinoma achieving higher tumour-to-background ratio compared 
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to its indium analogue [76]. A larger cohort study employing [68Ga]Ga-NOTA-MAL-Cys40-
exendin-4 demonstrated a 97.7 % sensitivity in localising insulinoma, outperforming all 
conventional disease modality for this condition [77]. 
2.2.7 Other receptors 
The urokinase-type plasminogen activator receptor (uPAR) and its peptide antagonist 
AE105 (Asp-Cha-Phe-D-Ser-D-Arg-Tyr-Leu-Trp-Ser-CONH2) are among the most recent 
receptor/peptide couples investigated clinically for gallium-68 based imaging. uPAR is 
frequently overexpressed in several malignancies such as breast, prostate, colorectal 
and urinary bladder cancer and higher expression has been correlated to poorer 
prognosis [78]. Phase I clinical trials of 68Ga-NOTA-AE105 proved the feasibility of 
cancer imaging with this tracer, which provided satisfactory image contrast and 
delineation of primary tumours and metastasis, with the most promising results 
obtained for breast cancer patients [79]. 
Imaging of the melanocortin system, whose receptor MC1R is overexpressed in 
melanomas, has also been attempted using 68Ga-labelled DOTA analogues of the α-
melanocyte stimulating hormone. Although results of preclinical examination in mouse 
melanoma models were encouraging [80], subsequent clinical evaluation had 
disappointing results, presumably due to lower expression of this receptor in human 
melanoma [81]. 
 Targeted 68Ga imaging beyond radiolabelled peptides 
Alongside peptide-based 68Ga imaging, in the last few years the radiochemistry 
community has started to explore new vectors for imaging with gallium-68. 
2.3.1 Mannosylated albumin for sentinel lymph node imaging 
Identification of the sentinel lymph node (SLN) and subsequent biopsy is crucial for 
decision making in the treatment of several cancers. The SLN can be identified by 
injection of radiolabelled mannosylated albumin (MSA) in the tumour area, owing to 
the expression of mannose-binding proteins in the reticuloendothelial system. Choi and 
coworkers developed a 68Ga-labelled-(MSA) by conjugation of albumin with mannose 
and a NOTA chelator and subsequent radiolabelling [82]. After successful preclinical 
investigation, a recent clinical trial in lung cancer patients demonstrated the success 
of this technique with a detection rate of 100 % and 0 false negatives [83]. 
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2.3.2 Bisphosphonates for the detection of skeletal metastasis 
Bone metastases are a common complication of several cancers and therefore an 
important target for radionuclide imaging. Detection of skeletal metastasis in clinics 
was traditionally performed with 99mTc-labelled bisphosphonates. In fact, geminal 
bis(phosphonate) groups can act as analogues of natural pyrophosphate (Figure 2.7) 
and efficiently deposit on skeletal hydroxyapatite [84]. More recently [18F]NaF has 
been progressively replacing 99mTc-bisphosphonate in clinics, due to the higher 
sensitivity and resolution of PET compared to SPECT.  
 
Figure 2.7. Chemical structure of pyrophosphate compared to that of a geminal 
bisphosphonate in their fully protonated form.  
68Ga-labelled bisphosphonates are therefore of great interest, because they can 
combine the superior imaging properties of PET contrast agents with the bone-seeking 
properties of bisphosphonate. Two different 68Ga-labelled bisphosphonate derivatives 
(Figure 2.8) have been recently developed by Rösch and coworkers and tested 
clinically with promising results. [68Ga]Ga-BPAMD is a DOTA-based gallium 
bisphosphonate, which proved to be comparable to [18F]NaF in the detection of bone 
metastasis in a prostate cancer patient [85]. A more recently developed NOTA-
bisphosphonate agent [68Ga]Ga-NO2ABP [86] was also compared to [18F]NaF, and in some 
cases with a 99mTc-bisphosphonate in a cohort of breast carcinoma patients showing 
results comparable to [18F]NaF and superior to 99mTc-bisphosphonate, while resulting 
in a lower effective dose compared to the other tracers [87].  
 




2.3.3 Antibody fragments and affibody molecules for HER2 imaging 
Antibodies possess a striking targeting ability for their antigen, but their slow 
pharmacokinetics is not compatible with the short half-life of gallium-68. Different 
strategies have been investigated to overcome this limitation. Recent developments 
in antibody engineering have led to biomolecules that retain the antibody affinity for 
their target receptor while displaying faster pharmacokinetics, thus opening new 
possibility for 68Ga-immunoPET.  
Antibody binding fragments F(ab) and F(ab’)2 are obtained by enzymatic digestion of 
full antibodies and, given their lower molecular weight, they present faster clearance 
while retaining the binding affinity of their full antibody counterpart. Clinical 
evaluation of 68Ga-DOTA-F(ab’)2-trastuzumab in breast cancer patients with and 
without HER2 expression was undertaken, demonstrating the safety and favourable 
pharmacokinetics of this imaging agent [88]. On the other hand, tumour targeting was 
suboptimal with malignant lesions identified in only 50 % of the HER2 positive group.  
Nanobodies are antibody fragments consisting of a single variable domain, which 
retains full antigen-binding capability. Recently, a 68Ga-NOTA-anti-HER2 nanobody was 
the first radiolabelled nanobody to be evaluated in clinical trials in breast cancer 
patients [89]. The tracer was found to be safe and able to visualise primary tumours 
and metastatic lesions. Contrary to the F(ab’)2 tracer, this nanobody targeted a 
different epitope of HER2 thus excluding any chance of competing with trastuzumab 
for binding to the target receptor in trastuzumab-treated patients. 
Affibody molecules are obtained by a combinatorial engineering approach on a protein 
scaffold and then selected based on their affinity for the desired target via phage 
display. They combine the high affinity for their target receptor typical of antibodies 
with the pharmacokinetics of small molecules thus providing a useful platform for 
imaging with gallium-68. The HER2 targeting affibody molecules ABY-002 and ABY-025 
were conjugated to DOTA either at the N-terminus (ABY-002 [90]) or at a cysteine site 
through a maleimide (ABY-025 [91]) and radiolabelled with indium-111 obtaining 
encouraging clinical/preclinical results. The same molecules were radiolabelled with 
gallium-68 and tested in breast cancer patients with encouraging results [92-94]. 
[68Ga]Ga-ABY-002 and its indium counterpart were comparable in [18F]FDG in detecting 
soft-tissue metastases although less sensitive for bone metastasis (suggesting lower 
HER2 expression in these tissues) [94]. High kidney and liver uptake was observed for 
both radiotracers. As part of the [68Ga]Ga-ABY-025 clinical trial dosimetry was 
investigated for both the 68Ga- and 111In-radiolabelled affibodies, revealing more 
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favourable dosimetry and sensitivity for the 68Ga-based tracer. Intriguingly, lower 
uptake in non-target organs (such as liver and kidney) and improved dosimetry for 
[68Ga]Ga-ABY-025 were obtained when the affibody was labelled at lower specific 
activity, possibly due to a partial blocking of HER2 receptor in non-target organs by 
unlabelled affibody. However, since tumour uptake for the two groups was not 
investigated in the study, it is impossible to predict if this lower non-target organs 
uptake will result in an improved tumour-to-background contrast [92].  
 Different approaches for imaging with 68Ga 
2.4.1 Pretargeting strategies for antibody-based imaging 
Another way to circumvent the short half-life limitation of gallium-68 in antibody-
based imaging is pretargeting. Following this approach, the unlabelled antibody (or 
antibody fragment) is injected first and allowed to reach its receptor target; a 
radiolabelled probe is then administered, capable of binding the antibody in vivo, at 
its receptor site. Owing to its smaller size (compared to the antibody), the 
radiolabelled probe quickly clears from the blood pool, reaches its target antibody and 
radiolabels it in vivo, allowing imaging shortly after the injection of radioactivity. 
Furthermore, the faster blood clearance of the radiolabelled probe reduces the 
exposure of non-target organs to radiation and improves dosimetry. 
 Several pretargeting methods have been attempted so far for 68Ga-immunoPET, all 
characterised by the presence of a high-affinity chemical pair, able to couple in vivo 
(i.e. in very mild conditions and low concentration) and they will be described in 
further details in Chapter 5. The bispecific monoclonal antibody (bsmAb)-hapten 
couple has been the more widely used high-affinity pair for 68Ga-based pretargeting so 
far, and resulted in a few clinical trials. In 2001, a pioneering work by Schuhmacher 
and coworkers described the pretargeted imaging of breast cancer patients using 
bispecific Anti-Tag12/Anti-Ga-chelate antibodies [95]. A bispecific antibody was 
assembled, able to target both the mucin-like Tag12 receptor overexpressed in most 
adenocarcinoma and the 68Ga-HBED-CC moiety. Eighteen hours after the 
administration of the bsmAb, blockage of the anti-Ga-HBED-CC sites in the circulating 
bsmAb was performed with natGa-HBED-CC-apotransferrin followed by administration 
of 68Ga-HBED-CC and subsequent PET imaging. The results of the study highlight the 
limitation of the chosen model: relatively low bsmAb affinity for the target receptor 
resulted in low tumour uptake, while shedding of the receptors and slow clearance of 
the 68Ga-HBED-CC lead to a disappointing tumour-to-blood ratio. On the other hand, 
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the trial confirmed the feasibility of this approach and its potential once a proper 
model is established.  
The trivalent bsmAb TF2, composed of a humanised anti–histamine-succinyl-glycine 
Fab fragment and two humanised anti-CEA Fab fragments is a promising candidate for 
pretargeting strategies aimed at imaging the carcinoembryonic antigen, a slowly 
internalising receptor expressed in a variety of malignancies. Its hapten molecule 
IMP288 is a DOTA-conjugated D-Tyr-D-Lys-D-Glu-D-Lys peptide, where the ε-amino 
groups of both lysine residues are substituted with a histamine-succinyl-glycine moiety 
[96]. The high-affinity pair TF2/68Ga IMP288 has been recently employed in clinical 
trials for imaging medullary thyroid carcinoma (clinical trial identifier: NCT01730638), 
HER2 negative breast carcinoma (NCT01730612), and metastatic colorectal cancer 
(NCT02587247). The first results of the study on medullary thyroid carcinoma patients 
were published recently [97] highlighting the feasibility of this approach with good 
image contrast and a radiation exposure comparable to an [18F]FDG scan. Decreasing 
the TF2-to-IMP288 molar ratio and delaying between antibody and hapten 
administration resulted in increased 68Ga-IMP288 blood clearance, but also decreased 
tumour uptake, with the best contrast achieved using a 20-fold excess of TF2 over 
IMP288 and a delay of 30 hours between the two injections. 
2.4.2 Imaging exploiting gallium localisation properties 
Historically radionuclide imaging with gallium isotopes has been focusing on exploiting 
gallium(III) ability to localise in malignancies, inflammation and infection sites (see 
Chapter 1). This imaging approach, which focused on the SPECT isotope gallium-67, 
has now been largely replaced by [18F]FDG scans, which provide better sensitivity and 
spatial resolution and do not require long delays between radiotracer injection and 
imaging [98-101]. In the context of infection imaging, white blood cell (WBC) labelling 
has proved superior to gallium-67 [102] and is now used as a method of choice or as an 
alternative to [18F]FDG [103].  
Nonetheless, gallium-67 imaging still plays a marginal role in clinics, especially in 
developing countries that have no convenient access to cyclotrons and for some 
pathologies where no better alternatives are available. A review of the literature of 
the last decades reveals a small but established niche for gallium-67 citrate use as a 
second-choice method for imaging infections and certain type of tumours when 
[18F]FDG/WBC scans are negative or not available. Recent research and retrospective 
studies have reassessed the use of gallium-67 citrate for the imaging of different 
conditions such as acute interstitial nephritis [104], tuberculosis related pathologies 
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[105,106] and occult sepsis [107]. However, the value of these studies is limited by a 
lack of direct comparison with [18F]FDG scans. Evaluation of gallium-68 as PET 
alternative to gallium-67 has also been undertaken for those conditions whose imaging 
is compatible with the short half-life of gallium-68 and an overview of the clinically 
relevant work in this area is provided below. In particular, 68Ga-citrate has been 
investigated for several purposes.  
A recent study suggested that 68Ga-citrate can be effectively used to detect a variety 
of inflammation and infection conditions and described an optimised method for the 
synthesis and quality control of tracer according to good laboratory practice [108]. 
Nanni and coworkers evaluated the use of 68Ga-citrate for the detection of skeletal 
infection in a cohort of 31 patients, resulting in favourable dosimetry and performance 
comparable to traditional methods for the diagnosis bone infections such as MRI or 
WBC scintigraphy [109]. More recently, 68Ga-citrate application in oncological settings 
has also been revaluated in clinics, with variable results. In a 2014 study on patients 
presenting indeterminate lung lesions, 68Ga-citrate was able to detect all malignant 
lesions, but could not discriminate between these lesion and tuberculosis or other 
benign lesions [110]. In a different study, prostate cancer patients were imaged with 
68Ga-citrate, which could identify 75 % of the metastatic lesions detected via 
Computed Tomography (CT) or 99mTc-bisphosphonate bone scan [111]. The optimal 
delay time between radiotracer administration and PET scan was also variable, and 
while the authors of the first study claim deterioration of image quality at 120 min 
post gallium-68 injection, in the prostate cancer study a delay of >210 min was 
required to obtained images of an adequate quality. Ongoing clinical studies evaluating 
68Ga-citrate involve patients suffering from prostate cancer (NCT02391025), lymphoma 
(NCT02776891) and orthopaedic infections (NCT03123289). 
2.4.3 Non-targeted imaging 
68Ga-citrate as pulmonary vascular permeability agent 
Beside its potential role in imaging malignancies and infections, 68Ga-citrate has also 
been evaluated in a non-targeted way, as a pulmonary vascular permeability (PVP) 
agent in healthy volunteers and in patients suffering from acute respiratory distress 
symptoms, assuming complete gallium transchelation to transferrin in vivo [112]. When 
administered 68Ga-citrate, patients presented significantly increased vascular 
permeability compared to healthy volunteers, demonstrating the feasibility of the 
approach. Intriguingly, the calculated permeability values were higher than those 
obtained with [99mTc]Tc-albumin measurements. While the authors did not investigate 
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the origin of this phenomenon, it is possibly due to presence, in equilibrium with 
gallium-transferrin, of a small percentage of [Ga(OH)4]
- which can more easily diffuse 
through membranes. Similar results were obtained in a more recent study comparing 
68Ga-citrate/transferrin and [99mTc]Tc-albumin for evaluation of PVP in patients with 
pulmonary oedema [113]. However, neither of these methods proved able to 
distinguish between noncardiogenic and hydrostatic pulmonary oedema. 
Ventilation and perfusion measurements 
Ventilation/perfusion measurements are normally performed using 99mTc-based agents 
such as Technegas for ventilation and 99mTc-macroaggregated albumin for perfusion. 
However, the development of PET agents for these imaging procedures is warranted 
to further increase their accuracy and in the context of 99mTc shortage. Evaluation of 
gallium-68 for ventilation perfusion imaging has been undertaken by Hofman and 
coworkers in pulmonary embolism patients [114] with encouraging results, and 
confirmed by a further study by Ament, where favourable dosimetry was also 
demonstrated [115]. In both studies, gallium analogues of the 99mTc-based tracers were 
used, namely [68Ga]Ga-macroaggregated albumin and Galligas: an ultrafine dispersion 
of 68Ga-labelled carbon particles that can be inhaled by the patients to evaluate 
ventilation. The safety and dosimetry associated with Galligas use were assessed with 
encouraging results [116].  
[68Ga]Ga-EDTA 
[68Ga]Ga-EDTA has a long history in nuclear medicine, being the form in which gallium-
68 was eluted from the first generator [13]. Over the decades this tracer has been used 
for a variety of non-targeted imaging applications. [68Ga]Ga-EDTA has been used to 
measure cerebrospinal fluid flow, and changes in permeability of the blood brain 
barrier in patients suffering from brain tumours, Alzheimer’s disease or multiple 
sclerosis [117,118]. Determination of the glomerular filtration rate also represents a 
classical application of [68Ga]Ga-EDTA imaging with the first clinical evaluation 
performed in 1988 with encouraging results [119]. While, at that time different agents, 
such as [51Cr]Cr-EDTA or [99mTc]Tc-DTPA, took over renal function evaluation, clinical 
use of [68Ga]Ga-EDTA was recently reconsidered by Hofman and coworkers [120,121] 
and found superior to the other radionuclide-based techniques. 
 New directions for imaging with gallium-68 
Although this chapter focussed on the clinical translation of gallium-68 imaging agents, 
the investigation of novel target receptors and the development of novel 68Ga-based 
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radiotracers for their imaging is blossoming, driven by the diffusion of clinical grade 
68Ga generator and by the recent approval of [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-
TOC for clinical use. In this section, a brief overview of some of the most promising 
new directions for gallium-68 imaging is provided. A more exhaustive description of 
the pool of new 68Ga-agents in preclinical development can be found in Baums’s book 
“Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized 
Diagnosis and Treatment” [13] and in Velikyan’s reviews [28,122].  
2.5.1 Different biomarkers for cancer imaging 
Alongside affibodies, nanobodies and F(ab’)2 fragments, other antibody-like molecules 
are potentially interesting for the development of 68Ga-immunoPET tracers and are 
undergoing preclinical evaluation. Vascular endothelial growth factor (VEGF) receptor 
is an important marker for angiogenesis and single chain analogues of VEGF (scVEGF) 
have been conjugated with DOTA and NOTA based chelators and proved able to 
delineate VEGF expression in vivo, but suffered from high kidney uptake [123]. 
Development of novel derivatives with improved biodistribution is ongoing [124]. A 
nanobody targeting the epidermal growth factor HER1 has also been radiolabelled with 
gallium-68 upon conjugation with DFO and evaluated in tumour bearing mice showing 
good targeting capabilities, but also high kidney uptake [125]. 
Folate receptor is upregulated in variety of cancers and therefore represents an 
important target for both imaging and therapy. Several 68Ga-folate radiotracers have 
been developed in the past few years and found able to detect tumours with high 
specificity in preclinical xenograft models [126]. However, clinical translation has been 
so far delayed due to high endogenous expression of the folate receptor in the kidneys, 
which results in low tumour/kidney ratio and in concerns about kidney radiation dose.  
The G-protein coupled neurotensin receptor 1 is a potentially good target for imaging, 
being overexpressed in a variety of cancers. However, metabolic instability of 
neurotensin analogues have been delaying the research on radiotracers targeting this 
receptor. Recently, DOTA/NODAGA derivatives of peptoid-peptide hybrid neurotensin 
analogues, with improved stability, were radiolabelled with 68Ga and evaluated 
preclinically in colon cancer xenograft with promising results [127].  
Cholecystokinin-2/Gastrin receptors hold a great promise for those neuroendocrine 
tumours in which the sensitivity of SSTR is limited, such as medullary thyroid 
carcinoma. Although imaging of this receptor with 68Ga is still a relatively unexplored 
field, preclinical results by Brom using DOTA-minigastrin peptides were encouraging 
and warrant further investigation [128]. 
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Hypoxia is commonly observed in myocardial ischemia and cancer, where it correlates 
with poor response to therapy. Being able to image hypoxic areas would be therefore 
extremely important for treatment planning in these conditions. Several 68Ga-based 
radiotracers have been developed and preclinically evaluated in the last decades, 
where the hypoxia-targeting nitroimidazole moiety has been conjugated to several 
chelators such as DOTA [129,130], NOTA [131] and TRAP, with the latter being a 
multimeric derivative [132]. Although these radiotracers showed tumour targeting in 
vivo, low tumour uptake and radiotracer accumulation in several non-target organs 
(kidney, liver and notably muscle for some of the derivative) is still a major issue, 
which need to be addressed. 
2.5.2 Non-oncological targets 
The decades-long quest for an agent able to selectively imaging inflammation and 
infection has been challenging due to the multitude of factors involved in these 
processes. It is beyond the scope of this chapter to review the several 68Ga imaging 
agents that are currently under investigation for infection and inflammation imaging, 
a comprehensive review of these radiotracers was published by Velikyan earlier this 
year [133].  
Recent development of new radiotracers for the imaging of infection and inflammatory 
processes has been driven by the identification of useful biomarkers for these 
conditions. Vascular adhesion protein 1 (VAP1) is translocated from intracellular 
storage granules onto the cell surface during inflammation and osteomyelitis and 
therefore represents a promising target receptor for imaging with radiolabelled 
peptides. Preclinical evaluation of several 68Ga-based VAP1 tracers has been performed 
recently with encouraging results [134]. Distinction between inflammation and 
infection is also challenging. 68Ga-labelling of the antimicrobial peptide ubiquicidin 
resulted in tracers potentially able to discriminate between infection and 
inflammation in preclinical models [118,135]. Siderophores such as TAFC and DFO can 
also be labelled with gallium-68 and localise at the infection site responding to 
bacterial iron requirements [136]. 
Fibrosis is involved in many chronic diseases and inflammatory injuries and a non-
invasive method for the accurate and specific localisation of fibrotic lesion is key to 
their prompt treatment. Because this process involves the excessive production of 
extracellular matrix proteins such as collagen, radiotracers targeting these proteins 
represents a promising way to image fibrosis. 68Ga radiotracers based on the collagen 
targeting peptide collagelin have been developed by Velikyan and co-workers and 
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showed targeting capability in vitro as well as favourable pharmacokinetics and 
dosimetry in healthy rats [137,138]. However, no data from a fibrosis animal model 
are available so far to confirm ability of the tracers to target the fibrotic process in 
vivo. 
Gallium-68 imaging of cardiovascular diseases is also an expanding area with several 
preclinical studies ongoing. Imaging of atherosclerotic plaques is currently performed 
with [18F]FDG, which is not ideal due to its high uptake in the heart. Development of 
new 68Ga tracers for imaging atherosclerotic plaques focusses on targeting molecular 
processes important for active plaques. Fucoidan is a polysaccharide with high affinity 
for selectin-P, a protein overexpressed on the endothelium overlying active plaques. 
Although the chemical structure of fucoidan is still unknown, direct labelling with 
gallium-68 was feasible and the radiotracer demonstrated specific uptake in active 
plaques in vivo [139]. In a different study, a peptide mimetic of an apolipoprotein was 
radiolabelled with 68Ga via a DOTA chelator and found able to delineate atherosclerotic 
plaques in preclinical models, based on their lipid burden [140]. Although both 
radiotracers could delineate atherosclerotic plaques a major limitation is their slow 
blood clearance and non-specific uptake in non-target organs.  
 Gallium compounds as therapeutic agents 
The serendipitous discovery that gallium salts localise in tumour tissues and that 
gallium interactions with biological system can be treated, to a certain extent, as an 
iron mimetic (see Chapter 1), prompted the investigation on the possible use of 
gallium compounds in cancer chemotherapy. 
2.6.1 Gallium salts 
Initial investigation on the cytotoxic activity of gallium salts, with focus on gallium 
nitrate, started in the early seventies [141]. Irrespective of the anionic component, 
gallium salts showed remarkable cytotoxicity related to disruption of cellular iron 
homeostasis [142] and inhibition of ribonucleotide reductase activity, which requires 
Fe3+ as an essential cofactor [143]. To counteract iron deprivation following Ga3+ 
uptake, expression of transferrin receptors is increased, resulting in further gallium 
accumulation and finally apoptosis. In vitro experiments using 59Fe suggested that 
gallium could induce iron deprivation also by inhibition of intracellular Fe(III) release 
from FeTf by insufficient acidification in the endosomes [142]. Gallium nitrate was 
investigated in several clinical trials, which demonstrated its potency in advanced 
bladder cancer and non-Hodgkin lymphoma, without showing any myelosuppresive 
activity [144]. However, injection of gallium nitrate as a bolus results in 
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nephrotoxicity, likely due to the inability of therapeutic doses of Ga(III) to bind to 
transferrin quantitatively upon rapid administration and consequent quick renal 
excretion of gallate [145]. On the other hand, the need for long intravenous infusion 
to administer the drug without incurring in nephrotoxicity is a major drawback for its 
widespread clinical use [146]. Beside its anti-tumour activity, gallium salts were found 
to affect bone metabolism and blood level of calcium [147]. Consequently, gallium 
nitrate (Ganite) was approved by the FDA for the treatment of malignancy-associated 
hypercalcemia [146]. 
2.6.2 Gallium complexes 
Alternative gallium compounds have been developed in order to increase oral 
bioavailability of this metal. Among these, it is worth mentioning gallium maltolate 
(gallium tris(3-hydroxy-2-methyl-4H-pyran-4-onate), Figure 2.9), which exploits the 
ability of pyranone ligands to deliver M3+ metal ions to tissues [148]. With its LogP of 
0.42 and its stability towards hydrolysis, gallium maltolate greatly enhances the 
solubility and gastrointestinal absorption of gallium. This is followed by gallium 
transchelation to transferrin in circulation, which lead to increased tumour uptake and 
decreased renal toxicity compared to gallium nitrate [145]. In vitro, gallium maltolate 
displayed enhanced and faster cytotoxic activity compared to gallium nitrate and was 
effective in cell lines resistant to gallium salts treatment [149]. However, this different 
behaviour may simply be related to direct cellular uptake of the lipophilic complex 
before gallium dissociation, which is likely to happen at short time points in vitro. 
Phase I clinical trials in normal subject show no adverse event and favourable 
pharmacokinetics for gallium maltolate [145] and a preliminary investigation on a 
patient with advanced hepatocellular carcinoma provided promising results [150]. 
However, the outcomes of a phase II clinical trial (NCT00050687) were never published 




Figure 2.9. Chemical structure of maltol and crystal structure of the (tris(3-hydroxy-2-
methyl-4H-pyran-4-onate)gallium(III) complex [145]. 
Tris(8-quinolonato)gallium(III) (Figure 2.10, also known as gallium-oxine, KP46 or 
FFC11) was originally investigated as a gallium-68 platelets-labelling agent [151]. More 
recently, this gallium complex has been reconsidered as an anticancer and 
antihypercalcemic agent, able to overcome the poor oral availability of gallium salts. 
In fact, owing to the lipophilic nature of 8-hydroxyquinoline ligands this complex is 
characterised by LogP = 0.88, which should ensure adequate membrane permeability, 
facilitating intestinal absorption of the drug and the achievement of adequate plasma 
levels [152]. Discordant literature exists on the interaction of this compound with 
transferrin and other serum proteins such as albumin [153-157], casting doubts on the 
mechanism of cellular uptake (i.e. whether it is transferrin dependent or rather 
diffusion of the lipophilic complex through the cell membrane) [146,158]. Similarly, 
the intracellular targets of gallium-oxine seem to be different from those of gallium 
nitrate [159]. Compared to gallium nitrate, KP46 displayed increased potency on a 
variety of cancer cell lines and in animal tumour models [146] and was found effective 
against renal cancer in phase I/II clinical trials [160,161]. Its mechanism of action is 
far from understood and investigations have been hampered by the low solubility of 




Figure 2.10. Schematic structure of the 8-hydroxyquinoline ligand (left) and crystal 
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3 Design of novel tris(hydroxypyridinone) 
ligands and evaluation of their chemical 
properties. 
 Introduction 
The tris(hydroxypyridinone) ligand THPMe, developed by our group, has proven 
extremely successful for 68Ga radiolabelling, achieving quantitative radiochemical 
yield in mild conditions and at low ligand concentration [1]. The ease of radiolabelling 
combined with a good (> 95 %) radiochemical purity obtained without eluate pre-
processing or purification of the radiolabelled compound renders THPMe a valuable 
candidate for the development of kit-based 68Ga radiopharmaceuticals. Indeed, one 
such radiopharmaceutical (THPMe-PSMA) is now commercially available and in clinical 
use for prostate cancer scanning [2]. 
Interestingly, the outstanding chelating ability of THPMe for 68Ga binding does not 
extend to other radiometals. Our group has previously demonstrated the instability of 
89Zr-THPMe in animal models compared to 89Zr-DFO [3] and in vitro investigations using 
different radiometals such as 213Bi, 177Lu and 111In led to similar results (unpublished 
data). While the selectivity of THPMe for gallium is certainly a limitation of our chelator 
in terms of the development of theranostic agents, it can also be advantageous when 
considering contamination from adventitious metals. In particular, owing to the very 
low concentration of 68Ga3+ in the generator eluate, contamination from adventitious 
metal ions is an important caveat to 68Ga radiolabelling. Therefore, preference for Ga3+ 
over other metal ions that may be present as contaminants in the 68Ga eluate or in the 
radiolabelling equipment is a crucial feature of gallium chelators, and necessary to 
obtain radiotracers with high specific activity. Because tris(hydroxypyridinone) ligands 
were originally developed as iron chelators and the THPMe structure has been optimised 
for Fe3+ binding [4], iron is the most critical contaminant for THP-based chelators. 
Selectivity for gallium(III) over iron(III) is all the more important since iron 
contamination is ubiquitous in syringe needles, vials and other equipment employed 
for radiolabelling. 
In the last five years, bifunctional derivatives of THPMe have been conjugated with 
several peptides to obtain radiotracers that specifically target receptors overexpressed 
in various diseases, enabling in vivo 68Ga PET imaging. Conjugation of both THPMe-NCS 
and THPMe-Ph-NCS with cyclic-(RGDfK) provided an αVβ3 integrin targeting tracers 
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(Figure 3.1). These were evaluated in mice bearing U87MG glioblastoma xenografts, 
obtaining results comparable to other 68Ga-based RGD tracers, although higher liver 
uptake was observed, especially for the THPMe-Ph-NCS derivative [5]. Extension of the 
tripodal scaffold to include three THPMe units and/or three RGD peptides was also 
performed [6] to obtain THPMe-Ph-NCS-RGD3 and THP
Me
3-Ph-NCS-RGD3 (Figure 3.1). 
Unexpectedly these multimeric tracers did not show any significant improvement in 
the affinity for the αVβ3 receptor. On the other hand, they exhibited increased tumour 
accumulation (expresses as % ID/g) compared to THP-c(RGDfk), likely due to a slower 
blood clearance. For the dendritic tracer THPMe3-Ph-NCS-RGD3, increased specific 
activity was also obtained.  
 
Figure 3.1. Structures of different THPMe derivatives conjugated to RGD peptides [5], 
including the dendrimeric derivative THPMe3-Ph-NCS-RGD3 [6]. 
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A THPMe-TATE derivative was produced by conjugation of THPMe-NCS with a PEGylated 
TATE peptide H-PEG2-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH [7] (Figure 3.2). 
Evaluation of THPMe-TATE and DOTA-TATE in mice bearing AR42J xenografts showed 
comparable tumour uptake for both tracers, however a higher tumour-to-blood ratio 
was observed for the DOTA derivative. Finally, conjugation of a glutaric acid derivative 
with the PSMA moiety resulted in THPMe-PSMA (Figure 3.2) which, despite lower 
affinity for the target receptor compared to the HBED derivative PSMA11, showed 
similar results in preclinical evaluation [8] and after a successful phase I trial [2] is 
now undergoing phase II multicentre clinical trials.  
 
Figure 3.2. Structure of THPMe derivatives of TATE and PSMA peptides [7,8] THPMe-
PSMA is currently undergoing phase II clinical trials. 
Notably, different THPMe-based tracers have shown different affinity for their target 
receptors and variable capability to provide good tumour to non-target organ ratio. 
This can be partially attributed to the different linkers that have been used for the 
different radiotracers, but also suggests that imaging of different targets may benefit 
from chelators with different properties even when the targeting vector is well-
established. The radiometallic complex itself is not simply a passive spectator of the 
peptide-receptor interaction, but plays an important role in determining the affinity 
of a radiotracer for its target receptors and the pharmacokinetics. This has been 
exquisitely illustrated by Maecke and co-workers, who compared SSTR2 
agonists/antagonists attached to different chelators and radiometals (or no radiometal 
at all) in their affinity for SSTR2 receptors [9-11]. 
Based on this consideration, it is important to optimise a chelator system for different 
radiometals/imaging applications. In the case of THP derivatives, this includes 
modification of the linker, of the tripodal scaffold or of the hydroxypyridinone units, 
to optimise target affinity, pharmacokinetics and Ga3+ affinity and selectivity. While 
several linkers for THP have been developed, optimisation of the tripodal structures 
and of the hydroxypyridinone unit has so far been neglected. In this chapter, the 
synthesis of a new tris(hydroxypyridinone) chelator THPH is described where the 
hydroxypyridinone unit has been modified to include a N1-H group in place of the N1-
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CH3 group. The benzylated tris(hydroxypyranone) BnTHPO is also described as a 
promising key intermediate in the synthesis of a library of THP and THPO chelators 




 Materials and methods 
3.2.1 Equipment and consumables 
Chemicals were obtained from Sigma Aldrich, unless otherwise specified, and used 
without further purification.   
1H, 13C and 71Ga NMR spectra were acquired on Bruker Advance 400 MHz spectrometers 
(Bruker, Germany) equipped with either a 5 mm QNP probe or a 5 mm BBO probe at 
298 K. Additional 1H NMR spectra were acquired on a Bruker Advance 700 MHz 
spectrometer (Bruker, Germany) equipped with a 5 mm QNP probe. Chemical shifts 
are referenced to the appropriate solvent peak. Positive ion mode mass spectra were 
recorded using an Agilent 6510 QTOF spectrometer. Analytical reverse-phase LC-MS 
were acquired on a Thermo Scientific Exactive Orbitrap Mass Spectrometer coupled to 
a Thermo Scientific Accela Pump with CTC Autosampler, using a ThermoFisher HyperSil 
GOLD column (2.1 x 150 mm, 5 m) with a 0.2 mL min-1 flow rate. Data were acquired 
and reference mass-corrected via a dual-spray electrospray ionisation source, using 
the factory-defined calibration procedure.  
Semi-preparative High-performance liquid chromatography (HPLC) was carried out 
using an Agilent Eclipse XDB-C18 column (9.4 x 250 mm, 5 μm) with a 3 mL/min flow 
rate and UV detection at 214 nm on an Agilent 1200 LC system. Mobile phase A 
contained water with 0.1 % trifluoracetic acid (TFA), mobile phase B contained 
acetonitrile with 0.1 % TFA. For method 1, concentration of B increased from 0 to 
100 % at a rate of 1 %/min. For method 2, concentration of B increased from 20 % to 
100 % in 100 min. Analytical reverse-phase HPLC was performed on the same system 
using an Agilent Eclipse XDB-C18 column (4.6 x 150 mm, 5 μm) with a 1 mL/min flow 
rate and UV detection at 214 or 254 nM coupled to a LabLogic Flow-Count detector 
with a sodium iodide probe (B-FC-3200). For methods 3 and 4, UV detection was set 
at 254 nm and isocratic gradient were used with 10 % B and 15 % B, respectively. For 
methods 5 and 6 UV detection was set at 214 nm and gradients included 5 min of 
equilibration at 0 % B at the start of the run. For method 5 concentration of B 
increased from 0 % (at 5 min) to 45 % (at 15 min) and subsequently decreased to 0 (at 
20 min). For method 6 % B increased from 0 % (at 5 min) to 75 % (15 min) and back to 
0 % (20 min). Size-exclusion chromatography was conducted using a BioSep SEC-s2000 
column (145 Å, 300 x 7.8 mm, 5 μm) with a flow rate of 1 mL/min and the mobile 
phase was PBS or PBS + 50 mM EDTA.  
68Ga was obtained from an Eckert & Ziegler 68Ge/68Ga generator that was eluted with 
high-purity 0.1 M HCl (Fluka). 67Ga-chloride (0.1 M HCl) was obtained by Nordion. 
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Instant thin layer chromatography strips (iTLC-SG, Varian Medical Systems) were run 
in two different mobile phases (mobile phase 1: 0.1 M citrate pH 5, mobile phase 2: 
50:50 ammonium acetate (2 M):methanol) and visualised using a Cyclone Plus Phosphor 
Imager (Perkin Elmer) and a Raytest Rita-Star TLC scanner. 
3.2.2 Synthesis 
Compound 1 (2-hydroxymethyl-3-benzyloxy-6-methyl-pyran-4(1H)-one, Figure 3.3) 
and the tripodal acid TA (4-acetamido-4-(2-carboxyethyl)heptanedioic acid, Figure 
3.3) were synthesised following established procedures [4,12]. In particular, 
compound 1 was synthesised from Kojic acid (Alfa Aesar) in four steps with an overall 
yield of 16 %. TA was synthesised in two steps from di-tert-butyl 4-Amino-4-[2-(tert-
butoxycarbonyl)ethyl]-heptanedioate available in the laboratory with an overall yield 
of 35 %. 
 
Figure 3.3. Structures of the synthetic precursors 2-hydroxymethyl-3-benzyloxy-6-
methyl-pyran-4(1H)-one (1) and 4-acetamido-4-(2-carboxyethyl)heptanedioic acid (2). 
A detailed synthetic procedure is reported below for the novel compounds, along with 
their chemical structures and characterisation data. High resolution ESI-MS, 1H NMR 
and 13C NMR were performed for all new compounds to demonstrate their identity and 
purity. For each compound, all signals above background are listed. 
Synthesis of the tris(hydroxypyranone) derivative THPO was performed by the intern 
Calum Foley under my day-to-day supervision (supervisor: Dr Ma). 
Compound 2 (3-benzyloxy-2-hydroxymethyl-6-methylpyridin-4(1H)-one) 
 
Two different procedures were used for the synthesis of this compound, the first 
involving protection of the C2-CH2-OH hydroxyl functionality, the second without it. 
Route A: to a solution of 1 (0.245g, 1 mmol) in 1 mL dichloromethane, 3,4-dihydro-
2H-pyran (185 μL , 2 mmol) and p-toluensulfonic acid monohydrate (6 mg, 0.1 mmol) 
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were added while stirring at room temperature. After 3 hours, the reaction mixture 
was washed with 5 % aqueous sodium carbonate (2 x 5 mL) and water (2 x 5 mL). The 
organic layer was then dried over anhydrous sodium sulfate, evaporated to give a 
yellow oil which was re-dissolved in 1 mL of ethanol/1 mL of 25 % aqueous ammonia 
solution (13 mmol). The reaction mixture was sealed in a thick-walled vial and stirred 
at 70 °C overnight. After removal of the solvent, the residue was re-dissolved in 5 mL 
ethanol. 1 mL of 2M hydrochloric acid was added and the mixture refluxed for 4 hours, 
prior to rotary evaporation and addition of 10 mL of water to the brown residue. 
Washes with diethyl ether (2 x 5 mL) were followed by adjustment of the aqueous 
phase pH to 11 with a concentrated NaOH solution and addition of NaCl. The aqueous 
phase was then extracted with ethyl acetate (4 x 15 mL), dried over anhydrous sodium 
sulfate, and evaporated to give a white solid (0.131 g, 53.5 % yield).  
Route B: Compound 1 (1.010 g, 4 mmol) was dissolved in 5 mL of ethanol and sealed 
in a thick-walled glass vial containing 20 mL of 25 % aqueous ammonia solution. The 
mixture was stirred at 75°C overnight. Addition of concentrated HCl to the mixture to 
reach neutral pH resulted in the precipitation of white crystals (0.609 g, 60.6 % yield), 
which were collected by filtration and washed with cold water and diethyl ether. 
ESI-MS (m/z): 246.12 [M+H]+, calculated: 246.11 for C14H15NO3 + H
+. 
1H NMR (methanol-d4, 400 MHz) δ: 2.33 (s, 3H, C
6-CH3), 4.34 (d, 2H, C
2-CH2-OH), 5.08 
(s, 2H, C3-O-CH2-Ph), 6.33 (s, 1H, C
5-H in pyridinone), 7.35 (m, 5H, C3-O-CH2-Ph). 




Ph) 117.1 (C5-H in pyridinone), 128.0 (o-CH in benzyl), 129.4 (p-CH in benzyl), 130.2 
(m-CH in benzyl), 138.6 (i-C-CH2 in benzyl), 143.0 (C
2 in pyridinone), 144.7 (C3 in 
pyridinone), 147.8 (C6 in pyridinone), 176.0 (C4 in pyridinone). 
Compound 3 (3-benzyloxy-6-methyl-2-phthalimidomethylpyran-4(1H)-one) 
 
A solution of 1 (1.05 g, 4.0 mmol), triphenylphosphine (1.395 g, 8 mmol) and 
phthalimide (1.181 g, 8 mmol) in 20 mL dry tetrahydrofuran under nitrogen was cooled 
to 0 °C and diethyl azodicarboxylate (2 mL, 8 mmol) was added dropwise. The mixture 
was left stirring overnight, then methanol was added to quench excess diethyl 
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azodicarboxylate prior to solvent removal by rotary evaporation. The white residue 
was recrystallised from methanol affording 1.157 g of white crystals (72.3 % yield).  
ESI-MS (m/z): 376.11 [M+H]+, calculated: 376.12 for C22H17NO5 + H
+. 
1H NMR (DMSO-d6, 400 MHz) δ: 2.14 (s, 3H, C
6-CH3), 4.73 (s, 2H, C
2-CH2-N), 5.10 (s, 2H, 
C3-O-CH2-Ph), 6.26 (s, 1H, C
5-H in pyranone), 7.40 (m, 5H, C3-O-CH2-Ph), 7.89 (m, 4H, 
phthalimide). 
13C NMR (DMSO-d6, 100 MHz) δ: 19.0 (C6-CH3), 34.4 (C2-CH2-N), 72.9 (C3-O-CH2-Ph), 
114.3 (C5-H in pyranone), 123.4 (C7-H and C4-H in phthalimide), 128.2 (o-CH in 
benzyl), 128.4 (p-CH in benzyl), 128.5 (m-CH in benzyl), 131.4 (C5-H and C6-H in 
phthalimide), 134.7 (C3a and C7a in phthalimide), 136.8 (i-C-CH2 in benzyl), 142.6 
(C2 in pyranone), 153.9 (C3 in pyranone), 165.1 (C6 in pyranone) 167.2 (C=O in 
phthalimide), 174.6 (C4 pyranone). 
Compound 4, BnHPH (2-aminomethyl-3-benzyloxy-6-methylpyridin-4(1H)-
one) 
 
Route A: 3 (264 mg, 0.7 mmol) was dissolved in 6 mL of ethanol under moderate 
heating in a thick-walled glass vial and allowed to cool to room temperature, 
whereupon 24 mL of 25 % aqueous ammonia were added, the vial sealed and heated 
at 75 °C under stirring overnight. ESI-MS analysis of the mixture confirmed product 
identity ([M+H]+ = 245 m/z). However after solvent removal under vacuum, ESI-MS of 
the mixture of the brown residue revealed a new principal species ([M+H]+ = 393 m/z) 
identified as the by-product in Scheme 3.4. 
Route B: 30 mL of a 7 M methanolic ammonia solution were added to a thick-walled 
glass vial containing 3 (500 mg, 1.3 mmol). The vial was sealed and heated overnight 
at 75 °C under stirring. ESI-MS analysis of the mixture confirmed presence of the 
phtalimido-protected pyridinone ([M+H]+ = 375, Scheme 3.4) a as well as some product 
4 ([M+H]+= 245). 0.5 mL of aqueous hydrazine was added to the reaction mixture and 
the solution heated at reflux for 3 hours. ESI-MS of the reaction mixture revealed the 
presence of the desired product ([M+H]+ = 245). Aqueous hydrazine (55 %, 0.2 mL) was 
then added to the reaction mixture and the solution heated at reflux for 3 hours. After 
removal of the solvent by rotary evaporation the brown residue was purified by silica-
gel chromatography (dry loading, mobile phase: CH2Cl2:MeOH = 80:20) to afford 317 
mg of pure product (45 % yield). Alternatively, reverse-phase solid phase extraction 
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(SPE) was performed using C18 cartridges (mobile phase: from 0 % to 20 % MeCN + 0.1 % 
TFA in H2O + 0.1 % TFA) and the purified product re-dissolved in an 25 % aqueous 
solution of NH3 and freeze-dried to obtain the free amine (47 % yield). 
ESI-MS (m/z): 245.13 [M+H]+, calculated: 245.13 for C14H16N2O2 + H
+. 
1H NMR (DMSO-d6, 400 MHz) δ: 2.20 (s, 3H, C
6-CH3), 3.52 (s, 2H, C
2-CH2-NH2), 4.49 
(broad, 2H, C2-CH2-NH2), 5.04 (s, 2H, C
3-O-CH2-Ph), 6.02 (s, 1H, C
5-H in pyridinone), 
7.35 (m, 5H, C3-O-CH2-Ph), 8.33 (s, 1H, N
1-H in pyridinone). 
1H NMR (methanol-d4, 400 MHz) δ: 2.33 (s, 3H, C
6-CH3), 3.60 (s, 2H, C
2-CH2-NH2), 5.14 
(s, 2H, C3-O-CH2-Ph), 6.39 (s, 1H, C
5-H in pyridinone), 7.36 (m, 5H, C3-O-CH2-Ph).  
13C NMR (methanol-d4, 100 MHz) δ: 19.4 (C
6-CH3), 38.8 (C
2-CH2- NH2), 74.6 (C
3-O-CH2-
Ph) 116.7 (C5-H in pyridinone), 129.6 (o-CH in benzyl), 129.6 (p-CH in benzyl), 130.4 
(m-CH in benzyl), 138.5 (i-C-CH2 in benzyl) 143.6 (C
2 in pyridinone), 143.8 (C3 in 
pyridinone), 149.0 (C6 in pyridinone), 174.2 (C4 in pyridinone). 





The tripodal acid TA (20 mg, 0.07 mmol), hydroxybenzotriazole (HOBT, 32.7 mg, 0.21 
mmol) and dicyclohexylcarbodiimide (DCC, 44 mg, 0.21 mmol) were individually 
dissolved in 500 µL of DMF and then combined under stirring. BnHPH (86 mg, 0.35 
mmol) was also dissolved in 500 µL of DMF and added to the mixture which was then 
stirred at 50 °C for 48 h. Formation of the product over time was monitored via LC-MS 
([M+H]+= 968 m/z). DMF was removed under high-vacuum and the product purified by 
silica gel chromatography (eluent CH3OH:CHCl3 = 20:80 followed by CH3OH:CHCl3:40 % 
aqueous NH3 = 20:80:2) to obtain 37 mg of product (48 % yield).  
Observation: when the same reaction was performed in a microwave reactor (30 min, 
120 °C) using HATU (80 mg, 0.21 mmol) and N,N-Diisopropylethylamine (DIPEA, 36 µL, 
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0.21 mmol) as coupling agents, a side product at [M+H]+ = 724 m/z was found (Scheme 
3.7). 
ESI-MS (m/z): 968.45 [M+H]+, 990.44 [M+Na]+, calculated: 968.46 for C54H61N7O10 + H
+. 
1H NMR (methanol-d4, 400 MHz) δ: 1.86 (s, 3H, CH3-CO-NH-tripod), 1.88 (m, 6H, CH2-
CH2-CO-NH-CH2-pyridinone), 2.09 (m, 6H, CH2-CH2-CO-NH-CH2-pyridinone), 2.28 (s, 
9H, C6-CH3), 4.10 (s, 6H, CO-NH-CH2-pyridinone), 5.11 (s, 6H, C
3-O-CH2-Ph), 6.31 (s, 
3H, C5-H in pyridinone), 7.35 (m, 15H, C3-O-CH2-Ph). 
13C NMR (methanol-d4, 100 MHz) δ: 18.8 (C
6-CH3), 23.6 (CH3-CO-NH-tripod), 30.8 (CH2-
CH2-CO-NH-CH2-pyridinone), 31.0 (CH2-CH2-CO-NH-CH2-pyridinone), 37.7 (CH2-CH2-CO-
NH-CH2-pyridinone), 58.9 (NHC-tripod), 74.5 (C
3-O-CH2-Ph) 117.3 (C
5-H in pyridinone), 
129.5 (p-CH in benzyl), 130.2 (m-CH in benzyl), 138.5 (i-C-CH2 in benzyl), 141.4 (C
2 in 
pyridinone), 144.8 (C3 in pyridinone), 148.0 (C6 in pyridinone), 173.0 (C4 in pyridinone), 
176.1 (CH2-CH2-CO-NH-CH2-pyridinone). 





17 mg of BnTHPH (0.018 mmol) were dissolved in the minimum amount of methanol 
and then diluted to 1 mL with dichloromethane. An excess of BCl3 (3 mL of a 1 M 
solution in dichloromethane) was added under inert N2 atmosphere. After 2 hours, the 
vial was placed on ice and an excess of methanol was added to quench excess BCl3. 
Solvent was removed by rotary evaporation. The residue was then re-dissolved in 
methanol and precipitation of the product was achieved by addition of cold ether. 
THPH (hydrochloride salt, 15.6 mg) were obtained (90 % yield).  
Observation: BCl3 is extremely toxic and corrosive. To safely add it to the reaction 
mixture, a PTFE cannula (Cole-Parmer) was used to connect the BCl3 solution and the 
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reaction vessel, while both were closed and under nitrogen and the solution 
transferred exploiting a difference in pressure created by adding a vent needle to the 
reaction vessel. 
ESI-MS (m/z): 698.32 [M+H]+, 349.67 [M+2H]2+, 233.44 [M+3H]3+, calculated: 698.31 for 
C33H43N7O10+H
+. 
1H NMR (D2O, 400 MHz) δ: 1.85 (s, 3H, CH3-CO-NH-tripod), 1.87 (m, 6H, CH2-CH2-CO-
NH-CH2-pyridinone), 2.17 (m, 6H, CH2-CH2-CO-NH-CH2-pyridinone), 2.47 (s, 9H, C
6-
CH3), 4.44 (d, 6H, CO-NH-CH2-pyridinone), 6.93 (s, 3H, C
5-H in pyridinone). 
13C NMR (D2O, 100 MHz) δ: 17.9 (C
6-CH3), 22.6 (CH3-CO-NH-tripod), 28.9 (CH2-CH2-CO-
NH-CH2-pyridinone), 29.2 (CH2-CH2-CO-NH-CH2-pyridinone), 36.6 (CH2-CH2-CO-NH-CH2-
pyridinone), 58.0 (NHC-tripod), 111.7 (C5-H in pyridinone), 136.4 (C2 in pyridinone), 
140.6 (C3 in pyridinone), 146.7 (C6 in pyridinone), 160.9 (C4 in pyridinone), 173.3 (CH3-
CO-NH-tripod), 176.4 (CH2-CH2-CO-NH-CH2-pyridinone). 
HPLC: 10 min, 45 s (method 5, Figure 3.4), 3 min 26 s (method 3), only one peak was 
visible for both HPLC methods utilised thus confirming purity of the product. 
.  


























Compound 7, BnHPO (2-aminomethyl-3-benzyloxy-6-methylpyran-4(1H)-
one) 
 
3 (499 mg, 1.33 mmol) was dissolved in 5 mL of ethanol and heated at reflux upon 
addition of aqueous hydrazine (1.5 mL, 5.5 % aqueous solution). After 3 hours, the pH 
was adjusted to 1 with concentrated HCl (37 %) and the flask cooled to 0 °C. 
Phthalhydrazide precipitate was then filtered and the solution evaporated to dryness. 
The resulting residue was redissolved in water (2 mL) and the pH adjusted to 10 using 
concentrated NaOH (10 M). The product was then extracted with dichloromethane (4 
x 2mL) and the solvent removed by rotary evaporation. The crude product was purified 
by silica-gel chromatography (dry loading, CH2Cl2:MeOH = 90:10) to obtain 90.0 mg of 
product (28 % yield). 
ESI-MS (m/z): 246.11 [M+H]+, calculated: 246.11 for C14H15NO3 + H
+. 
1H NMR (methanol-d4, 400 MHz) δ: 2.31 (s, 3H, C
6-CH3), 3.51 (s, 2H, C
2-CH2-NH2), 5.09 
(s, 2H, C3-O-CH2-Ph), 6.27 (s, 1H, C
5-H in pyranone), 7.37 (m, 5H, C3-O-CH2-Ph).  
13C NMR (methanol-d4, 400 MHz) δ: 19.5 (C
6-CH3), 39.3(C
2-CH2- NH2), 74.9 (C
3-O-CH2-
Ph) 115.0 (C5-H in pyridinone), 129.6 (o-CH in benzyl), 129.7 (p-CH in benzyl), 130.4 
(m-CH in benzyl), 137.9 (i-C-CH2 in benzyl) 142.3 (C
2 in pyranone), 162.9 (C3 in 
pyranone), 167.9 (C6 in pyranone), 178.4 (C4 in pyranone). 







TA (14 mg, 0.049 mmol), DIPEA (25.6 µL, 0.15 mmol) and HATU (55.74 mg, 0.15 mmol) 
were dissolved in the minimum volume of dimethylacetamide (DMA), combined while 
stirring and left at room temperature for 1 hour. A DMA solution of BnHPO (52 mg, 
0.16 mmol) was then added and the mixture left stirring for 72 hours. The DMA was 
removed under high vacuum and the product was purified using semi-preparative HPLC 
(method 1) to obtain 34.7 mg of isolated product (73.1 % yield).  
ESI-MS (m/z): 486.21 [M+2H]2+, 971.41 [M+H]
+, 993.38 [M+Na]+, calculated: 971.41 for 
C54H58N4O13 + H
+. 
1H NMR (methanol-d4, 400 MHz) δ: 1.91 (s, 3H, CH3-CONH-tripod), 1.96 (m, 6H, CH2-
CH2-CONH-CH2-pyranone), 2.17 (m, 6H, CH2-CH2-CONH-CH2-pyranone), 2.29 (s, 9H, C
6-
CH3), 4.23 (s, 6H, CONH-CH2-pyranone), 5.12 (s, 6H, C
3-O-CH2-Ph), 6.28 (s broad, 3H, 
C5-H in pyranone), 7.35 (m, 15H, C3-O-CH2-Ph). 
13C NMR (methanol-d4, 100 MHz) δ: 19.5 (C
6-CH3), 23.5 (CH3-CO-NH-tripod), 30.9 (CH2-
CH2-CO-NH-CH2-pyranone), 31.2 (CH2-CH2-CO-NH-CH2-pyranone), 37.3 (CH2-CH2-CO-
NH-CH2-pyranone), 58.9 (NHC-tripod), 75.0 (C
3-O-CH2-Ph) 115.2 (C
5-H in pyridinone), 
129.6 (p-CH in benzyl), 130.2 (m-CH in benzyl), 138.1 (i-C-CH2 in benzyl), 143.7 (C
2 in 
pyranone), 159.1 (C3 in pyranone), 167.9 (C6 in pyranone), 172.9 (C4 in pyranone), 
175.7 (CH3-CO 169.4), 178.2 (CH2-CH2-CO-NH-CH2-pyridinone). 





BnTHPO (6.65 mg, 0.0069 mmol) was dissolved in 7:1 = dichloromethane:MeOH (800 
μL), BCl3 was added via a cannula under N2 atmosphere. After 2 hours, the vial was 
placed on ice, reaction was quenched with MeOH and solution evaporated under 
reduced pressure. The residue was dissolved in 60:40 = water:acetonitrile and purified 
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by preparative HPLC (method 1). 5.6 mg of TFA salt of THPO was recovered in 78 % 
yield. 
ESI-MS (m/z): 702.26 [M+H]+, 723.24 [M+Na]+, 351.13 [M+2H]2+. calculated: 701.27 for 
C33H41N4O13 + H
+. 
1H NMR (methanol-d4, 400 MHz) δ: 1.91 (s, 3H, CH3-CO-NH-tripod), 1.99 (t, 6H, CH2-
CH2-CO-NH-CH2-pyranone), 2.22 (t, 6H, CH2-CH2-CO-NH-CH2-pyranone), 2.30 (s, 9H, C
6-
CH3), 4.40 (d, 6H, CO-NH-CH2-pyranone), 6.24 (s, 3H, C
5-H in pyranone). 
13C NMR (methanol-d4, 100 MHz) δ: 19.7 (C
6-CH3), 23.5 (CH3-CO-NH-tripod), 31.0 (CH2-
CH2-CO-NH-CH2-pyranone), 31.3 (CH2-CH2-CO-NH-CH2-pyranone), 37.3 (CH2-CH2-CO-
NH-CH2-pyranone), 59.0 (NHC-tripod), 112.3 (C
5-H in pyranone), 143.5 (C2 in 
pyranone), 148.9 (C3 in pyranone), 167.5 (C6 in pyranone), 173.0 (C4 in pyranone), 
176.1 (CH3-CO-NH-tripod), 176.4 (CH2-CH2-CO-NH-CH2-pyranone). 
HPLC: Retention time 11 min, 10 s (method 6, Figure 3.5), 4 min 43 s (method 4), only 
one peak above background was visible for both HPLC methods utilised thus confirming 
purity of the product. 
 
Figure 3.5. UV Chromatogram of THPO (9) using RP-HPLC method 3. 
BnTHPO to BnTHPH conversion 
11 mL of 7 M ammonia in MeOH were added to 22.4 mg of BnTHPO (0.023 mmol) and 
the mixture stirred at 75 °C under pressure. Monitoring of the reaction via LC-MS 
allowed us to determine that the reaction was complete after 72 hours (mobile phase: 
A = H2O + 0.1 % formic acid, B = acetonitrile + 0.1 % formic acid; gradient: 0-5 min 
100 % A, 5-55 min from 100 % A to 100 % B, flow rate 0.2 mL/min, mass range 900-1100 
m/z). The solvent was then removed under reduced pressure and the residue purified 
by preparative HPLC (method 2). 10.88 mg of product was obtained (49 % yield). Purity 





For all the radiolabelling experiments, elution of an E&Z generator was performed with 
5 mL of pure HCl 0.1 M (Fluka), the eluate was fractionated in five 1 mL fractions and 
their activity measured by a Capintec radionuclide dose calibrator. 100 µL of the 
highest activity fraction (15-20 MBq) were added to 100 µL of the ligand (concentration 
range 200-2 μM) in ammonium acetate 0.5 M. Radiolabelling of THPH and THPMe at 0.1M 
was performed using a different E&Z generator, eluted with clinical grade 0.1M HCl 
(E&Z). Verification of the radiolabelling was carried out after 5 min by reverse-phase 
HPLC (method 3 for THPH, method 4 for THPO) and iTLC-SG (mobile phase 1 and 2).  
Formation of the natural gallium complex 
natGa complexes of THPH and THPO were prepared by addition of an aqueous solution 
of Ga(NO3)3 (5 µL, 2 mg/mL, excess) to a solution of the ligands (50 µL, 150 µM) in 
ammonium acetate 0.2 M. Reverse-phase HPLC was carried out after 5 min (using the 
same methods as above) to confirm complex formation. 
[Ga(THPH)] ESI-MS (m/z): 764.22 [M+H]+, 698.32 [M-Ga+3H]+, 382.61 [M+2H]2+, 349.66 
[M-Ga+4H]2+. calcd: 764.22 for C33H40N7O10Ga + H
+. No peaks assignable to stoichiometry 
other than 1:1 were visible. 
NMR characterisation of [Ga(THPH)] complex 
600 μL of a 2 mM solution of THPH in H2O + 10 % D2O was mixed with 12 μL of a 50 mM 
solution of Ga(NO3)3 in the same solvent system, to obtain a Ga
3+/THPH ratio of ratio 
of ≈ 1:2 (pH ≈ 2.5). 1H NMR and 71Ga NMR spectra were acquired on a 400 MHz Bruker 
spectrometer. Further addition of Ga(NO3)3 to obtain a Ga
3+/THPH ratio of ratio of ≈ 
1:1 was followed by 1H NMR and 71Ga NMR analysis of the new sample. Attempts to 
neutralise the pH resulted in sample precipitation. 
300 μL of a 2 mM solution of NOTA (CheMatech) in H2O + 10 % D2O and 300 μL of 
Ga(NO3)3 2 mM in the same solvent, were mixed (pH ≈ 2.5) and a 
71Ga NMR spectrum of 
the mixture acquired as a comparison.  
1H NMR spectrum of THPH and 71Ga spectrum of Ga(NO3)3 (2 mM in H2O + 10 % D2O, pH 
2), were also acquired. The 71Ga NMR spectrum of the Ga(NO3)3 solution showed a single 
peak attributable to the hexaaqua ion species [Ga(H2O)6]
3+, which was fixed at 0 ppm 
as a reference. 
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3.2.4 Affinity constants measurements by spectrophotometric 
titration 
Spectrometric measurements of affinity constants were performed as a collaboration 
with Dr Yu-Lin Chen and Prof. Robert C. Hider (KCL).  
The automated titration system employed in this study, consisted of an Metrohm 765 
Dosimat autoburette, a Mettler Toledo MP230 pH meter with SENTEK pH electrode 
(P11), and an HP 8453 UV-visible spectrophotometer with a Hellem quartz flow 
cuvette. Circulation of the test solution between the titration chamber and the cuvette 
was controlled using Gilson Mini-plus #3 pump (speed capability: 20 mL/min). For pKa 
determinations, a cuvette path length of 10 mm was used, and for metal complex 
stability constant determinations, a cuvette path length of 50 mm was used. Analytical 
grade reagent materials were used in the preparation of all solutions. A potassium 
chloride electrolyte solution (0.1 M) was used to maintain the ionic strength. 
Temperature of the test solutions was maintained constant in a thermostatic jacketed 
titration vessel at 25 °C (± 0.1 °C) using a Fisherbrand Isotemp water bath. Vigorous 
stirring of the test solution was maintained during all the experiments.  
Calibration of the pH electrodes was performed by titration of a volumetric standard 
HCl (0.1 M) in KCl (0.1 M) with KOH (0.1 M) under an argon gas atmosphere (calibration 
data were analysed using the software GLEE [33]). The automated titration adopted 
the following strategy: the pH of a solution was increased by 0.1 pH unit by the addition 
of potassium hydroxide solution (0.1 M) from the autoburette. The pH readings were 
judged to be stable if their values varied by less than 0.01 pH unit after a set incubation 
period. For pKa determinations, an incubation period of 1.5 min was adopted; for 
metal stability constant determinations, an incubation period of 3 min was adopted. 
The cycle was repeated until the defined end point pH value was achieved. All the 
titration data were analysed with the HypSpec2014 program [13,14] 
(http://www.hyperquad.co.uk/). If recorded pH values were higher than 11.3 (outside 
the pH range in which electrode measurements are considered accurate), the values 
were neglected and re-calculated from the added KOH quantity (using “no pH” and 
“relative weighting scheme” functions of the HypSpec2014 program). The associated 
hydrolysis constants used in the analysis were collected from Martell’s Critical Stability 
Constants [15]. The metal affinity of compounds in this study was determined in 
competition with the metal hydrolysis species in a solution at a high pH (titrated up to 
pH 12.5). The speciation plot was calculated with the HYSS program [16].  
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3.2.5 Lipophilicity determination 
Radiolabelling of the chelators THPMe, THPH and THPO (200 μM in ammonium acetate 
0.5 M) was performed as described above and verified by means of iTLC-SG. 10 μL of 
each radiolabelling mixture were then added to vials containing a pre-equilibrated 
mixture of octanol/water = 500 μL/490 μL (for LogP measurement) or octanol/PBS = 
500 μL/490 μL (for LogD7.4 measurement), vortexed and then shaken for 30 min before 
separation of the two phases by centrifugation (2000 RCF, 3 min). The activity present 
in aliquots of each phase (20 μL aqueous phase, 100 μL octanol phase) was measured 
in the gamma-counter and corrected for the different volumes considered. Each 
experiment was repeated 4 times. 
3.2.6 Metal competition for THP binding 
Standard ICP-MS solutions of gallium (Sigma Aldrich) and iron (Alfa Aesar) in nitric acid 
were diluted to a final concentration of 2250 μM and 225 μM in 0.1 M nitric acid (Fluka 
analytical). 20 μL of the 225 μM gallium solution were mixed with 20 μL of the iron 
solution (225 or 2250 μM Fe, 0.1 M nitric acid as a control) and 20 μL of 68Ga eluate 
were added (Ga3+ concentration in the eluate is ≈ 2nM and was considered negligible). 
440 µL of the relevant THP ligand (11.3 μM in 0.5 M ammonium acetate buffer) were 
added to the radiolabelling mixture (final concentration: [THP] = 10 μM, [Ga3+] ≈ 9 μM, 
[Fe3+] ≈ 0, 9 or 90 μM). The radiochemical yield at different time points was measured 
by iTLC-SG (mobile phase 2). Statistical analysis of the data at different time points 
(unpaired t-test between no Fe and 1 eq. Fe group) was performed. 
3.2.7 Ligand competition for 68Ga3+ binding 
This competition experiment was performed by the Master’s degree student Yifu Wang 
under my supervision. Data analysis was performed entirely by me. 
A solution of THPMe and THPH, each 2 mM in D2O was diluted in aqueous ammonium 
acetate (0.5 M) to a 100 μM solution in each of the ligands. After NMR analysis had 
confirmed equal concentration of the two compounds, 50 μL of the mixture were mixed 
with an equal volume of 68Ga eluate. Verification of completed radiolabelling was 
carried out by iTLC-SG (mobile phase 2). Percentage of activity associated with each 
compound was measured by iTLC-SG (mobile phase 1) at different time points. 
3.2.8 Serum stability of [67Ga(THPH)] 
50 μL (15 MBq) of 67Ga-chloride, obtained from Nordion (Canada), were mixed with 50 
μL of THPH (100 μM) in 0.5 M ammonium acetate. Stability of the compound in serum 
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was measured using size-exclusion HPLC (mobile phase: PBS + 50 mM EDTA trisodium 
salt, 1 ml/min, 25 min). EDTA was added to the mobile phase to ensure complete 
elution of unchelated/non-protein-bound gallium and therefore quantitative 
measurements of radiochemical yield. Retention times for [67Ga(THPH)] (15.5 min) and 
67Ga-chloride (12.0 min, corresponding to [67Ga(EDTA)] complex) were measured 
before incubation with serum. 60 μL of each solution were then added to 600 μL of 
male, AB human serum (Sigma) and incubated at 37 °C. Size-exclusion 
radiochromatography of both mixtures was performed at 1 hour, 1 day and 8 days of 
incubation. 
3.2.9 In vivo biodistribution 
Male SCID/beige mice (7 months old, Charles River) were used for the animal studies 
based on the availability of these mice at the time of the experiment. The choice of 
this strain is particularly relevant for future studies in a xenograft model, which are 
likely to be performed using the same strain of mice. 
Dynamic PET scanning was performed using a nanoScan® PET/CT (Mediso Medical 
Imaging Systems) [17] using the following parameters: 
 PET: 1:5 coincidence, 5 ns time window, 400-600 keV energy window. 
 CT : 180 projection, 45 kVp. 
Respiration rate and bed temperature were monitored throughout all scans. PET/CT 
datasets were reconstructed using the Monte-Carlo based full 3D iterative algorithm 
Tera-Tomo (Mediso Medical Imaging Systems) [18]. All reconstructed datasets were 
analysed using VivoQuant 1.21 software (inviCRO). 
Mice were anesthetized with isoflurane (O2 flow rate of 1.0-1.5 L/min and isoflurane 
levels of 2-2.5 %), cannulated at the tail vein using a catheter (25 μL volume) and a CT 
scan was performed. Subsequently, a PET scan was started and the radiotracer 
injected via a tail vein.  
A 37 g mouse was injected with 307 μL of a [68Ga(THPH)] solution (5 μM, 6.59 MBq) and 
imaged for 1 hour to verify in vivo stability of the radiolabelled complex. A second 
mouse (33 g) was injected with 100 μL of acetate buffered 68Ga (0.1 M ammonium 
acetate, 4.68 MBq) while scanning, followed at 30 min by an injection of THPH (50 μL 
of a 50 μM solution in PBS). Upon procedure completion, animals were sacrificed by 
neck dislocation while still anesthetised, the urine collected and analysed by reverse-






A new tris(hydroxypyridinone) chelator THPH, was developed in this work, containing 
a modified hydroxypyridinone unit in which the N1-methyl group has been replaced by 
N1-H. The pyranone precursor, compound 1 was initially synthesised from Kojic acid in 
4 steps as described in the reaction scheme below, following published procedures [12] 
with an overall yield of 16 %. 
 
Scheme 3.1 Precursor 1 synthesis from Kojic acid according to published procedures. 
(a) SOCl2, 25 °C; (b) Zn/HCl, H2O, 70 °C; (c) HCHO, NaOH, H2O, 25 °C; (d) BnBr, NaOH, 
CH3OH/H2O, 70 °C. 
The tripodal acid TA was also synthesised following literature [4] procedures from the 
NH2-tripodal ester precursor, as in the scheme below. An overall yield of 35 % was 
obtained. 
 
Scheme 3.2. Synthesis of the tripodal acid TA from the NH2-tripodal ester precursor. (a) 
CH3COCl, triethylamine, dichloromethane, 0 °C, (d) formic acid. 
Different strategies were attempted for the synthesis of the new ligand, starting from 





Scheme 3.3. Synthetic pathways evaluated for the tris(hydroxypyridinone) compound 
THPH and its tris(hydroxypyranone) counterpart THPO (bottom). Dashed arrows 
represent unsuccessful synthetic steps. 
At first, the traditional approach to THPMe synthesis was employed (strategy A, [12]). 
Compound 1 was successfully converted into a pyridinone by reaction with ammonia. 
A subsequent Mitsunobu reaction using phthalimide as a nucleophile, followed by 
deprotection of the newly introduced nitrogen with hydrazine at reflux, was intended 
to yield the desired hydroxypyridinone precursor. However, the Mitsunobu reaction did 
not proceed to give the desired product, likely due to the presence of an N-H group in 
the hydroxypyridinone moiety (see Discussion). Therefore, new strategies for the 
synthesis of THPH were developed. In strategy B, the Mitsunobu reaction was 
performed directly on 1, to avoid any side reaction with the heterocyclic N1-H group. 
The pyranone-pyridinone conversion was then carried out on the product of the 
Mitsunobu reaction 3, followed by deprotection of the NH2 functionality without 
isolation of the phthalimido-protected pyridinone. The newly synthesised 
hydroxypyridinone unit BnHPH (4) was then coupled with the tripodal acid (TA), in the 
presence of HOBT and DCC to give compound BnTHPH (5). The overall yield for BnTHPH 
synthesis from compound 1 using strategy B was 16 %.  
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An alternative approach was also undertaken (strategy C), where the pyranone-
pyridinone conversion step was not performed until after the assembly of the 
hexadentate tripodal unit. Here, the phthalimido-protected hydroxypyranone 
derivative 3 was deprotected to give the hydroxypyranone-NH2 unit BnHPO 7 and then 
coupled to the tripodal acid, to obtain the benzyl-protected tris(hydroxypyranone) 
BnTHPO (8). Conversion of this derivative into BnTHPH (5) was performed by reaction 
with ammonia under pressure and monitored using LC-MS (Figure 3.6). LC-MS indicated 
that under these reaction conditions, mixed hydroxy-pyranone/pyridinone species can 
be observed. The overall yield for strategy C synthesis of BnTHPH (5) from compound 
1 was 7.3 %. 
Debenzylation of BnTHPH (5) with BCl3 furnished the chelator THP
H (6) in a quantitative 
yield. When the same deprotection procedure was applied to BnTHPO (8) the 
tris(hydroxypyranone) chelator THPO (9) was obtained in 78 % yield. 
For both the successful synthetic strategies, the main difficulties were found in the 
optimisation of reaction conditions (solvent, work-up) and purification of compounds 
containing primary and secondary amines by silica-gel chromatography as further 





Figure 3.6. LC-MS chromatograms showing the total ionic current (TIC) of the reaction 
mixture for the BnTHPO 8 to BnTHPH 5 conversion (strategy C) at A) 0 h B) 8 h C) 48 h 
and D) 72 h. RT: Retention time, MA: area of the peak, BP: m/z signal for the peak. 
Insets: BnTHPO and MS signal of [BnTHPO +1H]+ (purple), mono-substituted BnTHPO 
and MS signal (green), di-substituted BnTHPO and MS signal (blue), BnTHPH structure 




All the isolated compounds were analysed by accurate ESI-MS, 1H NMR and 13C-NMR to 
confirm identity and purity. 1H NMR analysis of THPH in H2O (+10 % D2O) was also 
performed on the 700 MHz spectrometer and the peaks assigned as below (Figure 3.7). 
 
Figure 3.7. 1H NMR spectrum of THPH in H2O +10 % D2O. The small signal at 2.17 ppm 
was assigned to acetone. 
3.3.2 Preliminary NMR studies on [Ga(THPH)] 
The 1H NMR of a mixture of THPH (2 mM) and Ga(NO3)3 (1 or 2 mM) at pH ≈ 2.5 was 
acquired (Figure 3.8) and compared to the 1H NMR of the THPH ligand. An important 
change in the spectrum was visible after 0.5 equivalents of Ga(NO3)3 were added, but 
free ligand signals only completely disappeared at 1 equivalent of Ga(NO3)3, in 
agreement with the formation of a 1:1 complex only. The resulting spectrum is 
extremely complicated, with most signals splitting and broadening. This could result 
both from the presence of more than one species in these conditions, or in the 
presence of a single species with a reduced symmetry, compared to an idealised 
pseudo-octahedral complex with C3 symmetry. Notably, an attempt to increase the pH 
of the solution by addition of d7-ammonium acetate resulted in the precipitation of 




Figure 3.8.1H NMR spectra of the THPH ligand in presence of different concentration of 
Ga(NO3)3. 
For each of the investigated ligand/metal ratios, the 71Ga spectrum was also acquired 
and compared with that of [Ga(H2O)6]
3+ (solution of Ga(NO3)3 in H2O + 10 % D2O, set at 
0 ppm as a reference) and of [Ga(NOTA)], whose chemical shift compared to the 
hexaaqua-ion is known [19]. 71Ga NMR spectra are reported in Figure 3.9. 
 
Figure 3.9. 71Ga NMR spectra of different mixtures of Ga(NO3)3 and ligands in H2O + 
10 % D2O. The spectrum of Ga(NO3)3 is also shown in the bottom panel, with one signal, 
representing [Ga(H2O)6]
3+, set a 0 ppm as a reference. 
Owing to the quadrupole moment of the 71Ga nucleus [20], signals in a 71Ga NMR tend 
to be broad and their width increases with decreasing of the symmetry around the 
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gallium ion. Complexes with a highly symmetric environment around the metal centre 
are most discernible in 71Ga-NMR. Remarkably, the peak visible for the hexaaqua ion 
disappeared once gallium was mixed with the ligand suggesting low symmetry of the 
resulting complex, in agreement with the 1H NMR data. On the contrary the [Ga(NOTA)] 
complex presented a sharp signal at 170.6 ppm, in agreement with literature reports 
[19]. 
3.3.3 Radiolabelling and comparison with THPMe and THPO 
The radiolabelling of THPH, THPO and THP
Me (as a comparison) was investigated at room 
temperature, using ammonium acetate to control pH (final concentration 0.25 M, 
pH ≈ 6). A reaction time of 5 min was used for all experiments. Verification of the 
radiolabelling was performed by reverse-phase HPLC and iTLC-SG.  
Analytical HPLC of a THPH radiolabelling mixture (100 μM), showed only one peak in 
the in the UV chromatogram (3 min 26 s) attributed to unreacted ligand, and one peak 
in the radiochromatogram at 4 min 56 s attributed to the radioactive [68Ga(THPH)] 
complex. HPLC analysis of non-radioactive [natGa(THPH)] also showed a single peak in 
the UV-Vis chromatogram, whose retention time (4 min 20 s) matched that of 
[68Ga(THPH)] when taking into account the different configuration of the two detectors 
in series (Figure 3.10). LC-MS of [natGa(THPH)] confirmed the product as possessing a 
1:1 ligand:metal stoichiometry, and no peaks suggestive of other gallium species were 
observed (Figure 3.11).  
 
 
Figure 3.10. Normalised chromatograms of THPH, showing both UV Chromatogram at 
254 nm for THPH and [natGa(THPH)] and the radiochromatogram for the [68Ga(THPH)] 
(HPLC method 3; the different configuration of the two detectors in series accounts for 




Figure 3.11. Mass spectrum for the [Ga(THPH)] complex. The peak at 764.22 m/z 
represent [Ga(THPH)] and shows the typical isotopic pattern of a natural gallium complex. 
Peak at 698.32 represents the THPH ligand, the other peaks are assigned to the sodium 
and iron complex of THPH, respectively. 
For THPO, RP-HPLC analysis (100 μM) revealed one peak in the UV chromatogram (4 
min 43 s) corresponding to the ligand and a single peak in the radiochromatogram at 8 
min 18 s, matching the UV peak of [Ga(THPO)] at 7 min 42 s (Figure 3.12). 
 
Figure 3.12. Normalised chromatograms of THPO, showing both UV chromatogram at 
254 nm for ligand and gallium complex and the radiochromatogram for the 68Ga complex 
(HPLC method 2; the configuration in series of the detectors accounts for the difference 
between the UV and radio-chromatograms of the [Ga(THPO)] complex). 
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The retention factors of the three radiolabelled complexes on iTLC-SG were 
determined for both mobile phase and compared with unchelated gallium in the same 
conditions (Table 3.1). 
Table 3.1. Retention factor (Rf) of the different gallium complexes in the two different 
mobile phases. *In the presence of gallium colloids, a species at Rf = 0 is also visible for 
unchelated gallium in mobile phase 1, in addition to the principal species at Rf = 1. Both 
colloidal and unchelated gallium are found at Rf = 0 for mobile phase 2. 
 Measured Rf 
Mobile phase 1 Mobile phase 2 
[Ga(THPH)] 0.64 1 
[Ga(THPMe)] 0 1 
[Ga(THPO)] 0 1 
Unchelated gallium 1 0 
Colloidal gallium 0 0 
 
iTLC analysis (mobile phase 2) of the radiochemical yield (RCY) at different ligand 
concentrations was performed using a phosphorimager. RCY higher than 95 % were 
considered quantitative. THPH was found capable of quantitative radiolabelling in 
these conditions at a ligand concentration as low as 1 μM, similar to THPMe (Table 3.2). 
When radiolabelling at a lower concentration (0.1 μM) was performed, THPH achieved 
almost quantitative radiolabelling with RCY of 93.9 %. At the same concentration, 
THPMe was only able to achieve a radiochemical yield of 83.0 %. The 
tris(hydroxypyranone) ligand THPO also radiolabelled quantitatively under the same 
conditions, but at higher ligand concentrations (100 M) compared to THP derivatives 
(Table 3.2). 
Determination of the partition and distribution coefficients (LogP and LogD7.4, Table 
3.2) for the 68Ga complexes of THPMe, THPH and THPO ligands was performed using the 
shake-flask method. Unexpectedly, [Ga(THPH)] was found to be more lipophilic than 
[Ga(THPMe)]. The THPO complex proved to be the most lipophilic of the three, in 
agreement with the earlier LC-MS results for the BnTHPO to BnTHPH conversion, where 




Table 3.2. LogP and LogD7.4 values for [Ga(THPMe)], [Ga(THPH)] and [Ga(THPO)] and 
radiolabelling yields for the same complexes at different ligand concentrations. Data are 
reported as mean ± standard deviation (N = 4 hydrophilicity measurements, N = 3 for 
radiolabelling yields). *Radiolabelling performed with 68Ga eluate from a different E&Z 
generator, eluted with clinical grade HCl.  
 [Ga(THPMe)] [Ga(THPH)] [Ga(THPO)] 
LogP -3.33 ± 0.02 -2.40 ± 0.02 -1.64 ± 0.01 
LogD7.4 -3.27 ± 0.02 -2.28 ± 0.05 -1.65 ± 0.03 
 Radiochemical yields 
100 μM 96.9 ± 1.0 98.9 ± 0.7 95.6 ± 0.2 
10 μM 97.8 ± 0.5 99.1 ± 0.2 83.0 ± 0.4 
1 μM 96.7 ± 0.2 98.1 ± 0.4 27.5 ± 0.7 
0.1 μM * 83.0 ± 0.5 93.9 ± 0.4  N/A 
3.3.4 Spectrophotometric measurements  
The proton affinity constants for the two tris(hydroxypyridinone) chelators THPH and 
THPMe, as well as their complex formation constants for Ga3+ and Fe3+ were studied 
using spectrophotometric measurements in the UV-Vis range. The bidentate 
hydroxypyridinone ligand deferiprone was also analysed using the same method to 
verify its reliability. Measurements of pKa were performed by titration in the pH range 
2.5-11. Ligand spectra at selected pH values are provided in Figure 3.13 and pKa 
values are reported in Table 3.3. 
 
Figure 3.13. Absorbance spectra of THPMe and THPH ligands (top panel) and deferiprone 
(bottom panel) at different pH values 
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The pKa values for THP chelators are better described as intrinsic protonation 
constants [21] since they represent the average pKa of the three hydroxypyridinone 
units, which could not be distinguished in this measurement. The measured 
protonation constants for THPH (Scheme 3.4 for protonation equilibria) are slightly 
higher than those for THPMe and lower than the pKa values measured for deferiprone 
with the same method. The first intrinsic protonation constant (pKa1 values: 3.2 for 
THPMe, 3.4 for THPH) is attributed to the carbonyl group of the HP unit, while the 
second is assigned to the adjacent hydroxyl group (pKa2 values: 9.4 for THP
Me, 9.5 for 
THPH). For THPH a third intrinsic protonation constant exists related to the N1-H group 
in the pyridinone ring, but was not measurable in the pH range used for the titration 
and was estimated to be approximately 13 from the spectral change of the [Fe(THPH)] 
complex in the pH 10-12.5 range. 
 
Scheme 3.4. Protonation equilibria for THPH. 
All the metal affinity constant measurements were performed by evaluating the 
competition between [M(THP)] species and [M(OH)4]
- species, whose formation 
constants from the hexaaqua ions are known (Logβ [Fe(OH)4]
- = -21.9, 
Logβ [Ga(OH)4]
- = -16.6 [15]). For every ML (metal-ligand) species observed in the 
system, relevant chemical equilibrium equations were defined and their equilibrium 
constants (Logβ, or Logβa for protonation equilibria) were calculated by fitting of the 
absorbance spectra in the UV regions (for gallium complexes) or in the visible region 
(for iron complexes). Values and speciation plots for every ligand are reported in the 






Chemical equilibrium equations 
𝑀3+ + 𝐿− ⇄ [𝑀𝐿]2+                                                                     𝐿𝑜𝑔 𝛽[𝑀𝐿]2+  
𝑀3+ + 2 𝐿− ⇄ [𝑀𝐿2]
+                                                                𝐿𝑜𝑔 𝛽[𝑀𝐿2]+  
𝑀3+ + 3 𝐿− ⇄ [𝑀𝐿3]                                                                  𝐿𝑜𝑔 𝛽 [𝑀𝐿3]
      
𝑀3+ + 4 𝑂𝐻− ⇄ [𝑀(𝑂𝐻)4]
−                                                  𝐿𝑜𝑔 𝛽[𝑀(𝑂𝐻4)]−  
Equilibrium constants* 




[FeL3] 37.5 [GaL3] 37.4 
[Fe(OH)4]
- 34.4 [15] [Ga(OH)4]
- 39.4 [15] 











* Overall experimental error <3% (fitting root mean square error <1%). 
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Chemical equilibrium equations 
𝑀3+ + 𝐿3− ⇄ [𝑀𝐿]                                                                     𝐿𝑜𝑔 𝛽[𝑀𝐿]  
𝑀3+ + 4 𝑂𝐻− ⇄ [𝑀(𝑂𝐻)4]
−                                                  𝐿𝑜𝑔 𝛽[𝑀(𝑂𝐻4)]−  
Equilibrium constants* 
[FeL] 30.7 [GaL] 35.0 
[Fe(OH)4]
- 34.4 [15] [Ga(OH)4]
- 39.4 [15] 











* Overall experimental error <3% (fitting root mean square error <1%). 
  


























































Chemical equilibrium equations 
𝑀3+ + 𝐿6− + 3 𝐻+ ⇄  [𝑀𝐿𝐻3]                                                  𝐿𝑜𝑔 𝛽[𝑀𝐿𝐻3]   
𝑀3+ + 𝐿6− ⇄  [𝑀𝐿]3−                                                                 𝐿𝑜𝑔 𝛽[𝑀𝐿]3−  
𝑀3+ + 4 𝑂𝐻− ⇄ [𝑀(𝑂𝐻)4]
−                                                   𝐿𝑜𝑔 𝛽[𝑀(𝑂𝐻4)]−  
Equilibrium constants 
[FeLH3] 66.6 [GaLH3] 76.2 
[FeL]3- 33.5 [GaL]3- 42.5 
[Fe(OH)4]
- 34.4 [15] [Ga(OH)4]
- 39.4 [15] 











* Overall experimental error <3% (fitting root mean square error <1%). 




























































In the case of deferiprone, the [M(OH)4]
- species start to compete with the 
[M(deferiprone)3] complexes (annotated as [ML3] in the speciation plot) at pH < 12, 
thus a typical pH range (2-12) could be used in this titration study. Notably, 
deferiprone showed very high complex formation constants for both metals, in 
agreement with literature values [22]. For hexadentate ligands higher pH had to be 
reached for the competition with [M(OH)4]
- species to take place. Therefore, titrations 
for THPH and THPMe were performed in a very high pH range (9.7-12.6). When THPH 
coordinate M3+ under these conditions, the resulting complex [MLH3] can undergo 
deprotonation at the pyridinone nitrogen atom, to give the triply negatively charged 
species [ML]3- (annotated as ML in the above THPH speciation plot). Complex formation 
constant and protonation constant for this [ML]3- species were both calculated. 
Notably, the reported Logβ [ML3]
3- clearly show THPH preference for Ga(III) over Fe(III). 
Interestingly, the neutral [Ga(THPH)] complex ([GaLH3]) is also less prone to 
deprotonation than [Fe(THPH)], as indicated by the calculated protonation constants. 
In contrast, when THPMe complexes M3+, the resulting complex [ML] (defined as ML in 
the above THPMe speciation plot) does not undergo further deprotonation in these 
conditions. Hence, in this case complex formation constant was calculated for this 
neutral [ML] species. Also for THPMe a clear preference for Ga(III) over Fe(III) was 
visible.  
Importantly, because of the different equilibria and species involved for THPH and 
THPMe, their complex formation constants are not directly comparable. Similarly, the 
complex formation constants for deferiprone are not accurately comparable with those 
of hexadentate ligands since they describe substantially different chemical equilibria. 
A more correct way to compare the metal affinity for these three different ligands is 
to consider their pM values, which can be calculated for each of them from the 
measured equilibrium constants. pM values are defined for a system at pH 7.4, with 
total ligand concentration of 10 μM and total metal concentration of 1 µM, according 
to the equation below: 
𝑝𝑀 =  − log[𝑀]𝑓𝑟𝑒𝑒 
These values are particularly useful since, irrespective of the chemical species 
involved, they provide a measure of the concentration of free metal present in the 
solution at a specific pH and at a fixed total concentration of metal and ligand. pM 
values for the three ligands are summarised in Table 3.3.  
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Table 3.3 Affinity constants for THPMe, THPH and deferiprone. *Intrinsic pKa values [21] 
were determined from a spectrophotometric titration; **Estimated pKa values were 
calculated from the intrinsic pKa values by plus/minus 0.6 log units (0.4-0.8 log units 
deviations from the intrinsic pKa values were also tried and no significant changes in pM 
values were found). ***This pKa value is estimated. No significant spectral change was 
observed from pH 11.5 up to 12.6. The change of the estimated pKa value can result in 
different Logβ values but no appreciable change in pM values.  






















pFe 25.7 22.3 20.8 
pGa 30.0 31.8 20.7 
 
The calculated pM values showed that THPH has superior affinity for Ga(III) compared 
to THPMe, while, unexpectedly, the situation is reversed for Fe(III), with THPMe having 
much higher Fe(III) affinity than THPH. Nevertheless, both hexadentate chelators have 
high selectivity for gallium over iron as shown by both pM values and the complex 
constants. On the contrary, deferiprone, displays lower pM values for both Ga(III) and 
Fe(III) and no marked preference for either metal.  
Importantly, the affinity constant obtained for THPMe (log β[ML] = 35.1) is lower than 
that measured for HBED (log β[ML] = 37.7 [23]), which represents the highest reported 
affinity constant for a gallium complex. However, the pGa value for THPMe is notably 
higher (pGa = 30.0 for THPMe and 27.7 for HBED) and it is even higher for THPH (pGa = 
31.8, log β of the neutral species MLH3 is not available), indicating higher capability of 
these ligands to coordinate Ga(III) in physiological conditions.  
Importantly, the metal affinity data obtained in this study has several limitations 
related to the method used. In general, the achievement of thermodynamic 
equilibrium for Ga(III) and Fe(III) complex formation and dissociation is a slow process 
[23]. Accordingly, Notni and co-workers recently emphasised how the traditional 
spectrophotometric and potentiometric techniques, which allow equilibration of the 
system for just a few minutes, only allow the determination of “short-term conditional 
constants” (defined in the paper as “non-equilibrium” stability constants [24]). The 
true equilibrium stability constants can only be obtained by lengthening the 
experiments over the course of weeks (out-of-cell titration).  
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In addition, the behaviours of gallium and iron interacting with oxygen-type ligands 
are substantially different when in the high pH range, as exemplified by the formation 
constant of [M(OH)4]
- species (Logβ [Fe(OH)4]
- = 34.4, Logβ [Ga(OH)4]
- = 39.4 [15]). On 
the other hand, titration in a high pH range was necessary to see competition with 
[M(OH)4]
- formation (due to the extremely high affinity of THP ligands for Fe3+ and 
Ga3+). This could potentially result in different rates of metal complex formation. For 
these reasons, an accurate comparison of pM values for THPMe and THPH can only be 
performed for the same metal, whereas comparison of pFe and pGa values for both 
THP ligands only indicates their strong gallium preference over a short period of time. 
3.3.5 Competition studies 
Two different sets of competition experiments were performed to investigate how the 
obtained spectrophotometric data applied to a practical radiolabelling experiment. In 
the first competition experiment, 68Ga radiolabelling of THPMe and THPH in the presence 
of different amounts of Fe3+ was investigated, to better quantify the preference of the 
two ligands for Ga3+ over Fe3+ in a radiolabelling setting. To avoid the presence of excess 
ligand that could complex 68Ga, thus invalidating the competition, natural gallium was 
added to 68Ga eluate to reach a gallium:ligand ratio of approximately 9:10, 
Additionally, a higher concentration of ammonium acetate buffer was used (final 
concentration 0.44 M), to ensure that the pH would not differ significantly for samples 
with different metal concentration. In the experiment, the relevant THP ligand (1 
equivalent, in 0.5 M ammonium acetate) was added to mixtures of nat/68Ga3+ (≈ 0.9 
equivalent) and Fe3+ (0, 0.9 or 9 equivalents) and radiochemical yield was measured at 




Figure 3.14. Graphs showing the influence of different concentrations of Fe3+ on the 
radiochemical yield of [68Ga(THPMe)] and [68Ga(THPH)] in presence of 1 equivalent of 
ligand and 0.9 equivalent of natGa3+. Data are reported as mean ± standard deviation, N 
= 6 for control samples (without Fe), N = 3 for the rest of the samples (for most data 
points error bars are too small to be visible). 
Unexpectedly, in these conditions THPMe could not reach quantitative radiochemical 
yield even in the absence of iron. This is likely related to the quasi-equimolar ratio 
between Ga(III) and ligand in the radiolabelling mixture, so that even the presence of 
a trace concentration of adventitious metals (e.g. from generator eluate, nitric acid 
or buffer), could significantly impact the radiochemical yield. Additionally, the 
presence of a higher concentration of buffers (ammonia, acetate, nitrate), compared 
to traditional radiolabelling conditions, could decrease the radiochemical yield since, 
at high concentration, those ligands can also compete for metal binding. Nonetheless, 
the experiment was able to demonstrate the effect of the presence of different Fe3+ 
amounts on the radiochemical yield. 68Ga radiochemical yields were not dramatically 
reduced by even a ten-fold excess of Fe3+, indicating strong preference for gallium over 
iron for both chelators. Notably, the presence of 0.9 equivalent of iron with 0.9 of 
gallium decreased the radiochemical yield for the two ligands only marginally (not 
significant for either ligand at later time points, P = 0.062 for THPMe, P = 0.224 for 
THPH), indicating that iron was not able to compete effectively with gallium for ligand 
binding when at the same concentration. When the amount of iron was increased to 
reach 9 equivalents (with 0.9 equivalent of gallium), still the majority of the ligand 
was binding gallium, indicating a ≈ 40-fold preference for gallium over iron in these 
conditions (calculated considering the 80:20 = gallium:iron complex ratio obtained in 
presence of a 10-fold excess of iron over gallium). 
The relative capability of THPMe and THPH to bind gallium in radiolabelling conditions 
was also investigated by means of a competition study. A solution of THPMe and THPH, 
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each at a concentration of 2 mM, was first prepared in D2O and analysed by 
1H NMR 
(Figure 3.15) to verify the equal concentration of the two chelators. 
 
Figure 3.15. 1H NMR of a solution 2 mM in THPMe and 2 mM in THPH in D2O. Peaks are 
referenced to residual solvent signal. Pink and blue arrows indicate signals from THPH 
and THPMe, respectively. Peak integration is reported (from left to right) for the pyridinone 
C5-H hydrogen, the C2-CH2-NH2 group and the C
6-CH3, confirming equal concentration 
of the two ligands. 
Integration was performed on selected hydrogen groups, for which the peaks were 
well-separated and resolved (namely C5-H hydrogen, the C2-CH2-NH2 group and the C
6-
CH3 for the hydroxypyridinone units) confirming equal concentration of the two 
ligands. The mixture was then diluted in ammonium acetate to obtain a solution in 
which the concentration of each ligand = 100 μM (in 0.5 M ammonium acetate). 68Ga 
was then added and gallium speciation measured via iTLC by sampling at different time 
points after the addition. The difference in Rf between the two complexes in mobile 
phase 1 (citrate pH 5, iTLCs reported in Figure 3.16 A) was exploited to quantify the 
fraction of activity bound to each chelator. Mobile phase 2 was also used to verify 
quantitative radiolabelling at 1 min (no unchelated or colloidal gallium at Rf = 0). 




Figure 3.16. iTLCs of the two radioactive complexes in mobile phase 1 (A) and of an 
equimolar mixture of THPMe and THPH treated with 68Ga3+ in mobile phase 2 (1 min time 
point) or in mobile phase 1 (1, 10 and 120 min) (B), imaged with a phosphorimager. (C) 
shows how the percentage of activity associated with the two chelators, as calculated 
from the images, changes over time. For every data point mean ± standard deviation is 
reported (N = 3, error bars are too small to be visible). 
As visible in Figure 3.16 B, after one minute the radioactivity was already 
quantitatively bound to the chelators showing an extremely fast radiolabelling for both 
compounds, but with preference for THPH (Figure 3.16 C, ratio: 70:30). Over time, the 
fraction of activity associated with THPH increased (as plotted in Figure 3.16 C) to 
plateau at ≈ 90 % at 120 min, confirming a that THPH binds gallium with higher 
thermodynamic affinity than THPMe, as expected based on the spectrophotometric 
titration data. 
3.3.6 Serum stability  
Evaluation of the serum stability for [67Ga(THPMe)] was first performed by Berry et al., 
who observed no sign of transchelation to serum proteins after 4 hours incubation in 
serum at 37 °C [1]. [67Ga(THPH)] stability upon incubation with human serum was 
determined in this work using size-exclusion HPLC comparing the elution profile of the 
complex with that of unchelated 67Ga in serum at different time points after incubation 
in serum at 37 °C (Figure 3.17). A high concentration EDTA (50 mM) was added to the 
PBS mobile phase in order complex any gallium not bound to either ligand and protein, 
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preventing precipitation onto the column and allowing its quantification by peak 
integration of the EDTA complex. [Ga(THPH)] proved to be stable in serum for at least 
8 days with no shift in its chromatographic peak (retention time 15 min 30 s) compared 
to the complex incubated in PBS. On the contrary, unchelated 68Ga eluted at 12 min 
at early serum incubation time points (as [67Ga(EDTA)]), but became more associated 
with serum proteins over time. After 8 days incubation, two different peaks were 
observed: one at 12 min ([67Ga(EDTA)]) and one at 9 min 30 s, attributed to 68Ga-
protein adducts. 
 
Figure 3.17. Radiochromatograms of [67Ga(THPH)] (left column) and 67Ga-chloride (right 
column) before and at different time points after incubation with human serum at 37 °C. 
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3.3.7 in vivo biodistribution 
The behaviour and stability of the [Ga(THPH)] complex in vivo was investigated in a 
SCID beige mouse by dynamic PET-CT scanning. PET-CT scans (Figure 3.18) 
demonstrate that the radiolabelled complex is quickly cleared from the blood via the 
kidneys after intravenous (IV) injection. A similar biodistribution was reported for 
THPMe [1]. HPLC analysis of the urine at 60 min post injection revealed the presence of 
a single radioactive species, corresponding to the intact radiolabelled [Ga(THPH)] 
complex (4 min 54 s, Figure 3.18).  
 
Figure 3.18. Top panel: Dynamic PET/CT maximum intensity projection (MIP) at 
different time points in a mouse injected with [68Ga(THPH)]. Quick blood clearance of the 
activity is visible with kidneys and bladder being the only visible organs already in the 
15-30 min image. Bottom panel: radiochromatogram of the urine 60 min after injection 
(method 1), showing only one peak attributed to [68Ga(THPH)]. 
The ability of THPH to bind gallium in vivo, acting as a 68Ga scavenger, was also 
investigated. A mouse injected IV with acetate buffered 68Ga (0.1 M ammonium 
acetate, 0.05 M HCl) was scanned for 30 min then injected with THPH (20 μg) while 
PET scanning continued. As shown in Figure 3.19, the biodistribution of 68Ga, initially 
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mainly in blood pool and clearing slowly to kidneys, liver and bone, dramatically 
changed upon injection of the chelator with most of the activity being cleared from 
the blood into the kidneys and the bladder. Analysis of the urine by HPLC confirmed 
the in vivo radiolabelling of the chelator (Figure 3.19) with the presence of one peak 
in the chromatogram with an elution time corresponding to [Ga(THPH)] 
 
Figure 3.19. Top panel: dynamic PET/CT MIP, at different time points, of a mouse 
injected with acetate buffered 68Ga at time 0 followed by THPH at 30 min (top panel). 
Blood clearance of 68Ga proceeds very slowly in the first 30 min. With the injection of the 
chelator a sudden change of the biodistribution is visible with the blood pool activity 
quickly clearing through the kidneys into the bladder. Bottom panel: radiochromatogram 






The tris(hydroxypyridinone) ligand THPMe, and its bifunctional derivatives, are 
outstanding chelators for Ga3+, achieving quantitative (> 95 % RCY) 68Ga radiolabelling 
in mild conditions. This enables one-step, kit-based radiopharmaceutical manufacture 
of 68Ga radiopharmaceuticals, in which 68Ga generator eluate can be simply added to 
a kit vial containing chelator-bioconjugate and buffer components, to provide the 
formulated radiopharmaceutical ready for patient administration. This eliminates the 
need of laborious radiosynthetic procedures to obtain radiotracers with high 
radiochemical purity and puts the ease of manufacture of 68Ga radiopharmaceuticals 
on a similar footing to that seen for 99mTc. Radiotracers based on peptide derivatives 
of THPMe have been evaluated in preclinical models with promising results and 68Ga-
THPMe-PSMA is undergoing a multicentre phase II clinical trial in the UK. 
Development of second generation THP chelators is warranted to investigate how the 
physicochemical properties of this class of chelators, such as lipophilicity and the 
thermodynamics, kinetics and selectivity of Ga3+ binding, are influenced by 
modification of either the hydroxypyridinone unit or the tripodal scaffold.  
Furthermore, it has been demonstrated that, far from being a passive spectator of the 
peptide/receptor interaction, the chelator plays a major role in determining the 
affinity of a peptide radiotracer for its receptor target [10], suggesting that, due to 
the variability of the chemical environment at the receptor binding sites, different 
targets will benefit from chelators with different structures and chemical properties. 
Therefore, the ultimate goal of this investigation would be the creation of a library of 
THP chelators able to meet the requirements of different imaging targets, rather than 
developing a single “ideal” THP chelator, optimised for any 68Ga imaging application.  
Previous preclinical investigations on THPMe peptide derivatives suggested that a more 
water soluble/hydrophilic ligand would enhance the in vivo biodistribution of the 
radiotracers and prevent chelator precipitation during attachment to biomolecules. 
Therefore, in this work we replaced the N1-CH3 pyridinone unit with a N
1-H unit with 
the aim of increasing the water solubility and hydrophilicity of the resulting 
tris(hydroxypyridinone) ligand. This very simple chemical modification not only 
resulted in remarkably different chemical properties and metal preferences, but also 
required different synthetic routes to be developed, generating new intermediates 





The traditional approach to the synthesis of hydroxypyridinone units involves pyranone 
to pyridinone conversion as an early step, prior to the substitution of the -CH2OH 
moiety in position 2 with the desired -CH2NH2 functionality. Conversion was performed 
by reacting the pyranone 1 with an excess of the selected amine under pressure. To 
avoid side reactions, the -CH2OH group is usually protected with 3,4-dihydropyrane 
prior to the conversion reaction and deprotected afterwards in acidic conditions. 
Compound 2 was successfully synthesised with this approach (53.5 % yield), but higher 
yields (60.6 %) were obtained when performing the pyrone to pyridinone conversion 
directly on 1 without the protection/deprotection step. The subsequent step in this 
traditional synthetic pathway is the SN2 substitution at the C
2-CH2-OH hydroxyl group, 
which is performed with a Mitsunobu reaction in the presence of phthalimide and is 
then followed by Ing-Manske deprotection of the newly introduced nitrogen to give the 
free -NH2 functionality. Unfortunately, a Mitsunobu reaction (scheme 3.5) on 
compound 2 failed to give the desired phthalimido-hydroxypyridinone.  
 
Scheme 3.5. Mechanism of the Mitsunobu SN2 substitution in the absence of side 
reactions. 
The purpose of the Mitsunobu reaction is to allow SN2 substitution of an alcohol with a 
weaker nucleophile. The core step of this reaction is formation of the C2-phosphine-
oxide adduct which activates the methylene for the substitution by the deprotonated 
nucleophile. In case of compound 2, two weak nucleophiles are present and able to 
attack the electrophile upon deprotonation: the phthalimide and the N1-H group of 
another pyridinone molecule (intramolecular attack is excluded, since it would result 
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in the formation of a three-membered ring). In the case of attack by the pyridinone 
N1-H group a variety of side products can form, resulting in an unsuccessful reaction. 
A number of different strategies could have been adopted to obviate this. BOC-
protection of the N1-H group would have been feasible, but would have increased the 
number of synthetic steps; use of tert-butyl amine instead of ammonia for the 
conversion step was hampered by the steric hindrance of this protected amine; finally, 
replacement of the Mitsunobu reaction and following Ing-Manske deprotection with a 
tosylation and subsequent SN2 reaction was also possible, but was not explored due to 
success of strategies B and C. 
Strategy B 
In strategy B the Mitsunobu reaction was performed on the pyranone 1, thus avoiding 
any side reaction due to the free amine group. Recrystallisation from hot methanol 
allowed recovery of the desired product 2 in good yield. Subsequent reaction with 
concentrated ammonia in methanol, at 75 °C and under pressure was expected to 
result in both conversion to pyridinone and deprotection in one step, given the harsh 
condition employed. However, mass spectrometry analysis of the reaction mixture 
revealed that deprotection from the phthalimide was not complete and any attempt 
to recover the product resulted in isolation of the phthalimido-protected intermediate. 
Changing the solvent from methanol to water enabled accomplishment of both 
reactions. However, another side-product with [M+H]+ of 393 m/z was also formed in 
the reaction mixture. A literature survey revealed a similar issue encountered by Pfizer 
for a phthalimide deprotection in methylamine, with by-products attributed to 
instability of the phthalic diamide and different side reactions depending on the 
utilised solvent [25]. A similar mechanism can also be proposed for our ammonia 
deprotection, as represented below (Scheme 3.6). 
 
Scheme 3.6. Mechanism proposed for pyrone/pyridinone conversion and subsequent 
side reactions in methanol and in water. 
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According to this proposed mechanism, reaction of compound 2 with ammonia gave 
the desired product irrespective of the solvent utilised; however, the resulting phthalic 
diamide was not stable under the reaction conditions utilised. In methanol, this 
resulted in a reversible deprotection reaction whose equilibrium is shifted to the 
protected form when NH3 is allowed to evaporate. On the contrary, the presence of 
water favours the irreversible hydrolysis of one amide group and reaction of the 
resulting acid group with 3 to obtain the observed side product with mass of 392 
(Scheme 3.6).  
Based on these observation, methanol was chosen as a preferred solvent for the 
reaction, and an additional step of reflux with hydrazine (without isolation of the 
phthalimide protected intermediate) was included in order to quantitatively deprotect 
the hydroxypyridinone unit, by precipitating the phthalhydrazide from the solution. 
Purification of the product by silica gel chromatography with high methanol percentage 
yielded the pure product 4 as a yellow oil with a yield of 47 %. In an attempt to optimise 
the purification process and to avoid loss of the amine by binding to silica particles, 
reverse-phase SPE was used. In this case the isolated product had to be treated with 
ammonia in order to obtain the free base necessary for the coupling. With this new 
procedure the product was obtained as a solid powder instead of as an oil. 
The new hydroxypyridinone precursor 4 was then reacted with TA to yield the 
benzylated tris(hydroxypyridinone) intermediate. A first attempt at coupling was 
performed using a microwave-assisted reaction with HATU and DIPEA as coupling 
reagents. However, mass spectrometric analysis of the reaction mixture revealed 
formation of a different compound with mass of 724.33 m/z [M+H]+ as well as of the 
desired product at m/z 484.73 [M+2H]2+. Although isolation and characterisation of the 
side product was not performed, it is possible that the harsh conditions employed in 
this first coupling favoured the intramolecular reaction between the secondary amine 
of one of the attached pyridinone and the free acid moiety of a different arm (proposed 




Scheme 3.7. Proposed mechanism for the side reaction taking place when coupling was 
performed using HATU and DIPEA in a microwave reactor, yielding a by-product at 
[M+H]+ = 724.33 m/z. 
The coupling was then repeated in a conventionally heated vial (T = 50 °C), using HOBT 
and DCC as coupling agents. In these mild and neutral conditions, the reaction of a 
primary amine is favoured compared to that of a secondary amine, especially 
considering the reduced nucleophilicity of the pyridinone amine, which should display 
pyrrole-like reactivity. Switching to these milder conditions allowed the desired 
product to be obtained in 2 days. It was then purified using silica gel chromatography 
to yield the benzylated tris(hydroxypyridinone) 5. Deprotection of this compound was 
performed using a dichloromethane solution of BCl3. Owing to the insolubility of 5 in 
dichloromethane, pre-dissolution in methanol was necessary to carry out the reaction. 
Quenching of BCl3 by methanol was minimised by using a minimum amount of methanol 
and a large excess of the reagent. To avoid metal contamination of the final product, 
the reaction was performed in new glass vials and BCl3 was added using a PTFE cannula. 
Benzyl deprotection was achieved in an almost quantitative yield. 
Strategy C 
In this strategy, the hydroxypyranone unit 7 was attached to the tripodal framework 
and only then reacted with ammonia to obtain the benzylated tris(hydroxypyridinone) 
BnTHPH (5). To achieve this, phthalimide deprotection with hydrazine at reflux was 
performed on product 3, and the resulting hydroxypyranone unit was attached to the 
tripodal acid using mild conditions (to avoid any possible substitution at the pyranone 
ring).  
Conversion of a tris(hydroxypyranone) into a tris(hydroxypyridinone) had already been 
performed for a different class of compounds [26]. In this case, we used the same 
conditions employed in strategy B (high pressure and temperature, excess of ammonia) 
and the reaction was monitored by LC-MS to verify formation of the desired product 5. 
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Purification of this benzyl-protected tris(hydroxypyridinone), followed by 
debenzylation with BCl3, yielded the final product THP
H. 
Strategy C added an additional step and provided lower yields (overall yield for the 
synthesis of BnTHPH from 1 was reduced from 16 % to 7.3 %). On the other hand, this 
strategy involves a benzylated tris(hydroxypyranone) precursor Bn(THPO), which is a 
flexible platform for the synthesis of a library of tris(hydroxypyridinone) compounds 
with different N-substituents, by reaction with a large excess of the relevant primary 
amine. Notably the conversion was found to take place in a step-wise manner, opening 
also the possibility of isolating mixed hydroxypyranone-hydroxypyridinone species. 
Debenzylation of BnTHPO using BCl3 gave rise to a functional tris(hydroxypyridinone) 
ligand THPO which was also characterised and tested for radiolabelling. 
3.4.2 Preliminary characterisation of [Ga(THPH)] 
The new chelator THPH rapidly reacted with Ga(NO3)3 in ammonium acetate buffer to 
give a 1:1 complex [natGa(THPH)], which was characterised by ESI-MS and HPLC. 
Attempts to obtain the X-ray-quality crystals of the complex were unsuccessful. 1H NMR 
also shows formation of a complex when mixing THPH and Ga(NO3)3 in D2O (pH ≈ 2.5). 
The resulting complicated spectrum, with splitting of most signals, suggests either 
formation of multiple species or a single species with low symmetry, either by 
protonation at low pH or by formation of intramolecular hydrogen bonds. 71Ga NMR of 
the same mixture showed a huge broadening of signal (compared to the hexaaqua ion 
complex, or [Ga(NOTA)]) with no peaks visible in the ppm range considered. This 
supports the hypothesis that a low symmetry species is formed in these conditions or, 
potentially, a population of species in a dynamic equilibrium with each other. 
Unfortunately, NMR experiments at neutral pH could not be performed because 
addition of deuterated ammonium acetate or bicarbonate to raise the pH caused 
precipitation and loss of any signal. No comparison with [natGa(THPMe)] could be 
performed since the latter complex is even less soluble in water at any pH, precluding 
the possibility of a NMR. Although crystallographic and NMR data are unavailable, it is 
hypothesised that both THPH and THPMe coordinate Ga(III) in a hexadentate fashion, 
yielding complexes with a distorted octahedral structure, similar to that of the Ga(III) 
tris(deferiprone) complex [27]. In these crystallographic studies, both deferiprone and 
the N1-H bidentate hydroxypyridinone were found exceptionally prone to hydrogen 
bonding (intramolecular and intermolecular with surrounding water molecules), both 
as ligands and complexes. A higher degree of intramolecular hydrogen bonding was 
found for the N1-H ligand compared to the N1-CH3, owing to the additional hydrogen 
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bond donor. Based on these considerations, it is possible that hydrogen bonding is 
significant for the hexadentate chelators, where the presence of additional hydrogen 
bonding donors and recipients (namely, the NH and carbonyl oxygen of amide bonds) 
are available for participation in hydrogen bonding. Also in this case, the additional 
N1-H moiety present for THPH can only increase the amount of hydrogen bonding for 
both the ligand and the gallium complex. 
3.4.3 Radiolabelling of THPH and comparison with THPMe and THPO 
Radiolabelling of THPH was easily accomplished under the conditions previously used 
for THPMe and did not require either eluate pre-processing or post-labelling purification 
to achieve a radiochemically pure product. The nature of the radiolabelled species was 
confirmed using HPLC by coelution with [natGa(THPH)], the identity of which had been 
confirmed by mass spectrometry. The tris(hydroxypyranone) compound THPO, 
obtained by debenzylation of the BnTHPO intermediate, was also able to bind 68Ga in 
the same mild conditions, but required significantly higher ligand concentration (100 
μM) to reach quantitative radiolabelling. This decreased efficiency in gallium binding 
was not unexpected for pyranone derivatives, whose lower electron density of the 
heterocyclic ring compared to the pyridinone analogues is known to also compromise 
binding to iron [4,28].  
An important characteristic of radiotracers is their lipophilicity, which influences their 
biodistribution and pharmacokinetics in vivo. Measurements of the lipophilicity of the 
radiolabelled complexes was performed using the shake-flask method followed by 
quantification of the activity in each solvent. Both LogP and LogD measurements were 
performed. As expected, [68Ga(THPO)], in which the heterocyclic amine group has been 
replaced by an ether, was found to be more lipophilic than its pyridinone counterparts. 
Interestingly, lipophilicity measurements for the tris(hydroxypyridinone) complexes 
revealed not only that both are very hydrophilic (Log P/Log D7.4 values < -2), but also 
that [68Ga(THPMe)] is significantly more hydrophilic than [68Ga(THPH)]. This result was 
unexpected and could not be predicted by cLogP calculation following Hansch method 
[29], which resulted in a LogP = -1.9 for both complexes when performed using the 
software BIO-LOOM (BioByte Corp.). However, subsequent comparison with literature 
revealed a parallel with their bidentate analogues ligands [30,31], as well as some 
amido-3-hydroxypyridin-4-one ligands [32], where, in both cases, the N1-H pyridinone 
derivative was more hydrophobic than the N1-methyl analogue. In the case of the 
amido derivatives, the authors suggested that increases in lipophilicity for the N1-H 
compound was due to the higher degree of intramolecular hydrogen bonding, as 
observed in crystallographic measurements, which reduced its ability to form 
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intermolecular hydrogen bonding with the solvent [32]. Likewise, the decreased 
hydrophilicity of the traditional bidentate N1-H hydroxypyridinone compound 
compared with the N1-methyl analogue, can be attributed to the increased 
intramolecular hydrogen bonding for this ligand, observed by Orvig [27]. Finally, a 
similar hypothesis can be formulated for [68Ga(THPMe)] and [68Ga(THPH)], the latter 
more engaged in intramolecular interactions (e.g. hydrogen bonding between the 
pyridinone N1-H and the amide carbonyl oxygen on a different arm or the tripod) and 
less able to form hydrogen bonding with the solvent. Although the absence of a crystal 
structure makes it difficult to prove the existence of such hydrogen bonding for 
[Ga(THPH)], this hypothesis is in agreement with the complicated NMR spectra obtained 
for [Ga(THPH)] as discussed above. However, the lower pH of the NMR solution 
compared to that of the radiolabelling solution used for lipophilicity studies, makes 
the two experiments not directly comparable. Notably, although more hydrophilic than 
its THPH counterpart, the [Ga(THPMe)] complex was found to be less water soluble than 
[Ga(THPH)], and no NMR spectrum could be acquired for this complex due to its low 
solubility at any pH. Energy minimisation studies for these complexes are warranted 
to verify the existence and extent of hydrogen bonding for these complexes.  
As previously discussed, the stability of a radiolabelled chelator in biological 
environments is critical to its utility as BFC in radiotracers. Serum stability of 
[67Ga(THPMe)] over 4 hours was previously demonstrated [1], and dynamic PET imaging 
of a mouse with [68Ga(THPMe)] revealed a favourable biodistribution in vivo, with rapid 
renal clearance of the activity typical of small hydrophilic complexes. In this work, 
serum stability of [67Ga(THPH)] over 8 days was verified by size-exclusion radioHPLC 
and in vivo biodistribution of [68Ga(THPH)] evaluated by dynamic-PET imaging, revealed 
a biodistribution/clearance similar to that of [68Ga(THPMe)]. The urine of the mouse 
was also analysed by radioHPLC confirming in vivo stability of the radiolabelled 
complex. Notably, THPH was also able to bind 68Ga(III) in vivo, when injected in a mouse 
30 min after the radiometal, and to accelerate its renal excretion, acting as a 
scavenger for Ga(III). This ability highlights the extraordinary efficiency of THPH 
radiolabelling, which can be performed even in extremely mild condition. The same 
behaviour was also observed for THPMe and will be extensively discussed in Chapter 4. 
3.4.4 Evaluation of metal affinity 
Selectivity for the relevant radiometal is crucial when considering chelators for 
radiopharmaceutical applications. Tris(hydroxypyridinone) ligands were originally 
designed as iron chelators and, as such, combine features of both hydroxamate- and 
catechol-based siderophores. Therefore, selectivity for gallium over iron is a 
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particularly important concern for these chelators and was assessed in this work by 
determining stability constants using spectrophotometric titrations and competition 
studies.  
Limitations of spectrophotometric titrations 
The affinity of THP chelators (and deferiprone as a control) for Fe3+ and Ga3+ was 
determined by titration of the [M(THP)] complex with a 0.1 M NaOH solution, resulting 
in alkaline hydrolysis of the complexes and formation of [M(OH)4]
- species. Metal 
affinity constants were obtained using the software HYSS, by analysing changes in the 
[M(THP)] UV-Vis spectrum, following the titration [16]. Owing to the different species 
and equilibria present for the different chelators (see speciation plots in the Results 
section), these compounds are better compared using pM values which have been 
calculated from the determined Logβ values under the same predefined conditions for 
all chelators.  
The affinity constants obtained in this study suffer from two limitations. In the first 
instance, these values may not be representative of the true thermodynamic affinity 
constants due to the slow achievement of the equilibrium for Ga3+ and Fe3+ 
complexation reactions, as highlighted in the results section. In order to obtain 
realistic values, the system should be left to equilibrate much longer than a few 
minutes for each titration point and the experiments extended over days/weeks as 
elegantly demonstrated by Notni [24]. On the other hand, the “short-term conditional 
constants” determined in our experiments are particularly suited to describing 
radiolabelling systems, whose reactions, especially for a short-lived radiometal such 
as 68Ga, necessarily span minutes and include both kinetic and thermodynamic 
components. 
A second limitation of the measurements is related to the high pH used for the 
spectrophotometric titrations. Owing to the THP chelators’ outstanding affinity for 
Fe(III) and Ga(III), competitive formation of [M(OH)4]
- was observed for THP chelators 
only when titrating in the high pH range (pH > 11, see speciation plot), while it was 
already visible at pH 8 for deferiprone. The use of a higher pH range has several 
implications for the measurement. First, the different conditions used for deferiprone 
do not allow an accurate comparison with the hexadentate chelators; second, in the 
case of THP ligands an accurate comparison of pM values can only be performed for 
the same metal. In fact, the behaviour of gallium and iron interacting with oxygen-
donor ligands is substantially different in the high pH range, as exemplified by the 
formation constant of [M(OH)4]
- species (Logβ [Fe(OH)4]




- = - 16.6 [15]). This can potentially result in different rates of metal 
complex formation, thus influencing the determined “short-term conditional 
constants” values. 
Finally, it is worth noting how the new pM values measured for THPMe (pFe = 25.7, pGa 
= 30.0, Table 3.3) contradict some previous data from our group (pFe = 29.8 [33], 28.5 
[4], pGa = 24.3 [34]) measured by competition against HBED. These differences reflect 
the different methods employed for their determination. Similar to the competition 
with [M(OH)4]
-, competition against [M(HBED)] also suffers from kinetic components 
interfering with the thermodynamic measurement due, in this case, to slow 
transchelation between the two chelators. Furthermore, in the case of gallium, whose 
complexes are colourless, competition with another ligand increases the overlap in the 
UV region between the absorbance spectra of the two complexes, leading to a more 
difficult and error-prone data analysis. Therefore, we believe that our current data 
more accurately represent THPMe affinity for Ga3+ and Fe3+. In addition, while the 
previously reported data were not accompanied by determination of metal affinity 
constants for a known compound as a control, we also determined the affinity 
constants for deferiprone, obtaining values in agreement with those reported in the 
literature (Log β values in the range of 35.9-37.5 for Fe(III), in the range of 35.8-38.4 
for Ga(III) [22]), confirming the reliability of our measurements. 
Ga3+ vs Fe3+ 
Our data revealed a clear preference of both tris(hydroxypyridinone) chelators for Ga3+ 
over Fe3+, ranging from 5 orders of magnitude in the case of THPMe to 9 in the case of 
THPH. No preference for either metal was observed for deferiprone. Selectivity for Ga3+ 
over Fe3+ was confirmed, for both hexadentate chelators, by competition experiments 
in a radiolabelling setting. Remarkably, these experiments show that Fe3+ is not able 
to compete effectively with Ga3+ for THP ligands even when present in large excess. 
For both THPMe and THPH, when Fe3+ was added to give a Fe3+-to-Ga3+ ratio of 1:1 at a 
ligand-to-Ga3+ ratio of 10:9, no significant impairment of radiochemical yield was 
measured. Even when the Fe3+:Ga3+ ratio was increased to 10:1, the radiochemical 
yield only dropped to 80 % of the value in the absence of iron, indicating a ≈ 40-fold 
preference for Ga3+ over Fe3+ in these conditions. Although preference for Ga3+ was 
dramatically more marked in the spectrophotometric titration data, these results are 
not directly comparable, because of the different conditions in which the two studies 
were performed. Nevertheless, both spectrophotometric titration and competition 
experiments clearly indicate that THPMe and THPH have a strong preference for binding 
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Ga3+ over Fe3+ and that the presence of significant amounts of iron should not 
negatively impact the performance of the chelators during radiolabelling or in vivo. 
By contrast, the bidentate hydroxypyridinone deferiprone displays a complete lack of 
selectivity for gallium. Although the different competition pH range used for 
deferiprone makes an accurate comparison of the pM values impossible, these data 
suggest that the tripodal scaffold plays an important role in determining the 
coordination preferences of these hexadentate chelators. Preference for Ga3+ is 
potentially linked to the geometric constraints imposed by the tripodal ligand, coupled 
with the different ionic radii (62 pm for Ga3+ vs 65 pm for Fe3+ [35]) and the different 
electron configurations of the two metals (d10 for Ga3+ vs. d5 for Fe3+), creating a better 
fit for Ga3+. In the absence of a crystal structure for these complexes, these hypotheses 
remain to be verified with structural NMR data (for the Ga3+ complexes) and/or 
computational studies. Our preliminary 1H and 71Ga NMR studies for [Ga(THPH)] (page 
115) are in agreement with the hypothesis of a low symmetry complex. Further NMR 
studies in the same pH range used for the radiolabelling and/or spectrophotometric 
titration will need to address the solubility issues for these complexes. 
THPH vs THPMe 
The spectrophotometric titration data also provide a good basis to directly compare 
chemical properties and metal preferences of THPH and THPMe. The pKa values 
measured for the two chelators were very similar, with THPMe displaying a slightly more 
acidic character, which was unexpected considering the presence of the electron 
donating N1-methyl group and suggests that other chemical interactions (e.g. hydrogen 
bonding) may actively influence the pKa of these compounds. Significant differences 
were found in the affinity constants of the two ligands for Ga3+ and Fe3+. Compared to 
THPMe, THPH shows slightly increased affinity for Ga3+ and markedly decreased affinity 
for Fe3+. The multidentate tripodal structure of THP ligands was found to increase their 
affinity for Ga3+ and Fe3+ compared to deferiprone, as shown by the pM values and the 
speciation plots. This was already evident when considering the higher pH range 
required for competition with [M(OH)4]
- for the two hexadentate ligand. 
The difference between THPH and THPMe in their binding affinity for Ga3+ was 
investigated by a second competition experiment, designed to determine which THP 
ligand is a more efficient chelator for 68Ga under radiolabelling conditions. 68Ga was 
incubated with an equimolar solution of THPMe and THPH and quantitative binding at 
the earliest time points (1 min) was verified by iTLC reflecting the fast complexation 
kinetics of both ligand.  
145 
 
The preference 68Ga3+ for binding to THPH over THPMe was already noticeable at 1 min 
(≈ 70 % of 68Ga associated to THPH) and increased with time up to a plateau of ≈ 90 % 
from the 30 min time point onwards, in reasonable agreement with the 
spectrophotometric measurements. These data show how in a radiolabelling setting, 
THPH outcompetes THPMe for 68Ga binding. 
Notably, preference for THPH at the 1 min time point does not necessarily reflect faster 
complexation kinetics for this ligand: it could be a result of a mixture of kinetic and 
thermodynamic factors. To accurately define a kinetic preference for gallium, 
measurements at even earlier time points (as soon as 68Ga has been complexed) should 
ideally be performed.  
Overall, these results show how modification at the hydroxypyridinone ring 
unexpectedly influences the preference of THP chelators for different metals. Because 
a similar effect was not observed for bidentate hydroxypyridinone compounds [36], 
this phenomenon could be related, once again, to geometric restrictions imposed by 
the tripodal structure of the ligand and their effect on metal complexation. By 
replacing the N1-methyl group with hydrogen, the steric constraints that were present 
for THPMe are altered, and the degree and type (e.g. intramolecular vs. intermolecular) 
of hydrogen bonding is modified compared to THPMe. Both these factors could result in 
marked changes in the geometry and rigidity of the coordination sphere, leading to 





A new tris(hydroxypyridinone) chelator THPH has been synthesised in this work, 
exploiting two new synthetic strategies. Development of a new tris(hydroxypyranone) 
intermediate BnTHPO, as part of strategy C, holds promise as a flexible platform to 
generate a library of tris(hydroxypyridinone) ligands with different substituents at the 
pyridinone nitrogen. The development, using this strategy, of N1-PEGylated derivatives 
could have particular importance, since PEGylation of the ligand may improve the 
solubility of the resulting gallium complexes allowing a more complete structural 
characterisation. 
The newly developed ligand THPH was radiolabelled quantitatively with 68Ga, in the 
same mild conditions employed for THPMe and with higher affinity and selectivity over 
Fe3+. The radiolabelled complex was found stable in serum and in vivo, and displayed 
a favourable biodistribution with rapid blood clearance of the radioactive complex to 
the kidneys. Development of bifunctional derivatives is ongoing and will result in new 
radiotracers containing THPH. Comparison of tracers only differing in the 
hydroxypyridinone unit of their THP ligand (e.g. THPMe-TATE vs THPH-TATE) will be 
particularly interesting to understand the role of the chelator in determining binding 
affinity, and pharmacokinetic properties of the radiotracer. 
Evaluation of the Fe3+ and Ga3+ affinity for THPMe and THPH, revealed a marked 
preference of both chelators for Ga3+, as confirmed by competition experiments in a 
radiolabelling setting. In particular, THPH was found to be more even more selective 
towards Ga3+ than THPMe and was able to bind the majority of 68Ga in a head-to-head 
competition between the two chelators. Conversely, no preference was identified for 
the bidentate ligand deferiprone, suggesting that the tripodal framework plays an 
important role in defining metal affinity, likely by posing geometrical constraints which 
fit Ga3+ better than Fe3+. A thorough structural analysis of tris(hydroxypyridinone)-
metal complexes (by computational experiments, NMR or X-ray crystallography, where 
feasible) is warranted to accurately identify the factors determining the affinity of 
those chelators for a particular metal. This will lead to a new rational design of 
hydroxypyridinone-based chelators for 68Ga and potentially other isotopes (e.g. 44Sc, 
177Lu, 52Mn).  
As well as modification of the hydroxypyridinone unit, the tripodal framework could 
also be altered to better accommodate one specific metal ion or to change the overall 
chemical properties of the complex in terms of hydrophilicity or steric hindrance. 
Development of different tripodal framework is ongoing. Finally, different linkers have 
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already been developed for THPMe [1,5,8], but the resulting bifunctional derivatives 
have not been compared in their ability to complex 68Ga or to bind a specific receptor 
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4 Tris(hydroxypyridinone) chelators as a tool to 
influence the in vivo trafficking of gallium 
 Introduction 
As discussed in the introductory chapters, gallium tends to accumulate in some 
tumours as well as in sites of inflammation/infection. This property has been widely 
exploited by the nuclear medicine community in the past, when 67Ga-citrate 
scintigraphy was the method of choice for the diagnosis of several malignancies 
including lymphoma [1]. Use of 67Ga-citrate in clinics has progressively diminished in 
the last three decades, and currently this radiotracer retains a niche application as a 
second-choice method for imaging tumour and infections, especially in developing 
countries where access to PET isotopes is still limited. 67Ga imaging presents several 
issues, such as significant 67Ga uptake in non-target organs and high variability in 
tumour uptake among different patients [2]. However, the principal factor underlying 
the abandonment of this technique was the concomitant advent of [18F]FDG, whose 
advantages over 67Ga imaging in cancer are multiple [3]. As well as better understood 
targeting mechanisms, importantly, [18F]FDG PET scans possess higher sensitivity and 
resolution than images obtained with 67Ga SPECT and planar imaging. Furthermore, 
[18F]FDG offered the possibility of scanning patients only 1 hour after injection [2], 
greatly simplifying the clinical practice compared to 67Ga, whose slow 
pharmacokinetics requires 48-72 hours between injection and imaging to obtain 
acceptable tumour-to-background contrast. 
Unlike its SPECT analogue 67Ga, the PET radiometal 68Ga can generate high quality 
images, comparable to those obtained with 18F. Although the higher positron energy of 
68Ga results in lower intrinsic resolution of the reconstructed images compared to 18F 
[4], this is only important for preclinical instruments, since in clinical settings the 
limiting factor is the resolution of the scanner. Use of 68Ga-citrate to image gallium-
avid cancers could therefore represent an interesting alternative to [18F]FDG, 
especially in those centres that have no access to a cyclotron but could afford a 68Ga 
generator. Recently, the use of 68Ga-citrate in the imaging of lung and prostate cancer 
has been evaluated in clinical trials [5,6].  
On the other hand, the poor match between the short half-life of this isotope and the 
long time required to get sufficient tumour-to-background ratio remains a major issue 
in the use of 68Ga salts for the imaging of cancer. A higher tumour-to-blood ratio and, 
accordingly, improved image contrast, could be achieved by clearance of residual 
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blood pool activity by treatment with a suitable Ga3+ chelator. Ideally, this blood 
clearance agent should be able to bind 68Ga quickly in mild conditions and low 
concentration, but unable to remove activity from tumour cells.  
In the past decades, different chelators have been investigated in their capability to 
bind Ga3+ in vivo or in biological systems, as a tool to better understand the biology of 
gallium [7], to assess the binding efficiency of a chelator [8], or notably, to evaluate 
the use of a chelator as a contrast-enhancing agent [9-16], when imaging tumours or 
abscesses. 
In particular, deferoxamine (DFO) was extensively evaluated for this purpose in 
preclinical studies, and found able to increase the tumour-to-blood 67Ga uptake ratio 
when administered at suitable time points after 67Ga injection [10,11,16]. Doses and 
modes of administration varied among the studies, with the lowest doses being 40 
mg/kg for intravenous (IV) administration and 160 mg/kg for intramuscular (IM) 
administration. Notably, DFO is already approved by the FDA as a treatment for iron 
overload, therefore its clinical translation as a blood clearance agent for Ga3+ would 
be facilitated [17]. However, the dosage investigated for these preclinical studies 
clearly exceed those for clinical administration of this chelator in the context of iron 
overload (0.25 mg/kg per min for a maximum of 60 mg/kg per day in the case of IV 
administration, 1 g in case of IM administration [18]). The contrast-enhancing 
capability of DFO was also evaluated in a preliminary clinical study, where 5 patients 
with known malignancies were injected intramuscularly with 10 mg/kg DFO 24 hours 
after 67Ga injection, and then imaged 24 hours later. Although blood clearance effect 
was visible in the scintigraphy images, only small contrast enhancement compared to 
control images of the same patients was obtained [12]. 
THPMe has attributes that make it a good candidate as a blood clearance agent for 68Ga, 
owing to its fast radiolabelling and high affinity for 68Ga. In addition, THPMe is likely to 
be incapable of removing 68Ga previously internalised in cancer cells, owing to the high 
hydrophilicity of its gallium complex (Chapter 3), which is unlikely to cross cell 
membranes. Although clinical use of the THPMe molecule is not approved, use of THPMe 
derivatives in clinical trials [19] could potentially facilitate clinical translation of THPMe 
itself.  
As an alternative to gallium salts, complexes of gallium could also be investigated to 
deliver 68Ga3+ to tumours. A compound of interest is the tris(8-quinolonato) gallium(III) 
complex (also known as gallium-oxine, see Chapter 2), which has been investigated as 
an orally available gallium chemotherapeutic, with increased potency compared to 
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gallium salts [20]. Mechanisms of accumulation of gallium-oxine in tumours are still 
unclear [21], and is therefore unknown whether 68Ga-oxine would benefit from a blood 
clearance step using a chelator such as THPMe. 
In this chapter, the ability of the tris(hydroxypyridinone) chelator THPMe to influence 
the trafficking of gallium in biological systems has been investigated in normal animals 
and in a cancer model (both in vitro and in vivo), with the aim of evaluating this 
chelator as a 68Ga blood clearance agent for imaging applications. Both 68Ga-acetate 




 Materials and methods 
4.2.1 General equipment and consumables 
THPMe was previously synthesized in Blower’s laboratory according to published 
procedures [22]. 8-hydroxyquinoline (oxine) and ammonium acetate (99.999 % trace 
metal basis) were obtained from Sigma Aldrich and used without further purification. 
67Ga-chloride (0.1 M HCl solution) was purchased from Nordion. 68Ga was eluted from 
an E&Z generator using high purity 0.1 M HCl (Fluka) in five fractions of 1 mL each. 
Reverse-phase HPLC analysis was performed on an Agilent 1200 LC system, using an 
Agilent Eclipse XDB-C18 column (4.6 x 150 mm, 5 μm) with a 1 mL/min flow rate and 
UV detection at 214 nM, coupled to a LabLogic Flow-Count gamma detector with a 
sodium iodide probe (B-FC-3200). Mobile phase A contained 0.1 % TFA in water, mobile 
phase B was acetonitrile + 0.1 % TFA. Gradient: 0-5 min 98 % A, 5-25 min from 98 % A 
to 100 % B, 25-30 min 98 % A. Instant thin layer chromatography strips (iTLC-SG, Varian 
Medical Systems) were quantified using a LabLogic iTLCS reader. Quantification of 
radioactivity in cells and organs was performed using a LKB Wallac 1282 Compugamma 
gamma-counter.  
4.2.2 Preparation of 67/68Ga-acetate 
Acetate-buffered 68Ga was prepared immediately before use by mixing 200 µL of the 
highest activity fraction of the generator eluate (30-40 MBq) with 200 µL of an aqueous 
solution of 0.25 M ammonium acetate to reach pH 5-6. 67Ga-acetate was prepared in 
the same way from the 67Ga-chloride solution. For in vivo experiments, maximum final 
concentration of ammonium acetate was kept under 0.125 M. 
4.2.3 Preparation of 68Ga-oxine 
Radiolabelling and in vitro tests for 68Ga-oxine were performed by the then Master’s 
degree student Joanna Bartnicka, under my day-to-day supervision. Data analysis was 
performed entirely by me. 
Radiolabelling of oxine was performed according to a modified literature procedure 
[12]. Briefly, an oxine solution in ethanol (500 μL, 0.017 M) was mixed with ammonium 
acetate (250 µL of a 0.5 M aqueous solution) and 68Ga eluate (250 µL of the highest 
activity fraction). The radiolabelling mixture was heated at 50 °C for 5 min then 
applied to a Sep-Pak C18 Plus Light Cartridge (Waters), previously preconditioned with 
ethanol (5 mL) followed by water (5 mL), and eluted in ethanol in five fractions of 100 
µL. iTLC analysis of the highest activity fraction was performed using 
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chloroform:methanol = 95:5 as a mobile phase [23] (Rf 68Ga-oxine = 1, Rf unchelated 
68Ga =0). 68Ga-oxine was diluted in ammonium acetate 0.25 M (for cell uptake studies) 
or PBS (for in vivo studies) to have a maximum of 10 % ethanol in the radiotracer 
formulation. 
4.2.4 Radiolabelling of THPMe 
Radiolabelling of THPMe was performed by mixing 100 µL of the highest activity 68Ga 
eluate fraction (15-20 MBq) with 100 µL of the ligand (≈ 20 μM, in 0.5 M ammonium 
acetate). Verification of the radiolabelling was carried out after 5 min by reverse-
phase HPLC. 
4.2.5 Cell culture 
The A375 melanoma cell line [24] was provided by Sophia Karagiannis’ s group (KCL). 
Cell cultures were maintained at 37 °C in a humidified atmosphere of 5 % CO2. High-
glucose DMEM (4500 mg/L, GibcoTM, ThermoFisher) supplemented with 10 % foetal calf 
serum, L-glutamine (2 mM), penicillin (100 units/mL), and streptomycin (0.1 mg/mL) 
was used as medium. A trypsin EDTA solution (0.05 % trypsin, 0.02 % EDTA in PBS) was 
used to passage the cells.   
For experimental procedures, cells were harvested using trypsin EDTA solution, 
subsequently deactivated with complete medium. Cell density and viability were 
determined by 1:2 dilution in trypan blue solution and counting with a 
haemocytometer. All the experiments were performed under serum-free conditions 
using Hank's Balanced Salt Solution (HBSS) as a medium.  
4.2.6 Uptake of 68Ga-acetate in A375 melanoma cells 
A375 cells were harvested, counted, washed twice and resuspended in HBSS (or HBSS 
+ 0.5 % Bovine Serum Albumin (BSA), when checking the effect of BSA on 68Ga uptake). 
Then they were transferred into microcentrifuge tubes (500 L, 2 million cells/mL) 
and incubated with 5 L of acetate-buffered 68Ga (50-70 kBq/tube) at 37 °C. After 30 
min the cells were centrifuged (3 min, 250 RCF) and the supernatant removed. Cell 
pellets were washed twice with ice-cold HBSS buffer (500 L/wash) and the uptake 
measured by γ-counting. Supernatant and washes were also collected and counted. 
The percentage of the added activity that was taken up by the cells (% uptake) was 
determined dividing the CPM obtained for the pellet-containing tube by the sum of 
CPM for pellet, supernatant and washes combined and multiplying by 100. As a control 
for non-specific binding to plastic, microcentrifuge tubes containing only buffer were 
treated in the same way. Each experiment was performed in triplicate.  
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4.2.7 Uptake of 68Ga-oxine vs 68Ga-acetate in A375 cells 
A375 cells were trypsinised, washed twice and re-suspended in HBSS at 2 million 
cells/mL. 500 μL of cell suspension or HBSS only, as a control for non-specific binding 
to plastic, were transferred to microcentrifuge tubes and incubated with 68Ga-
oxine/acetate (5 μL, 50-70 kBq) for 60 min at 37 °C. Tubes were then centrifuged for 
3 min at 250 RCF, supernatant removed, and cell pellet resuspended in HBSS (500 μL). 
This step was repeated twice. Activity in the cell pellet and in the supernatant and 
washings was determined by γ-counting. 
4.2.8 Effect of THPMe on the cellular uptake of 68Ga-acetate  
THPMe solutions in saline (1 mM, 100 M and 10 M) were prepared by serial dilutions.  
A375 cells were harvested, counted, washed twice and resuspended in HBSS, then 
transferred into microcentrifuge tubes (500 L, 2 million cells/mL).  
In a first set of experiments, referred to as the “pre-68Ga” study, cells were treated 
with 50 L of the relevant THPMe solution (or saline as a control) and incubated 37 °C 
for 30 min, before addition of 5 L of acetate-buffered 68Ga (≈ 50 kBq/tube) and 
subsequent incubation at 37 °C for further 30 min. In a second “post-68Ga” study, the 
order of the two incubations was reversed. The cells were centrifuged and washed as 
previously described, then cell pellets and the sum of supernatant/washings were -
counted and the percentage uptake determined. Each experiment was performed in 
triplicate and repeated at least twice. 
4.2.9 Cellular localisation of 67Ga/68Ga uptake in A375 cells 
The uptake assay was performed as described above, assessing uptake of acetate-
buffered 67Ga (≈ 50 kBq/tube), 68Ga (≈ 50 kBq/tube) or a mixture of the two (25 KBq 
of 67Ga + 25 kBq 68Ga per tube) and how this was affected by pre-Ga/post-Ga incubation 
with 100 mM of THPMe. The cells were centrifuged and washed as previously described, 
then an acid wash was performed according to a published procedure [25]. Briefly, 
after the final wash with HBSS the cells were exposed to glycine 0.1 M (pH 2.5) for 6 
min, then the cells were centrifuged and the pellets separated from the acid wash. 
Cell pellets, supernatant/washing and acid wash samples were then γ-counted. When 
γ-counting samples containing both isotopes, narrow energy windows were set on the 
γ-counter (175-235 bin for 68Ga, and 101-115 bin for 67Ga) to minimise spill over for 
each isotope. Each experiment was performed in triplicate.  
157 
 
4.2.10 Preparation of microautoradiography samples 
Microautoradiography samples were prepared according to a modified literature 
procedure [26,27]. A375 cells were harvested, counted, washed twice and resuspended 
in HBSS, then transferred into microcentrifuge tubes (500 L, 2 million cells/mL) and 
incubated with 50 kBq of 67Ga-acetate for 45 min. After this time the cells were 
centrifuged (3 min, 250 RCF), the supernatant removed and the pellets washed twice 
with ice-cold HBSS buffer (500 L/wash). Cells were then fixed by treatment with a 
4 % formaldehyde solution for 20 min at room temperature, washed twice with PBS and 
resuspended in 200 μL of PBS. The suspension was embedded in 400 µL of warm gelatine 
(final concentration 12 % w/v in PBS) by gentle mixing and, after solidification at 4 °C, 
the resulting samples were snap-frozen in isopentane, cut into 10 μm slices using a 
cryostat (Bright Instrument Company Ltd) and the slices collected on positively charged 
polylysine-coated slides. Slices of samples containing untreated cells or 67Ga in PBS 
only were also prepared as no-gallium and no-cells control, respectively. 
4.2.11 Microautoradiography 
Microautoradiography was performed according to a procedure previously established 
in Blower’s laboratory [27]. In a dark room, the slides were coated with a nuclear 
emulsion (37.5 % v/v Ilford K2 emulsion in gel form, 0.01 % v/v glycerol in deionised 
water), left to dry on a level plate and then incubated overnight in the dark at 4 °C. 
The following day, slides were warmed to room temperature and then developed by 
incubating them in a developer buffer (Kodak D19) for 5 min. The developing process 
was then terminated by incubation in 1 % acetic acid solution (30 seconds) and the 
slides were finally dipped into a 0.5 % gelatine solution to prevent slice detachment 
from the slides. Once dried the slides were fixed by incubation with (sodium 
thiosulphate 30 % w/v in deionised water) for 5 min and washed in deionised water for 
10 min. Coverslips were placed onto the slides using a DAPI-containing mounting 
solution and the slides were then imaged using an EVOS FL Cell imaging microscope 
(Life Technologies) using both fluorescence in the blue channel (λexc = 390 nm, λem ≈ 
460 nm) and transmitted light to image cells nuclei and silver grains respectively. 
4.2.12 Establishment of A375 xenografts in NSG mice  
Female NOD scid gamma mice (NSG mice) between 42-49 days old were obtained 
from Charles River. Animals were allowed to acclimatise for at least a week after 
arrival prior to tumour inoculation. Establishment of the xenograft model was 
carried out by subcutaneous injection of A375 cells above the shoulder. Briefly, 
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A375 cells were trypsinised, washed twice with PBS and resuspended in PBS at 1 
million cells/100 μL. Mice were anaesthetised using isoflurane (2.5 %, O2 flow rate: 
1 L/min) and 100 μL of PBS containing 1 million A375 cells was injected 
subcutaneously above the shoulder (right shoulder for the first study, left shoulder 
for the second study) after shaving of the area. Mice were monitored daily and, 
after tumours became palpable, tumour diameters were measured regularly until 
a mean orthogonal diameter of ≈ 8 mm was reached. An example of tumour growth 
curve (obtained for the second study) is reported below.  
 
Figure 4.1. Growth curve determined for A375 xenografts in NSG mice. Mean orthogonal 
diameter was measured daily for all mice and is reported as mean ± SD (N = 15). 
4.2.13 Biodistribution and clearance studies 
Biodistribution and clearance experiments included both PET/CT imaging and ex vivo 
biodistribution. BALB/c mice (female, 7-9 weeks, Charles River) were used for 
clearance experiments in healthy animals. NSG mice (female, 7-9 weeks, Charles River) 
were used for experiments with A375 xenograft.  
PET and CT scans were carried out on a nanoScan® PET/CT (Mediso Medical Imaging 
Systems) [28] with the following parameters: 
 PET: 1:5 coincidence, 5 ns time window, 400-600 KeV energy window. 
 CT: 180 projection, 45 KVp. 
Respiration rate and bed temperature were monitored throughout all scans. PET/CT 
datasets were reconstructed using the Monte-Carlo based full 3D iterative algorithm 
Tera-Tomo (Mediso Medical Imaging Systems) [29] using 1:3 coincidence and a voxel 
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size of 0.21 x 0.21 x 0.21 mm3. Images were analysed using VivoQuant software 
(inviCRO), which enables the co-registration of PET and CT images and the delineation 
of regions of interest for quantification of activity in specific organs (Otsu 
thresholding). 
Mice were anesthetised with isoflurane (O2 flow rate: 1.0-1.5 L/min and isoflurane 
levels: 2-2.5 %) and kept anaesthetised for all the procedure so that dynamic PET scan 
could be performed. Activity was injected into the tail vein using an in-house made 
catheter (25 μL volume) or an insulin syringe (0.3 mL, Terumo), followed, where 
applicable, with injection of the chelator after a defined time interval. Relevant 
PET/CT scans were performed. Upon procedure completion, animals were sacrificed 
by neck dislocation while still anesthetised, tissues harvested and ex vivo 
biodistribution assessed by γ-counting. Tubes containing different volumes of the 
radiotracer solution (corresponding to different % ID) were also counted as internal 
standards and the calibration curve obtained by linear regression of the data was used 
to convert measured CPM in % ID for every organ. An example of calibration curve is 
reported in Figure 4.2. 
 
Figure 4.2. Example of a calibration curve obtained by linear regression of CPM/%ID 
data from internal standards. 
Residual activity in the tail (due to an imperfect IV injection) was subtracted from the 
total activity injected, and tail-corrected % ID was calculated for each organ. % ID/g 
was obtained by dividing the tail-corrected % ID of each organ by its weight. Details 
for each experiment are reported in the following paragraphs. 
Dose finding experiment (pilot study) 
BALB/c mice were positioned on the PET/CT scanner bed and cannulated at the tail 
vein. A 90 min PET scan was started. Mice were injected with 100 µL of 68Ga-acetate 
(5-10 MBq), followed, after 45 min, by 100 µL of THPMe solution in saline (amounts are 
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reported in Table 4.1, each dose was tested in at least one mouse, two mice were 
used for 0 and 20 µg doses). When pH of the THPMe solution was lower than 5, pH was 
adjusted to 7 using 0.1 M NaOH. A CT scan was performed upon completion of the PET 
scan. Mice were culled at 100 min post 68Ga-injection.  
Table 4.1. Doses of THPMe (hydrochloride salt) utilised for in vivo experiments. 
Doses of THPMe 
Amount/µg Amount/nmol neutralised 
0 0 No 
1 1.2 No 
5 6 No 
20 24 No 
100 118 Yes 
500 590 Yes 
 
Ex vivo biodistribution was performed by collecting the whole organ in the case of tail, 
heart, lungs, liver, spleen, stomach and kidneys. The femur was used as representative 
of bone. Skin and fur were collected from the abdomen of the mouse and muscle was 
taken from the hindlimb. Only part of the small and large intestine was collected. 
Stomach, small and large intestine were emptied prior to counting. All organs were 
washed in water to eliminate residual blood. Urine of the mice treated with 0 or 20 µg 
of THPMe (≈100 μL) was analysed by reverse-phase HPLC  
Delay finding study  
BALB/c mice were anaesthetised and injected with 68Ga-acetate (100 µL, 5-10 MBq) 
via a tail vein cannula, as previously described. 100 µL of the relevant THPMe solution 
(0, 1, 5 or 20 µg) was administered in the same way at 5 or 90 min after the first 
injection. For those animals that were scanned (1 mouse per time point), CT was first 
performed, followed by start of a PET scan and activity injection. All animals were 
kept under anaesthesia for the duration of the experiment. Mice were culled 15 min 
after the second injection (20 or 105 min post 68Ga-injection). Biodistribution was 
determined as previously described. 
68Ga-acetate vs 68Ga-oxine accumulation in A375 xenografts 
Mice were anaesthetised and injected with 68Ga-acetate or 68Ga-oxine (200 µL, 13-18 
MBq, 5 mice per group) via a tail vein injection. Mice were kept under anaesthesia for 
the duration of the experiment. After 4 hours mice were sacrificed and ex vivo 
biodistribution determined as described earlier. Three animals per group were also 
imaged for the whole experiment time. 
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THPMe vs DFO Clearance in healthy mice and A375 xenografts 
The same clearance experiment was performed in healthy mice (9 subjects, BALB/c) 
and immunocompromised mice bearing A375 melanoma xenografts (15 subjects, NSG 
mice). In both cases, mice were anaesthetised and injected with 68Ga-acetate (100 µL, 
≈10 MBq) via a tail vein injection, as previously described. After 1 hour, 50 µL of a 
clearance agent solution (24 nmol of THPMe or DFO, or saline as a control) was 
administered in the same way. At least one mouse per group was imaged before and 
after the second injection (PET from 20 to 45 min and from 80 to 105 min after 
injection of 68Ga-acetate). Mice were kept anaesthetised for the whole experiment, 
sacrificed at 130 min post 68Ga injection and ex vivo biodistribution performed as 
described above. No emptying of stomach and intestines was carried out in these 
experiments and blood was collected by cardiac puncture. 
4.2.14 Power calculations and statistical analysis of the data 
Sample size for in vivo experiments was calculated in order to have a statistical power 
(1-β) of 80% and a type I error probability (α) of 5%. A minimal sample size of n = 3 was 
calculated, to detect a difference between a signal-to-noise ratio of 10 ± 2 
(experimental group) versus 5 ± 2 (control) when performing one-way analysis of 
variances (ANOVA) followed by up to 2 pairwise comparisons between groups (THPMe vs 
DFO experiments). When 3 pairwise comparisons were considered (delay finding 
experiment) a minimal sample size of n = 4 was calculated. 
Data obtained for in vitro and in vivo studies were analysed using GraphPad Prism, 
version 7.04 for Windows (GraphPad software). Unpaired, two-tailed Student’s t-test 
was generally used when comparing two groups. One-way ANOVA was used to analyse 
results where more than two groups were compared. In this case, Tukey post-hoc test 
was employed to correct for multiple comparisons when those were performed 
between all the groups. Dunnett post-hoc test was used for comparison between each 
of the experimental groups and the control group. Whenever variances of groups were 
found to be significantly different (according to an F test when comparing two groups, 
and to both Brown-Forsythe and Bartlett’s test when comparing more than two groups) 
the data were re-analysed using a Welch-adjusted t-test, which does not assume equal 






This work was aimed at evaluating the potential of THPMe as a blood clearance agent 
to increase tumour-to-background contrast in 68Ga salts imaging of cancer, using an 
A375 human melanoma model. To achieve this goal, two distinct streams of work were 
carried out. On one hand, the 68Ga-acetate uptake in the selected model was 
investigated, both in vitro and in vivo and compared with the uptake of a different 
gallium species such as 68Ga-oxine. On the other hand, the ability of THPMe to bind 
gallium in biologically relevant contexts and to influence the distribution of this 
radiometal in vitro and in vivo was examined. These two parallel streams converged 
into a final in vivo experiment, where the use of THPMe as a blood clearance agent was 
tested in mice bearing A375 melanoma xenografts.  
4.3.1 In vitro assays 
The A375 cell line was selected as a tumour model for this work based on preliminary 
evidence of 68Ga-acetate uptake in A375 xenografts in NOD-SCID mice by our group 
(unpublished data). However, before replicating the same in vivo study and testing the 
clearance effect of THPMe in tumour bearing animals, a set of in vitro experiments was 
performed to further characterise 68Ga uptake in the selected cell line.  
Cellular uptake of 68Ga-acetate 
The uptake of 68Ga in A375 cells in vitro was evaluated using uptake assays in 
suspension, by measuring the percentage of activity retained by 106 cells compared to 
the total activity (calculated as the sum of the activity in the pellet, supernatant and 
washings). Ammonium acetate was used to buffer the 68Ga eluate to pH of about 5.5 
before addition to the cells. Different conditions were tested in different studies as 
described in the following paragraphs.  
In a preliminary uptake study the effect of different amounts of 68Ga (18-74 kBq) was 
investigated to establish a range of activity for which the percentage uptake did not 
vary considerably. As reported in Figure 4.3, no significant difference in the uptake 
was found for the range of activity tested (18-74 kBq/tube). In the following 
experiments the amount of activity added to each tube was kept in the range 50-70 
kBq/tube.  
The ratio between the concentration of activity in the cells pellet and in the 
supernatant/washings was also calculated (Figure 4.3 B), considering A375 cells in 
suspension as spheres with an average diameter of 16 µm [30]. This value provides a 
measure of the 68Ga accumulation in cells, which is independent from the number of 
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cells used. Notably, the average % uptake of 5.5 ± 1.3 measured in this experiment 
over the three groups, corresponds to a 38 ± 9 higher concentration of activity in the 
cells pellet compared to the HBSS buffer. 
 
Figure 4.3. Uptake of 68Ga-acetate in A375 cells treated with different amount of activity 
(18-74 kBq), expressed both as a % Uptake (A) and as a ratio between cellular and 
extracellular concentration of activity (B). Data are represented as mean ± SD (N = 3) 
ANOVA analysis of the data was performed followed by Tukey post-hoc test for multiple 
comparisons between groups. No significant difference between the considered groups 
was found. 
Notably, this first experiment was performed in HBSS buffer containing 0.5 % of BSA, 
which is routinely added in uptake experiments by many investigators to avoid non-
specific uptake of the activity (e.g. due to activity sticking to the plastic walls of a 
plate or a microcentrifuge tube). However, BSA can also interact with the unchelated 
radiometal, potentially altering its cellular uptake and the ability of a chelator to 
sequester the radiometal. Therefore, in a second experiment the effect of BSA on the 
uptake of 68Ga was evaluated both in A375 cells and in a sham experiment, where the 
activity was added to microcentrifuge tubes containing the same buffer (with or 
without BSA) but no cells, to determine the fraction of uptake due to non-specific 




Figure 4.4. Preliminary assay evaluating the effect of BSA presence in the buffer on 68Ga 
uptake in A375 cells. Data are represented as mean ± SD (N = 3) Statistical analysis of 
the data was performed by ANOVA followed by Tukey post-hoc test for multiple 
comparisons between groups P values are defined as follows: **= 0.0048, and **** = P 
≤ 0.0001. 
Notably, although no significant difference was found between cellular 68Ga uptake in 
the presence of BSA and that in HBSS alone, a P value of 0.06 was calculated suggesting 
that % uptake in HBSS alone is higher, although the difference is not statistically 
significant owing to the low number of replicates. No difference was visible between 
68Ga uptake in HBSS only samples with or without BSA. Significant difference was found 
for both HBSS and HBSS + BSA groups when comparing the uptake in cells and in buffer 
only samples. Interestingly, this difference was even more pronounced in the absence 
of BSA (P value < 0.0001). Overall this experiment showed that BSA addition to the 
buffer was not necessary to minimise non-specific uptake of the microcentrifuge tube 
and subsequent experiments were all performed in HBSS only. 
Notably, variability in the total uptake (2-10 %) was found between experiments 
performed on different days (different generator elution, different batch of cells). 
Therefore, another set of experiments was performed to verify that a change in cell 
culturing factors such as different flask confluency, different passage number could 
not significantly affect the results. Ruling out possible causes of variability was 
particularly important in our serum-free uptake studies, for which the measured 68Ga 
uptake must be attributed to transferrin-independent pathways, whose mechanisms 
are still not understood. These additional experiments (Figure 4.5) showed that 
neither the confluency nor the passage number of the cells used in the assay had a 




Figure 4.5. Uptake assays evaluating the effect of difference confluency and passage 
number on the 68Ga cells uptake. Data are represented as mean ± SD (N = 3) ANOVA 
analysis of the data was performed followed by Tukey post-hoc test for multiple 
comparisons between groups. P values are defined as follows: *** = P ≤ 0.001, and 
**** = P ≤ 0.0001. 
In the subsequent experiments, a normalised uptake was used, with the average 68Ga-
acetate uptake (control group) set to 1 and variation observed for the experimental 
condition expressed as a fraction of the original uptake. In this way, it was possible to 
average data obtained from experiments repeated in different days, irrespective of 
the absolute percentage uptake measured in each individual experiment. 
68Ga-acetate vs 68Ga-oxine 
68Ga-oxine could in principle be used as an alternative way to deliver 68Ga to tumour 
cells, exploiting the ionophore character of the oxine ligand, which is able to cross the 
cell membrane to deliver its metal ion load. 68Ga-oxine was prepared according to 
literature procedures [31] and radiochemical purity > 95 % was verified by iTLC-SG. 
Uptake of 68Ga-oxine in A375 cells was assessed in comparison with that of 68Ga-acetate 
in the same cell line. As expected, given the increased lipophilicity of the oxine 
complex [32], a significantly higher cellular uptake of 68Ga-oxine compared to 68Ga-
acetate (≈ threefold higher uptake, Figure 4.6 A) was found. However, there was also 
a significantly higher plastic binding for 68Ga-oxine. Data were therefore corrected for 
the respective non-specific uptake and reanalysed (Figure 4.6 B), showing a significant 
difference between the uptake of the two 68Ga species, with a twofold increase in 




Figure 4.6. Comparison between cellular uptake of 68Ga-acetate and 68Ga-oxine in A375 
cells, expressed as a normalised uptake w/r to A375 uptake of 68Ga-acetate (mean ± SD, 
n = 8). Data for experimental groups are represented together with their buffer-only 
control (A) or already corrected for plastic uptake (B). A t-test to evaluate the difference 
between 68Ga-acetate and 68Ga-oxine uptake was carried out for every group. P values 
are defined as follows: ** = P ≤ 0.01, and **** = P ≤ 0.0001. 
Effect of THPMe on the cellular uptake of 68Ga 
Two different experiments were carried out to examine whether, and to what extent, 
THPMe could influence the cellular uptake of 68Ga. The first set of experiments was 
aimed at evaluating whether the presence of THPMe in the system could prevent or 
reduce cellular uptake of activity. In these experiments, referred to as the “pre-68Ga” 
studies, 68Ga was added to cells already incubated for 30 min with different 
concentration of THPMe in saline (or just saline as a negative control). Incubation was 
carried out for a further 30 min upon 68Ga addition, followed by washings and 
determination of the cellular uptake. In a second set of experiments, the ability of 
THPMe to remove 68Ga already taken up by cells was evaluated. In these experiments, 
referred to as “post-68Ga” studies, the order of the two additions was reversed: cells 
were first incubated for 30 min with 68Ga and THPMe was then added to the system. 
Results for both studies are reported in Figure 4.7. 68Ga binding to plastic was also 
measured with buffer-only samples containing THPMe, but values were very high and 




Figure 4.7. 68Ga uptake in A375 cells at different THPMe concentrations, expressed as a 
normalised uptake with respect to the 0 µM control, for cells treated with the chelator 
before (pre-68Ga) or after (post-68Ga) incubation with 68Ga-acetate. Values are expressed 
as mean ± SD (N = 6). ANOVA analysis of the data was performed followed by Dunnett 
post-hoc test for multiple comparisons between groups. P values are defined as follows: 
* = P ≤ 0.05, *** = P ≤ 0.001 and **** = P ≤ 0.0001.  
The significant decrease in 68Ga uptake observed in the presence of THPMe for both 
experiments, demonstrates that, in both the conditions tested, chelator binding to 
68Ga is competing with cellular uptake of the radiometal. Notably, this also implies 
that the radiolabelled complex [68Ga(THPMe)] does not accumulate in A375 cells (or 
accumulates less than unchelated 68Ga). In the pre-68Ga experiment, this decrease was 
more marked and showed a concentration dependent trend. This was expected as, in 
this study, the chelator starts to compete with cellular uptake of 68Ga from time 0 
after addition of the radiometal. Concentration dependence of the decrease reflects 
the increased ability of THPMe to compete for 68Ga binding when present at higher 
concentration. The less marked decrease in uptake observed for the post-68Ga 
experiment suggests that addition of the chelator to cells already incubated with 68Ga 
can only hamper further uptake of the radiometal, but cannot deplete the intracellular 
pool of 68Ga. No obvious concentration dependent trend was visible for the post-68Ga 
experiment although the maximum decrease in uptake was found at the highest 
concentration of the chelator. 
The two experiments were repeated, for the highest concentration group and the 
control, with the addition of an acid wash step, to strip any activity bound to the 
surface of the cells, thus discriminating membrane bound activity from the 
intracellular pool. This allowed further investigation on the distribution of the activity 





Figure 4.8. 68Ga uptake in A375 cells with and without THPMe treatment, expressed as 
normalised uptake (mean ± SD, N = 6) for both pre-68Ga and post-68Ga experiments. For 
all the samples an acid wash was performed to distinguish between intracellular and 
membrane uptake. A t-test to evaluate the difference between THPMe treated samples 
and control was carried out for every group (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001). 
As already observed in the previous study, addition of THPMe before incubation with 
the radiometal resulted in a larger decrease in total 68Ga uptake (to 54 % of that 
measured in the absence of THPMe), compared to addition of THPMe after 30 min of 
incubation (73 % of the uptake measured in the absence of THPMe). Notably, the vast 
majority of the activity was located intracellularly for all the considered groups and 
this percentage increased for the THPMe treated groups. In fact, while the membrane 
bound activity was drastically reduced for both experiments (to 36 and 43 % of that in 
the absence of THPMe for the pre-68Ga and post-68Ga experiments, respectively), a less 
marked reduction was found for the intracellular pool of 68Ga. In particular, for the 
post-68Ga experiment, the percentage of intracellular activity only decreased by 16 % 
compared to the untreated sample, while a 51 % decrease was measured for the pre-
68Ga experiment. These results agree with the hypothesis that the intracellular pool of 
gallium is not readily accessible to THPMe, which can only chelate the radiometal in 
the extracellular solution, thus preventing its cellular uptake. THPMe affects the 
percentage of intracellular activity to a lesser extent in the post-68Ga experiment, 
because in this case a large part of the activity has already been internalised before 
addition of the chelator. Notably, although no significant difference was found 
between the intracellular uptake groups for the post-68Ga experiment, the low P value 
calculated (P = 0.09) suggests that a difference may be present and detectable when 
increasing the number of replicates. 
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Microautoradiography and 67Ga uptake assays 
Microautoradiography (MAR) was used to further investigate the uptake of gallium in 
the A375 cell line. This technique allows visualisation of the activity taken up by single 
cells as dark silver grains in bright field microscopy images. In MAR experiments, cells 
are treated with the radioisotope and sectioned in thin slices upon freezing and/or 
fixation/embedding in a suitable matrix. Sections are immobilised on a slide and then 
covered with a thin film of a nuclear emulsion containing silver bromide. Interaction 
of AgBr with the particulate emission of the radionuclide results in formation of silver 
grains that can be visualised using bright field microscopy. Generally, sensitivity of this 
technique increases with the half-life of the radionuclide and the abundance of low 
energy electron emissions. On the contrary high-energy emission and large thickness 
of section and films impair the spatial resolution of MAR images [26]. Accordingly, 68Ga 
could not be used in this experiment and was replaced by 67Ga, for which MAR has been 
previously reported [33]. The amount of radioactivity added per tube was kept the 
same as in the uptake studies (50-70 kBq/tube). Cells were fixed and embedded in 
gelatine prior to snap-freezing in isopentane, and sections were cut at a 10 µm 
thickness with a cryostat. 
Some representative MAR images (blue channel and bright field images) are reported 
below (Figure 4.9) for 67Ga treated cells. 
 
Figure 4.9. Microautoradiography images of A375 cells treated with 67Ga. Blue 
fluorescence (DAPI) images are displayed on the left, bright field transmitted light images 
are on the right. Arrows indicate cells where radiometal accumulation is evident (black 
arrows) or low/absent (white arrow). 
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Representative images for control samples such as the cells only (no gallium) sample 
and the gallium only (no cells) sample are also reported in Figure 4.10. 
 
Figure 4.10. Microautoradiography images of cells only sample (no 67Ga treatment) and 
gallium only samples (no cells). Blue fluorescence (DAPI) images are displayed on the 
left, bright field transmitted light images are on the right.  
MAR images for 67Ga treated cells clearly show cellular uptake of 67Ga both at a surface 
and intracellular level. On the contrary, a uniform distribution of the activity was seen 
in the 67Ga-only control, while almost no silver grains were found in the cells-only 
samples. This technique revealed a highly inhomogeneous distribution of the activity 
in the cells, with many cells showing little or no evidence of 67Ga uptake and others 
taking up a high level of activity. Interestingly, these images also showed how the 
activity seemed prevalently located at the membrane level in contrast with the results 
obtained for 68Ga uptake assays. 
To verify whether this difference in distribution was due to the different gallium 
isotope used in this experiment, the uptake assay with acid wash was repeated using 
67Ga. Evaluation of the effects of pre-67Ga and post-67Ga incubation with THPMe was 




Figure 4.11. 67Ga uptake in A375 cells with and without THPMe treatment expressed as 
normalised uptake (mean ± SD, n = 6) for both pre-67Ga and post-67Ga experiments. For 
all the samples an acid wash was carried out to distinguish between intracellular and 
membrane uptake. A t-test to evaluate the difference between THPMe treated samples 
and control was carried out for every group (* = P ≤ 0.05, ** = P ≤ 0.01). 
Notably, similar to what was seen in the MAR images, membrane-bound activity was 
higher than the intracellular uptake for this 67Ga uptake study in contrast to what was 
previously observed for the same experiment with 68Ga. Interestingly, the effect of 
THPMe treatment was still significant for all groups except for the intracellular uptake 
in the post-68Ga study where no effect was noted (P = 0.33).  
Since isotopes of the same element are expected to possess identical chemical 
properties, we hypothesised that the different distribution pattern was imputable to 
the different molarity of gallium in the samples for the 67Ga and the 68Ga experiments. 
In fact, in both experiments cells were treated with the same amount of activity (50 
kBq). However, this corresponds to a different number of mole (and therefore 
concentration) of the radioisotopes in the sample, according to the equation reported 





where activity is expressed in Bq, Na is the Avogadro’s number, ni the number of moles 
of the isotope and t1/2 i its half-life expressed in seconds [34]. Since 
67Ga has a 70-fold 
longer half-life than 68Ga, this results in a 70-fold higher concentration of Ga3+ for the 
same activity in the same total volume in the case of 67Ga. This higher concentration 
could saturate the intracellular pool of gallium so that any further cellular uptake 
would take place at the membrane level only. This hypothesis also explained the 
complete lack of effect of THPMe on the intracellular uptake for the post-68Ga 
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experiment, suggesting that for this group saturation of the intracellular pool was 
reached in the first 30 min, before addition of THPMe. 
To confirm this hypothesis the same experiments were repeated in which each sample 
was treated with a mixture of 67Ga (25 kBq) and 68Ga (25 kBq) and the uptake of each 
radioisotope measured by γ-counting using different energy windows. As is evident 
from Figure 4.12, both isotopes showed the same behaviour in these experiments, 
with the higher concentration of gallium driving uptake on the membrane. 
 
Figure 4.12. Uptake of 67/68Ga in A375 cells with and without THPMe treatment expressed 
as normalised uptake (mean ± SD, n = 3) for both pre-67/68Ga (A) and post-67/68Ga (B) 
experiments. A t-test was performed to evaluate the difference between 68Ga and 67Ga 
samples and between THPMe treated samples and control for each isotope (* = P ≤ 0.05, 
** = P ≤ 0.01). 
4.3.2 THPMe-mediated 68Ga blood clearance in healthy animals 
Preclinical experiments in healthy BALB/c mice were initially carried out to evaluate 
to what extent intravenous injection of THPMe could influence the in vivo 
biodistribution of 68Ga. Three different studies were conducted and their results are 
reported in the sections below. 
Dose finding study 
In the first instance, a small pilot study was conducted to investigate whether THPMe 
could effectively bind 68Ga in blood, and the amount of the chelator that was needed 
to observe an influence on the in vivo biodistribution of the radiometal. Five different 
doses, ranging from 1 µg (1.2 nmol) to 500 µg (590 nmol) were tested and compared 
with a 0 µg control (saline injected). A 90 min dynamic PET/CT scan was performed 
for each mouse, 68Ga-acetate was injected intravenously at time 0 using a cannula, 
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followed by THPMe 45 min later. This amount of time was deemed sufficient to deliver 
enough of the injected 68Ga from the circulation to the tissues, but not so long as to 
result in poor image quality, given the short half-life of 68Ga. 
Ex vivo biodistribution was performed at 90 min post 68Ga injection. Percentage 
injected dose per gram (% ID/g) calculated for relevant organs are reported in Figure 
4.13. 
 
Figure 4.13. Biodistribution of 68Ga in selected organs expressed as % ID/g at different 
amounts of injected THPMe. (N = 1, pilot study). 
Although this was a pilot experiment, with N =1 for each group, some qualitative 
considerations can be made. Notably, a difference was found for the activity in the 
blood pool when comparing treated animals (average of 1.7 ± 1.0 % ID/g, or 1.2 ± 0.3 
% ID/g when excluding the 1 µg dose) and the mouse injected with saline (2.2 % ID/g). 
However, a larger difference was visible for most of the other organs, where the 
uptake was lowered for animals treated with THPMe. Importantly, the graph also 
highlights high variability for the % ID/g values, with particularly high activity in the 
kidneys for the 1 μg dose (67 % ID/g vs an average of 3.4 % ID/g for the other animals) 
and in the liver for the 0 and 500 μg doses (20.8 and 13.7 % ID/g, respectively vs an 
average of 4.6 % ID/g for the other animals). PET/CT images confirmed this variability 
and showed how in the case of the liver, high uptake was visible from the beginning of 
the scan. Maximum intensity projections (MIP) for the 20 µg dose and the control are 




Figure 4.14. Maximum intensity projections (MIP) for the 20 µg (upper panel) and 0 µg 
(lower panel) doses scaled with respect to the injected activity.  
Notably, despite the observed variability, in all the mice treated with THPMe a sudden 
change in biodistribution was visible after THPMe injection as shown in Figure 4.14 A 
for the 20 µg dose. 68Ga accumulation in the kidneys and then in the bladder was 
observed as the activity was cleared from the blood into urine. No such effect was 
visible for the saline treated mouse (Figure 4.14 B). 
Repetition of the experiment for both the 20 and 0 µg doses, confirmed both the 
reproducibility of the clearance effect and the high variability of 68Ga-acetate 
biodistribution, as shown in Figure 4.15. In this case, the mouse injected with saline 
only (Figure 4.15 B) showed extremely low liver uptake compared to the previous 
control experiment (Figure 4.14 B). On the contrary the mouse injected with 20 µg of 
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THPMe (Figure 4.15 A) presented higher liver and spleen uptake compared to the first 
mouse treated with the same dose (Figure 4.14 A). Importantly, notwithstanding this 
variability, the clearance effect was still visible in the 20 µg scan, while no clearance 
was observed for the control experiment. The reasons for the observed inconsistency 
in 68Ga-acetate biodistribution are not completely understood, but likely related to 
differences in generator elutions (see Discussion). 
 
Figure 4.15. Maximum intensity projections (MIP) for normal mice injected with 20 µg 
(upper panel) or 0 µg (lower panel) of THPMe. Images are scaled with respect to the 
injected activity. Compared to Figure 4.14, a different initial 68Ga biodistribution for the 
two animals is visible. 
To verify that blood clearance effect seen for THPMe treated animals was actually due 
to in vivo chelation of 68Ga, the urine of the mouse injected with 20 µg of the chelator 
(MIP shown in Figure 4.14 A) was analysed by reverse-phase HPLC, obtaining a single 
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peak in the radiochromatogram at 15 min 43 s (Figure 4.16). Comparison with the 
radiochromatogram obtained for [68Ga(THP)] using the same method and displaying a 
unique peak at 15 min 28 s (Figure 4.16) confirmed in vivo chelation of 68Ga by THPMe.  
 
Figure 4.16. Comparison between the reverse-phase HPLC radiocromatograms for the 
urine of the mouse treated with 20 µg of THPME (top panel, retention time: 15 min 43 s) 
and for [68Ga(THPMe)] (bottom panel, retention time: 15 min 28 s). 
When the same procedure was applied to the urine of the saline treated mouse, no 
peak corresponding to [68Ga(THPMe)] was observed in the radiochromatogram, and the 
activity remained trapped in the HPLC column. This behaviour is commonly observed 
for unchelated 68Ga at neutral pH. 
An alternative way to visualise the clearance effect is provided by time/activity 
curves, showing the amount (or concentration) of activity in different organs as a 
function of time, as quantified from dynamic PET scans. Representative examples of 
time/activity curves showing the amount of activity associated with heart (as a 
measure of blood), kidneys and bladder (as a measure of urine) are reported in Figure 





Figure 4.17. time/activity curves showing the % ID in selected organs as a function of 
time, for a mouse injected with saline (0 µg THPMe, A) or with 20 µg of THPME (B) at 45 
min after 68Ga injection. Each data point represents a 5 min interval (the end point of the 
time interval was set as “x” value for each data point). 
As it is clearly noticeable from the graphs, a sudden change of trend is visible for the 
animal injected with 20 µg of chelator between 45 and 50 min, with a sudden increase 
of activity in the bladder. A decrease in the activity in the heart is also visible, although 
less dramatic. % ID in the kidneys initially rose after THPMe injection. followed by a 
decrease as the activity is moving towards the bladder. Owing to the already 
mentioned variability in 68Ga-acetate biodistribution, time/activity curves for 
different mice displayed different absolute % ID/organ values (data not shown). 
However, they all showed a similar trend with a sudden change in the profile at 45-50 
min for treated animals while no appreciable changes were visible for the control mice. 
Overall this first experiment showed how THPMe is able to bind 68Ga in vivo when 
administered at 45 min post injection of the activity. This resulted in a sudden 
acceleration in the blood clearance of the activity and, accordingly, in lower 68Ga 
uptake in most of the organs. The 20 µg dose showed the most promising results and 
no further improvement was found for the 100 µg and 500 µg doses, which were 
therefore not included in further investigation. 
Delay finding study 
The preliminary in vivo experiment highlighted 68Ga clearance ability of THPMe at 45 
min post injection for THPMe doses as low as 1 µg. The investigation was then repeated 
in a larger number of animals using two different time delays between injection of 
68Ga-acetate and THPMe, with the aim of assessing the influence of this time interval 
on the clearance effect. Two extreme time intervals were chosen, namely 5 and 90 
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min, between injection of 68Ga and of THPMe. For each time delay, THPMe doses of 1, 5 
and 20 µg were investigated and compared to an injection of saline (0 µg dose). Four 
animals were randomly assigned to each group. Notably, biodistribution studies of mice 
belonging to the same group were spread over several days of experiments to avoid 
systematic error due to difference associated with external factors such as 68Ga elution 
or time of the day and to unambiguously assign any significant differences to THPMe-
mediated clearance. This is all the more important given the high variability in 68Ga 
biodistribution observed in the pilot experiment.  
One animal per group also underwent dynamic PET/CT imaging. However, due to 
technical problems with the PET scanner, no CT was performed for the control (0 µg) 
mice, and therefore the scans are reported as PET only images (Figure S1 and S2, 
Supplementary Information). In both experiments mice were culled 15 min after 
THPMe injection, organs harvested and % ID/g determined. 
Ex vivo biodistribution for the 5 min delay groups (20 min post 68Ga injection) is 
reported in Figure 4.18. A general trend is clearly visible in the graph: the activity in 
urine and in the organs involved in renal clearance increased with increasing amount 
of chelator injected. The opposite was true for blood and, most notably, for those 
organs where gallium tends to concentrate over time such as bone and liver [35]. 
 
Figure 4.18. Ex vivo biodistribution of 68Ga in mice treated with different doses of THPMe, 
with a delay of 5 min between the two injections. Values are expressed as mean ± SD 
(N = 4 except for urine where N = 3 for 0, 1 and 5 µg). Statistical analysis was performed 
for each organ using one-way ANOVA, followed by Dunnett post-hoc test to correct for 
multiple comparisons (black *). For the groups shaded in blue, unequal variances were 
obtained (Brown-Forsythe and Bartlett test) and Welch-adjusted t-test was also carried 
out (blue *). P values for a given concentration are evaluated in comparison with the 
relevant 0 µg value (* = P ≤ 0.05, ** = P ≤ 0.01). 
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Importantly, these data are characterised by high variability, especially in those organs 
involved in excretory and metabolic pathways of gallium. Accordingly, the statistical 
significance of differences between groups is limited. Data were initially analysed by 
one-way ANOVA, which highlighted a significant difference in the femur % ID/g for each 
treated group compared to the control. Similarly, a difference from the control was 
found for the 5 and 20 µg groups in the lungs and, unexpectedly, for the 1 µg group in 
the skin and fur. Importantly for some organs (shaded in blue in Figure 4.18), unequal 
variances among the groups were calculated both by the Brown-Forsythe and Bartlett 
test, thus questioning the validity of one-way ANOVA for those groups. Re-analysis of 
those data was performed using a Welch-adjusted t-test between each of the treated 
groups and the control. According to this analysis, the kidneys % ID/g for 20 µg was 
also statistically different from the control, while the differences in the femur % ID/g 
remained statistically significant only for the 5 and 20 µg groups.  
In the case of the 90 min delay experiment, the ex vivo biodistribution (Figure 4.19) 
showed significantly fewer differences between treated and untreated groups, 
although a trend was still visible in the kidneys. However, due to the large variability 
for this organ, no significant difference was found for the kidney uptake of the treated 
groups compared to the control.  
 
Figure 4.19. Ex vivo biodistribution of 68Ga in mice treated with different doses of THPMe, 
with a delay of 90 min between the two injections. Values are expressed as mean ± SD 
(N = 4 except for the 20 µg group where N = 3 and for urine where N = 2 for 1 and 20 µg 
groups). Statistical analysis was performed for each organ using one-way ANOVA, 
followed by Dunnett post-hoc test to correct for multiple comparisons (black *). For the 
groups shaded in blue, unequal variances were obtained (Brown-Forsythe and Bartlett 
test) and Welch-adjusted t-test was also carried out (blue *). P values for a given 
concentration are evaluated in comparison with the relevant 0 µg value (* = P ≤ 0.05). 
180 
 
Scarcity of statistical significance in both cases can be partially attributable to high 
variability in key organs, reducing the statistical power of the experiment compared 
to the predicted value for a sample size of n = 4 (see Materials and Methods). In an 
attempt to increase the statistical power of the experiment, the data of each 
experiment were regrouped as non-treated and treated group, with the latter group 
now having N = 12. Ex vivo biodistribution values for the regrouped data are reported 
in Figure 4.20 A and B. Statistical analysis of the data, in this new regrouped form, 
revealed statistically significant differences between treated and untreated group.  
 
Figure 4.20. Ex vivo biodistribution of 68Ga in mice treated with THPMe or saline at 5 min 
(A) or 90 min (B) after 68Ga injection, regrouped as treated and untreated groups. Values 
are expressed as mean ± SD, N = 4 for the untreated groups, N = 12 for the 5 min treated 
group, N = 11 for the 90 min treated group except for urine (N = 8). Statistical analysis 
was performed for each organ using a t-test (black *). For the groups shaded in blue, 
unequal variances were obtained (F test) and therefore Welch-adjusted t-test was also 
carried out (blue *). P values for a given concentration are evaluated in comparison with 
the relevant 0 µg value (* = P ≤ 0.05, ** = P ≤ 0.01).  
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For the 5 min time-delay group, a significantly reduced femur uptake was found for 
the treated group, together with significantly enhanced uptake in organs related to 
excretory pathways (kidney and urine/bladder). Unsurprisingly, the statistically 
significant increment observed for the skin and fur in the original data, is present also 
in this regrouped version. For the 90 min time-delay, only a trend in kidney uptake was 
observed and, accordingly, the only statistically significant difference arising for the 
regrouped version of the data is an increased kidney uptake for the treated group.  
Overall, these results show that the clearance effect of THPMe, originally observed at 
45 min after 68Ga injection, is also visible as soon as the 68Ga enters the circulation (5 
min delay), but is largely lost when using a delay of 90 min between activity and 
chelator injection. 
4.3.3 THPMe-mediated 68Ga blood clearance in A375 xenografts  
68Ga-acetate uptake in A375 xenografts  
The biodistribution of 68Ga-acetate in NSG mice bearing A375 xenografts was 
evaluated, to assess tumour uptake of 68Ga, and to verify whether timing of tumour 
accumulation is compatible with the time frame in which 68Ga blood clearance is 
feasible. Alongside 68Ga-acetate,68Ga-oxine, which displayed significantly higher 
uptake in A375 cells in vitro was also evaluated. 5 mice were randomly assigned to 
each group and treated with either 68Ga-acetate or 68Ga-oxine. A 4-hours dynamic 
PET/CT scan was then performed for 3 animals per group. Ex vivo biodistribution was 
determined for all animals by organ counting at 4 hours post 68Ga injection. 
Representative PET/CT images at different time points are shown for 68Ga-acetate 
(Figure 4.21 A) and 68Ga-oxine (Figure 4.21 B). From PET/CT images of mice injected 
with 68Ga-acetate, a time/activity curve for the accumulation of the activity in the 




Figure 4.21. PET/CT images at different time points for a mouse injected with 68Ga-
acetate (A) or 68Ga-oxine (B). For each image, MIP are shown in the upper panel (scaled 
with respect to the injected activity), a transverse section showing the tumour is displayed 
in the lower panel for the same time points. A white arrow is used to indicate the position 







Figure 4.22. Time-activity curve describing accumulation of 68Ga-acetate into A375 
xenografts, reported as concentration of activity (% ID/cm3). Values are reported as 
single data points for each of the three mice for which a PET/CT scan was performed 
(coloured points). The end of the considered time interval was set as “x” value for each 
data point. Average and standard deviation at different time points are also reported 
(black line and error bars). 
Figure 4.21 A showed how tumour uptake of the radiometal was low but clearly visible 
from the PET/CT scan for mice injected with 68Ga-acetate. Image contrast increased 
over time as a combined result of increased 68Ga tumour uptake and blood clearance. 
Accordingly, no contrast was achieved at 30 min post injection, while tumour uptake 
became evident (and distinct from the blood pool) from 60 min post injection. Time 
activity curves for the 3 mice of the 68Ga-acetate group that underwent PET/CT scan 
also showed tumour accumulation of 68Ga increasing over time with maximum uptake 
visible between 1 and 2 hours, followed by a plateau or slight tumour wash out at the 
latest time points. 
As expected, even at the latest time point, the achievable contrast was low (tumour-
to-blood ratio = 0.87). High bone uptake was observed in all the mice injected with 
68Ga, uptake in the gut was also observed, while no significant liver uptake was 
observed. On the contrary, mice injected with 68Ga-oxine showed extremely high liver 
uptake since the earliest time point, with uptake also visible in the myocardium and 
the gut. Unexpectedly, no uptake in the tumour was visible for those mice at any time 
point after 68Ga-oxine injection. 
Ex vivo biodistribution data, comparing mice injected with 68Ga-acetate and 68Ga-






Figure 4.23. Biodistribution of 68Ga in mice treated with 68Ga-acetate or 68Ga-oxine, as 
determined by ex vivo organ counting at 4 hours post injection. Values are expressed as 
mean ± SD, N = 5. Statistical analysis was performed for each organ using a t-test (black 
*). For the groups shaded in blue, unequal variances were obtained (F test) and therefore 
Welch-adjusted t-test was also carried out (blue *). P values are defined as follows: 
* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001.  
Neither of the 68Ga tracers accumulate in the brain (despite the lipophilic, uncharged 
character of 68Ga-oxine), and uptake in muscles was minimal. A difference in uptake 
is visible for the rest of the organs, and becomes statistically significant whenever 
variability is small. Notably, 68Ga-acetate presents significantly higher tumour uptake 
(6.1 ± 2.4 % ID/g) than 68Ga-oxine (2.6 ± 0.9 % ID/g), highlighting different mechanisms 
of 68Ga accumulation in tumours compared to uptake in vitro (see Discussion). 68Ga-
acetate uptake was remarkably higher than 68Ga-oxine uptake also for skin and fur 
(3.9 ± 0.6 % ID/g vs 1.6 ± 0.3 % ID/g) and femur (15.7 ± 6.5 % ID/g vs 5.4 ± 1.2 % ID/g). 
On the contrary, 68Ga-oxine uptake was higher in liver (27.7 ± 5.9 % ID/g vs 5.1 ± 1.5 
% ID/g for 68Ga-acetate) and heart (15.3 ± 2.8 % ID/g vs 2.0 ± 0.8 % ID/g for 68Ga-
acetate).  
Comparison with DFO 
Based on the results of the previous experiments in healthy mice, a time delay of 90 
min between 68Ga injection and THPMe injection was deemed too long to observe an 
appreciable change of the biodistribution (except for the kidneys). On the other hand, 
in order for the blood clearance to provide appreciable contrast enhancement, the 
time delay should be long enough to allow accumulation of 68Ga in the tumour prior to 
the clearance step. From the preliminary experiment in NSG mice bearing A375 
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xenografts, 68Ga uptake in tumours reached its maximum between 1 and 2 hours post 
injection. Therefore, 60 min represented a good compromise between tumour 
accumulation and clearance effect and was chosen as the delay between the 
radiometal and blood clearance agent injections. 
Before performing the experiment in xenograft models, a pilot experiment was carried 
out in normal animals using the new determined 60 min time delay. Alongside THPMe, 
DFO was also evaluated as a clearing agent in this experiment. DFO is a clinically 
approved agent for the treatment of iron overload [17] and its clinical translation as a 
68Ga-blood clearance agent would therefore be facilitated compared to that of an 
unapproved molecule such as THPMe. Accordingly, a close comparison between the two 
molecules as 68Ga blood-clearance agents was warranted. 
Notably, DFO had been tested as a blood clearance agent in several studies, and found 
able to increase tumour-to-blood ratio when administered, either IV or IM, following 
67Ga-citrate injection [10,11,16]. However, only very high doses of the chelator, far 
above those in clinical use, were considered in these studies. Instead, when patients 
were treated IM with a clinically relevant dose of DFO (10 mg/kg) only a small contrast 
enhancement effect was visible [12]. 
In our experiment intravenous administration of DFO at the same low 24 nmol dose 
used for THPMe (corresponding to 15 µg of DFO), was investigated. 3 healthy mice were 
allocated per group, injected intravenously at time 0 with 68Ga-acetate and then at 1 
hour with either THPMe, DFO or saline as a control. Mice were then culled at 2 hours 
post 68Ga-acetate injection and ex vivo biodistribution carried out. One animal per 
group was also imaged for 25 min before and after the second injection. PET/CT images 
are shown in Figure 4.24, and ex vivo biodistribution is reported in Figure 4.25. 
 
Figure 4.24. PET/CT images of normal mice injected with 68Ga-acetate, followed at 1 




Figure 4.25. Biodistribution as determined by ex vivo organ counting of 68Ga in mice 
treated with 68Ga-acetate followed at 1 hour post injection by administration of a blood 
clearance agent (THPMe or DFO) or saline. Values are expressed as mean ± SD, N = 3. 
Statistical analysis was performed for each organ using ANOVA followed by Dunnett 
post-hoc comparison between each experimental group and the saline control (black *). 
For the groups shaded in blue, unequal variances were obtained (Brown-Forsythe and 
Bartlett test) and therefore Welch-adjusted t-test was also carried out (blue *). P values 
for each blood clearance agent are evaluated in comparison with the negative control 
group (* = P ≤ 0.05, *** = P ≤ 0.0001). 
From ex vivo biodistribution data, the only statistically significant difference between 
THPMe and the control group was found in kidney uptake when using an ANOVA/Dunnett 
test. On the other hand, the clearance effect was clearly seen in the PET/CT images 
and the scarce statistical significance of biodistribution data is imputable to the low N 
number, as already observed in previous experiments. Data for THPMe suggest that this 
chelator is efficient in accelerating renal clearance of 68Ga when injected 60 min after 
the radiometal, resulting in increased kidney uptake and decreased accumulation in 
bones, liver and, to a lesser extent, in the blood. On the contrary, DFO does not seem 
to have an effect on 68Ga blood clearance as shown in both the PET/CT scans and ex 
vivo biodistribution, which is similar to that of the control. However, a slightly lower 
uptake in the bones and increased activity in the urine was found, potentially 
indicating some effect on the clearance, whose significance may be hidden due to the 
low N number. Therefore, despite the lower efficiency observed in this experiment, it 
was decided to test DFO alongside THPMe as a 68Ga blood clearance agent in mice 
bearing A375 xenografts. 
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THPMe and DFO as blood clearance agents for 68Ga in A375 xenografts 
In the final experiment, the clearance effect of THP and DFO, with saline as a control, 
was assessed in the same A375 xenograft model found to take up 68Ga in the previous 
study. Similar to the experiment in normal mice, NSG mice bearing A375 xenografts 
were injected with 68Ga-acetate, followed, at one-hour post injection by treatment 
with 24 nmol of one of the clearance agents or saline (5 animals per group). Mice were 
culled 2 hours after 68Ga injection and ex vivo biodistribution performed. 3 mice per 
group were also scanned for 25 min before and after the second injection.  
Representative PET/CT images for each group and ex vivo biodistribution for all the 
mice are displayed in Figure 4.26 and 4.27, respectively. For each group tumour-to-
blood ratio was calculated from ex vivo biodistribution data (error was determined 
using the propagation of error formula for ratios of correlated values). 
 
 
Figure 4.26. PET/CT images of NSG mice bearing A375 xenografts, injected with 68Ga-
acetate, followed at 1 hour post injection by treatment with 24 nmol of THP, DFO or 





Figure 4.27. 68Ga Biodistribution, as determined by ex vivo organ counting, in NSG mice 
bearing A375 xenograft, treated with a blood clearance agent (THPMe or DFO) or saline 
at 1 hour post 68Ga injection. Values are expressed as mean ± SD (N = 5). For each 
group tumour-to-blood ratio was calculated Statistical analysis was performed for each 
organ using ANOVA followed by Dunnett post-hoc comparison between each 
experimental group and the saline control. P values for each blood clearance agent are 
evaluated in comparison with the negative control group (* = P ≤ 0.05). 
As is evident from both the PET/CT images and the biodistribution data, the 
experiment did not show any enhancement in the tumour to blood ratio, when using 
THPMe or DFO at one hour after 68Ga administration. However, the two distinct sets of 
data shed light on different aspects of the experiment outcome. 
Ex vivo biodistribution showed a clear effect of THPMe in reducing blood levels of 68Ga 
and accumulation in bones and other organs. However, accumulation in tumours was 
also reduced, thus making the tumour to blood ratio unvaried compared to the saline 
control. Treatment with DFO did not have an effect on the biodistribution of 68Ga. 
Unexpectedly, no increased uptake in kidneys or urine was visible for the THPMe group 
compared to the control, but instead high % ID/g for both kidney and urine was found 
for all the three groups. Furthermore, tumour uptake in the control group was also 
found considerably lower than in the previous experiment (2.7 ± 0.5 % ID/g versus 6.1 
± 2.4 % ID/g). Although, in principle, this could be imputable to the different time 
points considered, the time activity curve for 68Ga accumulation in tumours calculated 
for the first experiment (Figure 4.22) reveals only 15 % difference between tumour 
uptake at 2 and 4 hours. 
When considering the PET/CT images new aspects of the experiment appear. In fact, 
for all the images, most of the activity seems located in the kidneys and /or bladder 
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even before the treatment with the clearance agent. Consequently, accumulation in 
all other organs is largely decreased, as it is evident when considering the tumours. 
Notably, in the particular case shown in the PET/CT of the THPMe treated animal, the 
tumour does not seem to accumulate any 68Ga even before injection with the chelator.  
A better understanding of this unusual 68Ga biodistribution can be obtained by 
comparing the ex vivo biodistribution for the control groups in the two experiments 
performed in the A375 xenograft model (Figure 4.28).  
 
Figure 4.28. Comparison of 68Ga Biodistribution for NSG mice bearing A375 xenograft 
at 4 hours post injection (first experiment) and 2 hours post injection (second 
experiment). Mice belonging to the second experiment were also injected with saline at 
1 hour after 68Ga injection. Values are expressed as mean ± SD (N = 5). Statistical 
analysis was performed for each organ using a t-test. For the groups shaded in blue, 
unequal variances were obtained (F test) and therefore Welch-adjusted t-test was also 
carried out (blue *). * = P ≤ 0.05. 
Although the different time points for the biodistribution and saline injection for the 
second experiment do not allow a fair comparison between the two groups, some 
considerations can be made. Unsurprisingly, uptake in organs known to accumulate 
gallium is higher at later time points (i.e. in the first experiment). However, contrary 
to the expectations, uptake in organs associated to renal clearance is higher at earlier 
time points (i.e. in the second experiment). This suggests an abnormal clearance 
behaviour of 68Ga in the second experiment, which may have influenced the 





In this work, we assessed the THPMe chelator as a blood clearance agent to be used in 
combination with 68Ga salts for cancer imaging, with the aim of improving image 
contrast by enhancing the tumour-to-blood activity ratio. 
It is important, for this type of study, to administer gallium in a form that provides 
ionic 68Ga3+, able to accumulate in cancer cells via transferrin-dependent and/or 
independent mechanisms. Although radioactive gallium is mainly administered in clinic 
as gallium citrate this was avoided in our study, since citrate itself could potentially 
hamper THPMe in vivo complexation by acting as a competing ligand. Instead, 
ammonium acetate was used to buffer the 68Ga eluate. Acetate represents a weaker 
chelator for Ga3+ than citrate, and, although able to prevent precipitation of poorly 
soluble gallium hydroxide, cannot compete efficiently with THPMe for gallium binding 
[36]. 
As a cancer model for this study, we chose the human melanoma cell line A375, whose 
xenografts were previously found to take up unchelated 68Ga by our group. Notably, 
this cell line is known to overexpress transferrin receptors [37] and is therefore able 
to take up gallium via transferrin-dependent mechanisms.  
4.4.1 Uptake of 68Ga-acetate in the A375 melanoma model 
Uptake of 68Ga-acetate in A375 cells was first evaluated in vitro using cells in 
suspension, and then in vivo in mice bearing A375 xenografts. This set of studies aimed 
to characterise the model in terms of 68Ga uptake to obtain a better understanding of 
the effect of THPMe in the selected biological system. 
In vitro assays were carried out in HBSS buffer, rather than full cell culture medium, 
to avoid presence of bovine transferrin from foetal calf serum that could compromise 
cellular uptake of gallium. In fact, bovine transferrin is able to complex gallium with 
an affinity similar to human transferrin, but unlike human transferrin, this protein does 
not efficiently interact with the Tfr receptors expressed on human cancer cells to 
deliver its gallium payload [38,39]. Cell culture medium supplemented with human 
serum or apotransferrin could have been used for the assay to exploit transferrin-
mediated uptake of gallium as well as transferrin-independent mechanisms. However, 
comparison of 68Ga uptake in A375 in DMEM medium with and without human serum, 
performed by our group, showed no significant difference between the two groups for 




Figure 4.29. Comparison between cellular uptake of 68Ga-acetate in A375 cells in 
medium with or without human serum at different time points, expressed as a normalised 
uptake w/r to A375 uptake of 68Ga-acetate at 1-hour incubation (mean ± SD, n = 8). A t-
test was performed to evaluate the difference between the two groups at each time point. 
P values are defined as follows: * = 0.033, **= 0.0056. Reproduced with permission of 
Fahad Al-Salemee (KCL). 
Since incubation periods longer than 2-3 hours are not relevant for a short-lived isotope 
such as 68Ga, a transferrin-free buffer was preferred in our experiments to avoid any 
additional ligand (serum proteins, glutamine and other amino acids) that could 
interfere with 68Ga uptake. For the same reason, use of BSA as a supplement to reduce 
non-specific uptake was avoided after verifying that its absence did not increase non-
specific binding to the plastic. HBSS, whose concentration of phosphate salts is lower 
than PBS, was chosen as a buffer, to reduce the risk of gallium precipitation as poorly 
soluble gallium phosphate.  
In these conditions, A375 cells demonstrated a 68Ga uptake significantly different from 
non-specific 68Ga binding to plastic, with most of the gallium located in the 
intracellular fraction (70-80 %). However, the absolute extent of the uptake was found 
variable among different experiments, (ranging from 2 to 10 % of the total added 
activity). Mechanisms for transferrin-independent cellular uptake of gallium are 
currently unknown, raising concerns that the observed variability may be dependent 
on experimental factors that could vary between different experiments, such as 
amount of activity used, passage number of the cells, confluency of the cell culture 
flask. Some uptake studies were therefore conducted to investigate the influence of 
these factors on cellular uptake of 68Ga and showed that the percentage uptake was 
not influenced by the amount of activity added to each tube (in the 18-70 kBq range 
utilised for the experiments), nor the passage number or the confluency of the cell 
culture flask.  
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Variability in cellular uptake of gallium was also visible between different cells in the 
same sample, as observed in 67Ga microautoradiography experiments. Interestingly, 
higher membrane uptake was observed for these cells both in MAR images and in 67Ga 
uptake studies performed on the same batch of cells. This apparent discrepancy 
between 68Ga and 67Ga uptake was found attributable to the different concentrations 
of the two metal ions at a given amount of activity, owing to their different half-life. 
In fact, when cells were incubated with both isotopes, 68Ga presented the same 
distribution of activity as 67Ga, owing to the increased total concentration of the metal 
ion.  
68Ga uptake was also investigated in NSG mice bearing A375 xenografts. Although 
tumour uptake was found to be moderate but significant (6.5 ± 2.4 % ID/g), tumour to 
blood ratio was still poor at 4 hours post injection (0.87 ± 0.06). Notably, femur 
displayed the highest % ID/g among all organs in the ex vivo biodistribution and PET 
images confirmed accumulation in bones, mainly joints and spine, although variability 
was observed. This suggests that transferrin-independent mechanisms for uptake are 
taking place and could potentially contribute to tumour accumulation of 68Ga. Notably, 
variability in liver uptake (commonly found for BALB/c mice in previous studies) was 
not observed in this case, with consistently low liver uptake shown by all mice. 
Although this suggests inter-strain variability in 68Ga biodistribution, it could also be 
hypothesised that presence of the tumour in the NSG mouse somehow altered 
biodistribution of the radiometal. 
4.4.2 Uptake of 68Ga-oxine in the A375 melanoma model 
The lipophilic 68Ga-oxine complex could in principle be used as an alternative way to 
deliver 68Ga to cancerous tissues, exploiting the increased membrane permeability of 
oxine complexes. Ga-oxine (Tris(8-quinolonato)gallium(III)) has recently been 
investigated clinically as an orally-available gallium anticancer drug (also known as 
KP46 and FFC11, see Chapter 2)[40,41]. Although its mechanisms of accumulation in 
cancerous tissues are not completely understood, several studies suggest that gallium-
oxine, even when administered orally, reaches the tumour intact and only then 
releases gallium [21], contrary to other orally-available gallium drugs, which already 
leak gallium in the gastrointestinal tract.  
Here 68Ga-oxine uptake was investigated both in vitro and in vivo, in the same A375 
melanoma model considered for 68Ga-acetate. As expected, owing to its lipophilicity 
(Log P = 0.88 [32]), 68Ga-oxine was found to accumulate into cancer cells in vitro to a 
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higher extent compared to 68Ga-acetate. However, higher non-specific 68Ga-oxine 
binding to plastic was also found in buffer-only samples. 
A different result was obtained for in vivo tumour uptake. When 68Ga-oxine was 
injected intravenously in NSG mice bearing A375 melanoma xenografts, no tumour 
uptake was visible in the PET images and very little accumulation was measured from 
ex vivo biodistribution at 4 hours after 68Ga-oxine injection. Instead, 68Ga-oxine 
accumulated in the liver and, intriguingly, in the myocardium (15.3 ± 2.8 % ID/g). High 
uptake of 68Ga-oxine in the heart may be of interest as a basis for designing tracers for 
myocardial imaging applications. 
Several reasons can be hypothesised to explain the discrepancy between the expected 
tumour accumulation of this tracer and the experimentally determined biodistribution, 
where cancerous tissue showed very little % ID/g. Surprisingly, despite interest in the 
use of tris(8-quinolonato)gallium(III) as an anti-cancer agent, its biodistribution in 
tumour models has never been investigated, although studies in healthy animals (using 
inductively-coupled plasma atomic emission) exist [42]. It is therefore impossible to 
predict in which frame time and to what extent, if at all, gallium-oxine accumulates 
into tumours. If we assume, mainly based on the preclinical/clinical evidence that the 
complex possesses anticancer activity, that gallium-oxine does indeed accumulate in 
tumours, the different behaviour displayed in our investigation is likely due to either 
the different administration route or the timing in which the biodistribution was 
assessed. If the intravenous administration of 68Ga-oxine was responsible for its lack of 
tumour accumulation, it must be concluded that, when administered orally, gallium-
oxine actually releases gallium in the gastrointestinal tract and that gallium then 
reaches the tumour either as gallate or GaTf complex. On the contrary, when 
administered intravenously, gallium-oxine does not release gallium and the gallium 
does not bind to Tf but rather, owing to its hydrophobicity, accumulates in the liver. 
If the short time points considered for 68Ga-oxine are instead responsible for the lack 
of tumour uptake, it must be concluded that both routes of administration initially 
lead to liver uptake of the radiotracer. There, the complex is metabolised and can 
then re-enter the circulation and accumulate into tumours. Notably, both the 
hypotheses presented disagree with the common opinion that gallium-oxine reaches 
the tumour intact when administered orally. Experimental investigation of the 
proposed hypotheses would require a preclinical experiment where 68Ga-oxine is 
administered orally in the same A375 xenograft model and its biodistribution followed 
over the same amount of time. Overall, it appears that several questions and anomalies 
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need to be resolved about the pharmacodynamics and pharmacokinetics of this gallium 
anti-cancer drug. 
4.4.3 THPMe influence on 68Ga-acetate uptake 
The influence of THPMe on the biological behaviour of gallium-68 acetate was 
investigated in several ways, including the assessment of its effect on 68Ga 
accumulation in A375 cells and evaluation of its ability to clear gallium from circulation 
in vivo in healthy and tumoured animals. To be useful as a contrast-enhancing tool in 
the context of cancer imaging with 68Ga salts, THPMe should be able to remove 68Ga 
efficiently from circulation while leaving 68Ga tumour uptake unaltered or only 
marginally affected. 
The main goal of the in vitro investigation was to verify that 68[Ga(THPMe)] itself could 
not accumulate into A375 cells and that THPMe could not deplete the intracellular pool 
of gallium. Two different experiments were performed, in which cells were treated 
with THPMe before or after addition of 68Ga. Importantly, total incubation time with 
68Ga was different for the two experiments, resulting in different absolute values for 
68Ga uptake. However, this was not considered an issue since data were normalised 
(uptake of non-treated sample set equal to 1 for each experiment) and only differences 
in uptake between treated and untreated samples was considered.  
Incubation with THPMe before addition of gallium was found to reduce gallium uptake 
in A375 cells, suggesting that THPMe can bind gallium in the medium and that this 
process competes with cellular accumulation of the radiometal. The extent of the 
reduced uptake was larger at higher chelator concentration, reflecting an increased 
efficacy/rapidity of 68Ga binding at increasing concentration of the chelator. When the 
order of the two incubation steps was reversed, the decrease in uptake was found less 
significant and did not depend on concentration of the chelator. Analysis of the cellular 
distribution of 68Ga showed that, in this experiment, the chelator was mainly 
decreasing membrane binding of gallium while intracellular uptake was only marginally 
affected. This result suggests that THPMe is not able to remove gallium already 
internalised in cells. The uptake reduction observed in this experiment is likely due to 
complexation of extracellular 68Ga competing with further cellular uptake of the 
radiometal. Notably, when the same experiment was performed with gallium-67, for 
which intracellular uptake may be saturated due to higher concentration of gallium at 
equal amount of radioactivity, no effect whatsoever was observed for the cells treated 
with THPMe after addition of 68Ga (post-gallium samples). This supports the hypothesis 
that THPMe cannot remove internalised gallium, but also suggests that, in these 
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conditions, the intracellular pool of gallium is saturated in as little as 30 min and 
further uptake only happens at the membrane level. 
In vivo studies with THPMe were initially conducted in healthy mice to test the 
chelator’s ability to bind gallium in vivo, sequestering it from transferrin and clearing 
it from the circulation. In a first dose-finding study, THPMe was found able to chelate 
68Ga in vivo, when injected 45 min after the radiometal, at doses as low as 1 μg (1.2 
nmol). The blood clearance effect was very evident in the PET/CT images, but less 
dramatic in ex vivo biodistribution data, where the main decrease in uptake was found 
for organs where gallium tends to accumulate (such as femur and liver). This suggests 
that THPMe treatment significantly increases the renal clearance of the activity from 
the blood, which in turn reduces delivery of the radiometal to the different organs. 
However, complete removal of residual blood pool activity could not be achieved. This 
was also observed in image-derived time/activity curves, where only a relatively mild 
decrease in % ID for the heart (considered as a measure of blood uptake), was visible 
after THPMe injection, despite the dramatic % ID increase in bladder. 
Importantly, even in this pilot study, high variability in biodistribution of 68Ga was 
observed when administered as 68Ga-acetate, particularly concerning uptake in the 
liver. In one particular case high spleen uptake was also observed (Figure 4.15 A), 
likely resulting from the presence of colloidal gallium for that particular 68Ga-acetate 
batch [43]. Although the reasons behind formation of colloidal gallium species are not 
fully understood, it is worth noting that an elution from an “old” 68Ga generator, 
potentially richer in metal contaminants, was used for that mouse. Presence of other 
metal ions is known to favour formation of Ga(III) colloids [44]. To avoid the same 
situation, only relatively new and regularly eluted generators were used for further 
experiments and high spleen uptake was not re-encountered. 
The high variability observed in 68Ga biodistribution could be imputable to several 
factors, such as time of the day, mice diet and metabolism, different elution in terms 
of metal impurity or pH, depth of anaesthesia. Therefore, in further experiments, 
precautions were taken so that we could unambiguously assign any observed effect to 
THPMe-mediated clearance instead of other, difficult-to-control, variables. 
Confounding effects that could be avoided were eliminated (e.g. mice were 
maintained under anaesthesia all the time). To minimise the effect of other factors, 
the different experimental groups were spread over different cages, time of the day, 
generator elutions, day of experiment. On the other hand, the higher variability 
resulting from this choice, not only decreased the possibility of type 1 error (false 
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positive) as desired, but also increased the possibility of type 2 error (false negative), 
reducing the overall statistical power of the experiments. 
Before moving to A375 xenografts, more studies in healthy animals were performed, 
aimed at understanding the influence of the time delay between 68Ga and chelator 
injection on the blood clearance effect of THPMe, and at comparing the effect of this 
chelator with the effect of DFO. In the first experiment, the effect of two extremely 
different time delays, namely 5 and 90 min, between 68Ga and THPMe injection was 
evaluated. A clear effect of the THPMe was visible when the chelator was injected 5 
min after 68Ga, while a delay of 90 min resulted in a very small difference between 
control and THPMe-treated mice. This observed difference is at least partially 
attributable to the fact that, for the 90 min experiment, the % ID/g in the blood had 
already decreased before the THPMe injection, thus limiting the possible clearance 
effect of the chelator. Notably, a P value of 0.026 was obtained by t-test comparison 
of % ID/g in blood for the control groups of the two experiments, suggesting a 
significant decrease in blood activity even in the 90 min study. On the other hand, ex 
vivo biodistribution was performed 15 min after injection of the chelator and the 
resulting % ID/g in the blood may differ from that at the time of THPMe injection 
(especially for the 5 min group). Remarkably, data from both experiments confirmed 
the inability of THPMe to remove 68Ga from the circulation completely. Whether this is 
due to continuous re-equilibration between blood and perfused organs, or to a fraction 
of non-labile gallium present in the blood pool, is still uncertain. 
Interestingly, the % ID/g associated with kidneys in the 90 min delay experiment was 
significantly higher for animal treated with THPMe, while no significant decrease in the 
% ID/g for other organs was observed. This discrepancy is only apparent because the 
biodistribution graphs compare concentrations (% ID/g), rather than total amount of 
uptake (% ID). A large increase in concentration, for small organs such as the kidneys, 
can actually reflect a relatively small difference in the total uptake of the organ. On 
the other hand, for a large, high-capacity system such as the skeleton, a very small 
change in the % ID/g can account for a large difference in % ID. Therefore, in principle, 
the small % ID/g decrease observed for bone could underlie the increased kidney 
activity. Unfortunately, since no measure of the total % ID in the skeleton was available 
(only femur activity was measured in ex vivo biodistribution, and no quantification of 
the images was possible due to lack of CT), this hypothesis cannot be demonstrated. 
Finally, an increased skin and fur uptake was observed for treated animals in the 5 min 
group. Since, for all these mice, skin and fur was removed from the abdomen, we can 
hypothesise that contamination from urine happened. Contamination is much more 
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likely for treated animals, which in general had more activity in the urine than control 
animals. To avoid this issue, in further experiments skin and fur were collected from 
the ears of the mice (less likely to be contaminated with urine), and the issue did not 
recur. 
Overall, for both experiments, standard deviations were very high for THPMe treated 
mice, especially in those organs involved in renal excretion of the activity, suggesting 
that clearance worked to a different extent in different experiments. Although this 
can be explained by several reasons related to the different mice, generator elutions 
et cetera, the simplest explanation is difference in the success of THPMe injection (i.e. 
how much of the injected volume was actually injected IV and not subcutaneously). In 
fact, this second injection was performed on mice that have been under anaesthesia 
for up to 90 minutes and was therefore difficult due to lower body temperature and 
consequent shrinkage of blood vessels. Furthermore, contrary to the injection of the 
radiometal, when the chelator is injected there is no way to quantify the amount of 
chelator remaining in the tail and to correct the administered dose accordingly. 
Although a cannula was used to ensure the needle was kept in the same position used 
for the radiometal injection, on a few occasions the vein occluded due to blood clotting 
and injection of THPMe was then performed with an insulin syringe. Notably, the rate 
at which 68Ga is cleared from the kidneys, which was found very variable between 
experiments, could also be attributable to a variable success of the THPMe injection. 
While a successful IV injection can quickly clear 68Ga from the blood, through the 
kidneys and into the bladder, a less successful injection (subcutaneous) can still have 
a blood clearance effect, but mediated by the slow diffusion of the chelator into the 
circulation. As a result, 68Ga clearance is in this case slower and the activity is present 
in the kidney for longer. 
Based on the results from these clearance experiments, and on the observation that 
68Ga starts to selectively accumulate in tumours from 30-60 min post injection, 60 min 
was chosen as a suitable time delay between injections in animals bearing A375 
xenografts. The 24 nmol dose (20 µg of chelator) was chosen as a suitable chelator 
dose. These conditions were first tested in healthy mice and, on this occasion, the 
effect of THPMe was compared to that of the hydroxamate based chelator DFO, which 
had previously been investigated for similar purposes. The two chelators were 
administered via the same route (IV) and, notably, at the same dose (24 nmol) to 
investigate which chelator possessed higher blood clearance capability. This was 
important since DFO is already approved for clinical use in the treatment of iron 
overload and could therefore represent a privileged candidate for clinical translation. 
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The study showed that the clearance effect was still visible when THPMe was injected 
60 min after 68Ga, not only in kidneys but also in femur and liver, although the 
difference was not significant due to low N number and high variance. The clearance 
effect observed by injection of DFO was significantly smaller than that seen for THPMe 
(especially in kidney), but some reduced uptake in femur and liver and increased 
excretion of 68Ga in urine was still visible. It was therefore decided to investigate both 
THPMe and DFO as clearance agents in a cancer model. 
Finally, the blood clearance ability of THPMe and DFO was finally evaluated in NSG mice 
bearing A375 xenografts using both PET/CT and ex vivo biodistribution. Unexpectedly, 
in this experiment neither THPMe nor DFO were able to selectively clear 68Ga from the 
blood pool and thus they did not enhance tumour-to-blood ratio. In particular, while 
DFO appeared not to have an effect on 68Ga biodistribution and clearance, data for 
THPMe suggest that this chelator clears gallium equally from both blood and tumour 
tissue, leaving the tumour-to-blood ratio unaffected. However, although extremely 
valuable, ex vivo biodistribution only represents a snapshot of the activity distribution 
at a given time and does not give us any information on what happened between 68Ga 
injection and culling of the animal. This information can be instead provided by 
dynamic PET imaging, which in this case was extremely important to correctly 
interpret the data. In fact, PET/CT images unexpectedly showed how gallium was 
mostly cleared from the blood of all animals very quickly after administration, so that 
activity was already largely in the kidneys/bladder before the second injection. In this 
situation, the clearance effect observed for THPMe is attributable to in vivo chelation 
of residual circulating radiometal, preventing further accumulation in the tumour or 
in other organs. Notably, this increased renal clearance also explains why the % ID/g 
measured for the kidneys (Figure 4.28) is extremely high not only for the THPMe-
treated group but also for the DFO-treated group and the control. 
The reasons behind this unexpectedly fast clearance of 68Ga are uncertain and cannot 
easily be explained by considering any of the classical species that Ga3+ is known to 
form in serum. For example, quick renal clearance was previously observed in mice 
overloaded with iron, depleted in the transferrin pool or not expressing the transferrin 
receptor, and was attributed to gallium presence as [Ga(OH)4]
-. However, in all those 
cases uptake in the bones was also increased [45,46], while, in our case % ID/g in the 
femur is largely decreased compared to the first experiment. On the other hand, full 
binding to transferrin should produce low bone uptake but also increase the uptake in 
highly perfused organs and, notably, the overall clearance time [47]. Finally, colloidal 
gallium should accumulate mainly in liver/spleen [43]. 
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Overall, with this experiment we cannot definitively conclude whether THPMe can be 
used as a blood clearance agent in this model. The same conclusions hold, in principle, 
also for DFO, since rapid renal clearance also affected biodistribution in the DFO-
treated animals. However, inability of this chelator to influence biodistribution of 
gallium, both in healthy animals and xenograft models makes it safe to rule out any 
blood clearance efficacy of DFO when injected IV at a 24 nmol dose (15 µg, ≈ 0.75 
mg/kg). Importantly, while this dose already exceeds the clinically used dosage for IV 
administration (0.25 mg/kg/min), the therapeutic dose for IM administration is 1000 
mg/kg, therefore IM administration of DFO at this higher dose could potentially be 
investigated as an alternative to THPMe. 
Repetition of this final experiment is warranted, but requires prior understanding of 
the reasons behind the observed fast clearance, in order to avoid its recurrence. The 
causes of the variable uptake seen in liver and bones should also be investigated in 
order to reduce variability and increase reproducibility and significance of our data.  
Preliminary data from our laboratories suggest that part of the variability in 68Ga 
biodistribution could be related to different generator elutions. In particular, the first 
elution of the day (up to 24 hours elapsed from previous elution) was generally found 
to give higher liver and spleen uptake and lower bone uptake compared to successive 




In this work, the use of radioactive gallium salts for cancer imaging was reassessed 
using 68Ga-acetate combined with THPMe as a blood clearance agent, with the aim of 
increasing tumour-to-blood ratio and, accordingly, image contrast at short time points. 
A375 human melanoma cells were found to moderately accumulate gallium through 
transferrin independent mechanisms in vitro. Significant uptake was also found in A375 
xenografts in vivo with maximum uptake occurring between 1 and 2 hours after 68Ga 
injection. Although transferrin dependent mechanisms were likely involved in the in 
vivo studies, the intense bone uptake observed suggests that transferrin independent 
mechanism were still prevalent. 68Ga-oxine was also able to transport gallium into A375 
cells in vitro, but unable to deliver the radiometal to the tumour in vivo when injected 
intravenously. Further studies with 68Ga-oxine were therefore abandoned. 
Interestingly, high uptake in the myocardium was found for 68Ga-oxine and warrants 
further exploration. 
THPMe was found able to influence the biodistribution of 68Ga-acetate in healthy mice 
when injected 5 to 60 min after the radiometal. The chelator was effective at a 1 
mg/kg dosage (20 µg per mouse), at least 40-fold lower than what previously tested in 
the literature for other blood clearance agents [11]. In vitro experiments 
demonstrated that [68Ga(THPMe)] does not accumulate in A375 cells and that THPMe 
cannot deplete the intracellular pool of gallium. Therefore, THPMe was deemed an 
interesting chelator to investigate as a blood clearance agent in A375 xenografts at 24 
nmol (20 µg) and with a delay of 1 hour between injection of activity and chelator. 
DFO, whose 67Ga blood clearance activity had been previously examined in the 
literature, was also tested in the same conditions, although superiority of THPMe at this 
concentration was already established in a previous experiment in healthy animals. 
Unfortunately results of the final experiment were confounded by an extremely quick 
clearance of the activity for all animals, whose reasons are currently unknown. 
Repetition of the experiment will require further understanding of the reason for the 
unusual in vivo behaviour observed for 68Ga in the last experiment.  
In general, 68Ga-acetate biodistribution was found to be extremely variable and 
unpredictable in different mice for all our experiments and this resulted in high 
standard deviations and reduced statistical power of the studies. Although similar 
issues were previously reported for 67Ga-citrate studies, both at a preclinical and 
clinical level, the choice of using a weak Ga ligand may have exacerbated the problem. 
Providing gallium in a more stable chelate form (but not as stable as gallium-oxine) 
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could help in reducing variability. Potentially, gallium citrate could be used, even at 
the cost of increasing the required THPMe dosage in case citrate can compete for in 
vivo binding of 68Ga. Alternatively, transferrin itself could be used, upon verification 
that 68Ga-transferrin can actually accumulate in A375 tumours in the same time range 
observed for 68Ga-acetate (or at least in a time frame compatible with the use of 68Ga). 
Notably, in this last case it would be interesting to compare human and mouse 
transferrin in their ability to deliver 68Ga to the xenograft tumour. 
Finally, investigation should be repeated in different tumour models, possibly 
characterised by higher 68Ga uptake. Lymphoma is the cancer that more widely 
benefited from 67Ga-citrate historically and would represent the ideal model for this 
investigation. However, establishment of a transgenic lymphoma mouse model is 
relatively complex compared to that of xenograft tumours [48]. Alternatively, 
screening different human cancer cell lines for uptake of 68Ga could identify the most 
promising cell lines to use for establishing tumour xenografts in future investigation. 
In this regard, a preliminary experiment in a SW1222 colorectal cancer xenograft model 
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5 Pretargeting via metal chelation exploiting the 
Ga(III) tris(hydroxypyridinone) couple 
 Introduction 
The development and clinical translation of monoclonal antibodies (mAb), following 
the advent of hybridoma technology in 1975 [1], represented a paradigm shift in cancer 
therapy. In a field dominated by small-molecule chemotherapeutics, whose selectivity 
was often solely based on the accelerated metabolism of tumour cells, antibody-based 
therapy introduced the ability to selectively target cancer lesions expressing a 
particular antigen [2]. The therapeutic activities of mAbs may result from direct action 
(agonistic/antagonistic) on the target receptor, or indirect mechanisms such as 
recruitment of the immune system or through effects on tumour vasculature and 
stroma. Many antibodies may function by a combination of direct and indirect 
mechanisms [2].  
Monoclonal antibodies can also be employed as highly selective vectors for the delivery 
of drugs or, notably, radionuclides. Depending on the decay properties of the 
radioisotope, radiolabelled mAbs can be useful for cancer diagnosis 
(immunoSPECT/immunoPET) or radioimmunotherapy [3]. Non-metallic radioisotopes 
such as iodine-131 can be incorporated directly into antibodies by chemical 
modification of an amino acid side-chain [4]. Direct radiolabelling with radiometals 
has been explored for 99mTc and 188Re, using disulfide bond reduction to create free 
sulfhydryl groups able to coordinate the M(V) metal ion [5]. Nevertheless, radiometals 
incorporation into proteins generally involve a chelating moiety, which can be a 
polyhistidine-tag inserted into the amino acid sequence of the antibody, like in the 
case of 99mTc [6], or more commonly a bifunctional chelator (BFC) covalently bound to 
an antibody through an amino acid side-chain. This useful approach has found wide 
applicability and allows for a variety of radioisotope/amino acid residue matchings by 
simply changing the chelating or functional group of the BFC. Conjugation of the 
bifunctional chelator to the antibody can be site-specific, exploiting single cysteines 
engineered into the amino acid sequence or, more commonly, free thiols generated by 
reduction of disulfide bonds [7]. Alternatively, non-specific conjugation to amino 
groups (lysine side chains and amino terminus) can be performed [8]. A schematic 
representation of a radioimmunoconjugate is presented in Figure 5.1. Several 
chelating systems useful for gallium were described in Chapter 1, and chelators for 




Figure 5.1. Schematic representation of a radioimmunoconjugate showing an antibody 
covalently attached to a bifunctional chelator (BFC), which is in turn coordinating a 
radiometal via its chelating moiety. 
Antibody fragments were also developed, such as the antigen binding fragments (Fab, 
F(ab)2 and Fab’) obtained by enzymatic digestion of the full antibody, which could be 
radiolabelled following the same principles, but offered modulation of the 
pharmacokinetics due to the lower size (Figure 5.2) [10]. 
5.1.1 Clinical application and limitations 
Despite the numerous potential advantages of radiolabelled antibodies over 
conventional imaging and radiotherapeutic agents, only four radiolabelled full-length 
mAbs and two radiolabelled Fab’ have been approved by the FDA for cancer 
imaging/treatment since the approval of 111In-satumomab pendetide in 1992 as 
reported in Table 5.1. Even more surprisingly, four of them have been subsequently 
withdrawn from the market [11]. In addition, despite the growing popularity of PET 
and the increasing number of clinical trials involving mAb radiolabelled with positron-
emitting isotopes [12], no immunoPET derivatives have been approved for clinical use 
so far.  
Table 5.1. FDA-approved radioantibodies for cancer imaging (orange) and treatment 
(light blue). 
 





















































While the reasons behind the limited clinical success of radiolabelled antibodies are 
multiple and certainly include both the cost and technical difficulties associated with 
their preparation and administration [13], the slow pharmacokinetic properties of full-
length and Fab derivative antibodies also represent an important limitation for their 
routine clinical utilisation. In fact, partly owing to the high molecular weight of 
antibodies, tumour accumulation and blood clearance of radioactivity is slow, 
requiring extended periods of time (6-48 hours or more) to reach an adequate tumour-
to-blood ratio. Accordingly, only radioisotopes with half-life > 6 hours can be used to 
label the antibody, to deliver sufficient radioactivity to the target tissue to allow 
effective imaging or therapy. In addition, the slow blood clearance of these 
radioimmunoconjugates results in an increased exposure of non-target organs to 
radiation, and limits the maximum radiation dose that can be administered to a patient 
for therapeutic purposes [14]. 
Today, different types of antibody-like molecules are also available alongside full-
length mAbs and Fabs, such as minibodies, diabodies and single domain antibody 
fragments (dAb), as well as the fusion proteins scFv (single chain variable fragments) 
and affibodies. A schematic representation of their structure is provided in Figure 5.2, 
alongside an approximate molecular weight. Because of the lower molecular weight of 
these molecules, they display faster tumour uptake and blood-clearance than full-
length antibodies, thus allowing higher doses of radiation to be injected. On the other 
hand, often these derivatives show lower tumour accumulation and higher kidney 
uptake compared to full-length antibodies [15,16]. 
 
Figure 5.2. Schematic representation and approximate molecular weight of different 




5.1.2 Pretargeting approaches to imaging and therapy with 
antibodies 
Pretargeting represents a promising alternative to traditional radioimmunotherapy 
/radioimmunodiagnostic techniques. As mentioned in Chapter 2, pretargeting 
combines the exquisite selectivity of antibodies with the favourable pharmacokinetics 
of small molecules and is based on decoupling the slow antigen-targeting performed 
by the antibody from the delivery of the radioisotope [17]. In a pretargeting approach, 
the unlabelled antibody is administered first and allowed to reach its tumour target; 
then a radioactive probe is delivered to radiolabel the antibody at its receptor site. 
Here the antibody-BFC-radioisotope triad is reconstructed in vivo exploiting a high-
affinity chemical pair (schematic representation of pretargeting strategies and high-
affinity chemical pairs is reported in Figure 5.3). Since this radiolabelled probe is far 
smaller than the antibody, the probe quickly reaches its target antibody and clears 
from the blood pool, thus reducing exposure of non-target organs to radiation and 
enabling the use of short-lived radioisotopes. Importantly, the pretargeting approach 
also presents some limitations, such as the need for a target receptor (i) highly 
expressed on cancer cells surface and (ii) internalising slowly upon antibody binding, 
so that the pretargeted antibody is accessible to the radiolabelled probe. Furthermore, 
to achieve sufficient tumour uptake of the radiotracer, relatively large amounts of 
antibody are needed which may results in toxicity. Four major approaches to 
pretargeting, exploiting different high-affinity chemical pairs, have emerged in the 
last decades and are extensively discussed in a number of recent reviews [15,17,18]. 
A summary of these strategies is presented in the paragraphs below. 
An early pretargeting method employed bispecific mAbs. These are artificial antibodies 
consisting of two different arms: one to target the tumour receptor in an early 
pretargeting stage, the second to specifically bind the hapten moiety of a radiolabelled 
probe injected after the bispecific mAb is cleared from the blood [19]. This is the 
pretargeting strategy most widely investigated in clinics, and underwent an extensive 
optimisation of the type of haptens and antibody constructs. The most recent and 
promising examples exploit a trivalent construct in which two Fab moieties are 
targeting the desired tumour antigen and the third is binding to a histamine-succinyl-
glycine hapten moiety of the radiolabelled probe [20] (see Chapter 2 for clinical 
application using 68Ga).  
In a different strategy, the outstanding affinity of streptavidin for biotin [21,22] is 
exploited in two different ways. The two-step method, developed by Hnatowich, 
utilises a streptavidin-conjugated antibody that pretargets the tumour antigen. After 
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excess immunoconjugate has cleared from the blood (e.g. using a blood clearing agent 
such as glycosylated avidin), radiolabelled biotin is administered and binds to the 
pretargeted streptavidin-conjugated antibody [22]. The reverse combination: 
biotinylated mAb followed by radiolabelled streptavidin probe, was also tested but 
found less effective due to slow blood clearance of streptavidin. In a second approach, 
referred to as three-step pretargeting, a biotinylated antibody is administered and 
allowed to reach its target, followed by glycosylated avidin to clear excess 
immunoconjugate from the blood to the liver. Streptavidin is then injected and binds 
to prelocalised biotinylated mAbs, creating the functional pretargeted complex that 
can finally interact with radiolabelled biotin molecules, administered in the final step 
[23]. Although this pretargeting strategy is very promising, the immunogenicity of 
streptavidin is a major obstacle for its clinical translation [24]. 
A third pretargeting approach investigates the use of two complementary DNA-
analogue fragments, one conjugated to the antibody and the other to the radiolabelled 
chelator, acting as bridging agents between the two molecules [25]. While native 
phosphodiester DNA suffers from in vivo hydrolysis by nucleases, the use of synthetic, 
non-immunogenic DNA analogues based on a different backbone, such as 
phosphorodiamidate morpholino oligomers [26,27] and peptide nucleic acids [28], has 
proved to be more successful. 
A more recent approach to pretargeting exploits “click” reactions between a suitable 
diene and dienophile couple. Compared to the previous approaches, this strategy 
exploits a covalent bond between antibody and probe rather than relying on high 
affinity non-covalent interactions [17]. To be useful for pretargeting purposes, a 
chemical reaction needs to proceed quickly at low concentration and in the absence 
of catalyst, but also to be completely bioorthogonal, so that it would not interact with 
endogenous molecules [29]. While Staudinger ligation and strain-promoted alkyne–
azide cycloaddition were initially considered for pretargeting purposes, an inverse 
electron demand Diels-Alder (IEDDA) cycloaddition has recently gained attention due 
to its faster kinetics [18]. In particular, promising preclinical results have been 
obtained, exploiting an IEDDA cycloaddition between a radiolabelled tetrazine-
chelator and a trans-cyclooctene conjugated antibody [30,31].  
The concept of pretargeting via metal chelation proposed by our group [32] is based 
on the hypothesis that a suitable metal/chelator couple could be used as the high-
affinity chemical pair, able to bind in vivo. In a first step, an integer antibody-BFC 
immunoconjugate would be administered and allowed to reach its target, then 
radiolabelling of the immunoconjugate would be performed in vivo, following the 
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injection of an ionic or weakly complexed formulation of the radiometal. A schematic 
comparison of metal chelation pretargeting against more traditional pretargeted 
strategies is presented in Figure 5.3. Notably, pretargeting via metal chelation does 
not involve any radiosynthetic work, thus minimising handling of the radioisotope and, 
consequently, operator exposure to radiation. Compared to traditional pretargeting 
strategies, this new approach could allow for a quick and easy protocol, well-suited 
for clinical translation. 
 
Figure 5.3. Schematic representation of pretargeting strategies employing different high-
affinity chemical pairs. Traditional pretargeting strategies (A) employ radiolabelled 
probes to bind the pretargeted antibodies. On the contrary, in the pretargeting via metal 
chelation strategy (B), the radiometal could be administered as a salt, avoiding any 
radiosynthetic procedure. 
Owing to the great selectivity of THPMe chelators for Ga(III) (as discussed in Chapters 
1 and 3) and to their ability to radiolabel rapidly with 68Ga in vivo, in extremely mild 
conditions (as described in Chapter 4), the tris(hidroxypyridinone)/68Ga(III) couple 
seemed ideal to test the pretargeting via metal chelation hypothesis. In this chapter, 
two different attempts to assess the feasibility of this approach have been 
investigated. In the first approach, a new THPMe-dithiophenolmaleimide derivative 
(THPMe-mal-DTP) has been conjugated site-specifically to an anti-CEA antibody and its 
pretargeting capability tested in vitro in LS174T colon cancer cells expressing the 
carcinoembryonic antigen (CEA). In the second approach, undertaken as part of a 
research visit at the Memorial Sloan Kettering cancer centre (MSKCC, New York) and 
Hunter College (New York), a non-site-specific conjugation of THPMe-Ph-NCS to an 
huA33 antibody was adopted. In this case, the pretargeting via metal chelation 
hypothesis was evaluated in vivo exploiting a xenograft SW1222 colon carcinoma model 
expressing the A33 antigen.  
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 Materials and methods 
5.2.1 Equipment and consumables 
THPMe-NH2 was obtained from Chematech (France). Unless otherwise stated, all 
reagents and buffers were purchased from Sigma-Aldrich and used without further 
purification. The full-length human IgG1 anti-CEA antibody ME1 was kindly provided by 
Dr Miranda Rota (Prof. Chester laboratories, UCL). The fully humanized IgG1 huA33 
was obtained from the Ludwig Institute and the Olivia Newton-John Cancer Research 
Institute [33]. The DFO-huA33 conjugate used for 89Zr radiolabelling was previously 
produced in Zeglis’ laboratory according to published procedures [31]. All the buffers 
used for the huA33 experiments were prepared using Chelex-treated deionised water. 
Preparative HPLC was carried out using an Agilent Zorbax XDB-C18 column (21.2 x 150 
mm, 5 µm) with a 5 mL/min flow rate and UV detection at 214 nm on an Agilent 1200 
LC system. Mobile phase A was water with 0.1 % TFA, and mobile phase B was 
acetonitrile with 0.1 % TFA. A gradient from 0 % to 100 % B (1 %/min) was employed. 
Analytical size-exclusion HPLC was performed on the same system using an BioSep SEC-
s2000 column (145 Å, 300 x 7.8mm, 5 μm) with a 1 mL/min flow rate and UV detection 
at 280 or 254 nM coupled to a LabLogic Flow-Count detector with a sodium iodide probe 
(B-FC-3200). Mobile phase was PBS (2 mM EDTA was added for radiolabelling 
experiments).  
68Ga was obtained from E&Z generator, by elution with 5 mL of 0.1 M ultrapure HCl 
(Fluka). The eluate was collected in ≈1 mL fractions and the activity of all fractions 
was measured with a dose calibrator (Capintec). The highest activity fraction was used 
for radiolabelling. 89Zr was produced at Memorial Sloan Kettering Cancer Center 
through proton-beam bombardment of yttrium foil [34], and isolated as 89Zr-oxalate. 
Uptake of radioactivity in cells and organs was measured using a LKB Wallac 1282 
Compugamma Gamma-counter at KCL, an Automatic Wizard gamma–counter (Perkin-
Elmer) at MSKCC. 
5.2.2 Synthesis of THPMe-Ph-NCS 
Bn-THPMe-Ph-NCS was synthesised according to published procedures [35]. Briefly, p-
phenylene-NCS (135 mg, 0.77 mmol) and DIPEA (75 μL, 0.44 mmol) were added to a 
solution of THPMe-NH2 (75 mg, 0.077 mmol) in DMF (2 mL) under stirring. After 15 min 
the DMF was removed under high-vacuum and the crude residue purified by preparative 
HPLC, yielding 43.7 mg of Bn-THPMe-Ph-NCS (0.035 mmol, 45 % yield). Benzyl 
deprotection was then performed by addition of 5 mL of BCl3 solution (1 M in 
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dichloromethane) and stirring under nitrogen followed by quenching with methanol on 
ice, solvent removal by rotary evaporation and purification via preparative HPLC to 
give 27.2 mg of THPMe-Ph-NCS (0.028 mmol, 80 % yield). Product purity was verified by 
1H NMR and high-resolution mass spectrometry. 
5.2.3 Synthesis of THPMe-mal-DTP 
The dithiophenolmaleimide derivative of THPMe was obtained as part of a collaboration 
with Dr Ma (KCL). Briefly, benzyl deprotection of THPMe-NH2 (115 mg, 0.11 mmol) was 
performed as described above to give 86 mg of product (0.08 mmol, 85 % yield). 
dithiphenolmaleimide-NHS ester (10 mg, 0.02 mmol) was dissolved in DMSO (500 μL) 
and mixed with debenzylated THPMe-NH2 (20 mg, 0.023 mmol in 200 μL of DMSO). DIPEA 
(14 μL, 0.09 mmol) was added to the reaction mixture and the solution stirred at room 
temperature for 15 min before purification using preparative HPLC to yield 10 mg of 
pure product (0.009 mmol, 41 % yield).  
1H NMR (DMSO-d6, 400 MHz) δ: 1.70 (t, 2H, mal-CH2-CH2-CH2 CONH),1.79 (t broad, 6H, 
CH2-CH2-CO-NH-CH2-pyridinone), 2.04 (t broad, 6H, CH2-CH2-CO-NH-CH2-pyridinone), 
2.17 (t, 2H, CONH-CH2-CH2-CO-NH), 2.46 (s, 9H, C
6-CH3), 3.17 (t, 2H, CONH-CH2-CH2-
CO-NH), 3.40 (t, 2H, mal-CH2-CH2-CH2-CONH), 3.75 (s, 9H, N
1-CH3), 4.51 (d, 6H, CO-
NH-CH2-pyridinone), 6.83 (s, 3 H, C
5-H in pyridinone), 7.22 (m, 10 H, S-Ph), 7.78 
(broad, 1 H, mal-CH2-CH2-CO-NH), 8.46 (t, 3 H, CO-NH-CH2-pyridinone). 
5.2.4 Anti-CEA conjugation to THPMe-mal-DTP 
Prior to conjugation, the anti-CEA antibody (0.5 mL of 0.855 mg/mL PBS solution) was 
loaded onto a PD10 column previously equilibrated with borate buffer (pH 8.2, 50 mM 
sodium tetraborate, 50 mM NaCl, 5 mM EDTA) and eluted to give 215 μL of a 1.940 
mg/mL anti-CEA solution (98 % yield) as measured by spectrophotometric 
measurement on a Nanodrop 2000 spectrophotometer (Thermo scientific). Purity of 
the sample was verified by size-exclusion HPLC (mobile phase: PBS) 
1.03 μl of a 10 mM solution of tris(2-carboxyethyl)phosphine (TCEP, 10.3 nmol, 8 eq. 
or 2eq./disulfide bridge) was added to 100 μL of the antibody solution (1.3 nmol), the 
mixture was vortexed and incubated for 2 hour at 37°C , after which THPMe-mal-DTP 
(15.5 nmol, 12 equivalents) was added and the mixture vortexed and incubated at 37°C 
for one hour. All conjugation steps were monitored by SDS-PAGE (Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, see below). The conjugation solution was 
then left at room temperature for 24 hours to promote maleimide hydrolysis to the 
more stable open form, favoured by the slightly basic pH of the borate buffer. The 
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immunoconjugate was then purified by ultracentrifugation with 50000 molecular 
weight cut off (MWCO) filters (vivaspin 500, MWCO 50000, GE healthcare) using 
ammonium acetate 0.2 M as a buffer. 200 μL of an THPMe-mal-Anti-CEA solution in 0.2 
M ammonium acetate were obtained and concentration was determined by NanoDrop 
measurements to be 89 ± 0.13 mg/mL for a 92 % recovery yield. Purity of the 
immunoconjugate was verified by size-exclusion HPLC (mobile phase: PBS). 
5.2.5 SDS-PAGE 
Gel preparation 
Stacking and resolving acrylamide gels were prepared by mixing acrylamide with 
water, tris(hydroxymethyl)aminomethane (TRIS) buffer at pH 8.8 and sodium dodecyl 
sulfate (SDS) in the quantities reported in Table 5.2. Tetramethylethylenediamine 
(TEMED) and ammonium persulfate (APS) were then added to initiate the 
polymerisation. 
Table 5.2. Ingredients for the preparation of resolving and stacking acrylamide gel. 
 Resolving gel 
(12 % acrylamide) 
Stacking gel 
(4 % acrylamide) 
ACRYLAMIDE 6.4 mL 2 mL 
2.5 M TRIS (PH 8.8) 4 mL 2.5 mL 
DEIONISED H2O 5.3 mL 5.3 mL 
SDS (10 % W/V) 160 μL 100 μL 
TEMED 16 μL 10 μL 
APS (90 %) 160 μL 100 μL 
 
Two glass plates were assembled onto a setting rig, the resolving gel was prepared as 
described above, added between the plates and covered by 1 mL of ethanol. The 
resolving gel was left setting while the stacking gel was prepared according to Table 
5.2, then the ethanol was removed and the stacking gel added. A comb was positioned 
at the top of the rig to create the wells for sample loading. 
Loading buffer (5x stock) was prepared by mixing glycerol (8 mL), water (4 mL), SDS 
(1.6 mL, 10 % w/v in water), 0.5 M tris-HCl buffer (1 mL, pH 6.8) and bromophenol pH 
6.8 (0.2 mL). 1 L of running buffer pH 8.3 (10x stock) was also prepared by dissolving 
TRIS (tris(hydroxymethyl)aminomethane, 30 g), glycine (14 g) and SDS (10 g) in water. 
Both buffers were diluted to 1x with water prior to use. 
Sample preparation and analysis 
The following samples were analysed in duplicate: 
214 
 
 Native antibody 
 Antibody + TCEP (after a 2-hours incubation) 
 Antibody + TCEP + THPMe-mal-DTP (after 1-hour incubation) 
Samples for SDS-PAGE were prepared by mixing 4 μL of protein (10 μg), 2 μL of loading 
buffer and 4 μL of milliQ water, then denatured by shaking for 5 min at 75 °C. 5 μL of 
sample were loaded into each well, and one lane was dedicated to a broad-range MW 
marker (10-250 kDa, BioLabs). A 35 mA current was applied to the plates for 45 min. 
The gel was then washed with water and stained with Coomassie blue (0.05 % 
Coomassie brilliant blue R250 in 40 % methanol, 10 % glacial acetic acid and 50 % 
water), by covering it with the dye and heating for 1 min with a microwave heater. 
Finally, the gel was washed with water three times, then covered in a de-staining 
solution (10 % acetic acid, 10 % methanol in water) and left shaking for 1 hour at 37 °C 
until the gel was clear. 
5.2.6 HuA33 conjugation to THPMe-Ph-NCS 
A solution of huA33 in PBS (7 μM, 0.8 mL, pH 7.4) was adjusted to pH 8.8-9.0 with a 
0.1 M solution of Na2CO3, and 5, 10, 30 or 50 equivalents of THP
Me-Ph-NCS (10 mM in 
DMSO) were added in small aliquots to prevent precipitation. The reaction mixture was 
shaken for one hour at room temperature, then purified by size-exclusion 
chromatography on a PD-10 column (Sephadex G-25M PD-10 column, GE Healthcare) in 
ammonium acetate 0.2 M (for preliminary radiolabelling) or PBS (for preclinical 
experiments) and concentrated using centrifugal filtration units with a 50000 
molecular weight cut off (AmiconTM ultra 2mL, Millipore Corp). The final concentration 
of the immunoconjugate was measured spectrophotometrically using a Shimadzu 
Biospec nano (considering ε280 = 2.1 10
5 L/mol cm) and used to determine the 
conjugation yield (Table 5.3). 
5.2.7 MALDI-ToF mass spectrometry 
THPMe-Ph-NCS-huA33 Immunoconjugates were analysed by MALDI-ToF MS/MS using a 
Bruker ultraflex MALDI-ToF/ToF (Bruker Daltonic GmbH) according to the following 
procedure. 1 μL of each sample (1 mg/mL) was mixed with 1 μL of sinapic acid (10 
mg/ml in 50 % acetonitrile: water and 0.1 % TFA). 1 μL of the sample/matrix solution 
was spotted onto a stainless-steel target plate and allowed to dry. Ions were analysed 
in positive mode and external calibration was performed by use of a standard protein 
mixture (BSA). The measure was repeated three times for both the native antibody 
and each conjugation batch. The difference between the average mass of the 
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immunoconjugate, as determined by a profile measurement of the sample and that of 
the native antibody was divided by the exact mass of the chelator to determine the 
average number of chelators per antibody. 
5.2.8 68Ga radiolabelling of immunoconjugates  
THPMe-mal-Anti-CEA radiolabelling:  
80 μL of a THPMe-mal-Anti-CEA solution (0.15 mg/mL, ≈ 1μM in 0.2 M ammonium 
acetate) was mixed with 80 μL of 68Ga eluate (≈ 8 MBq) at room temperature and 
pH ≈ 5.5. Radiolabelling was verified via size-exclusion radioHPLC using (mobile phase: 
PBS + 2 mM EDTA).  
THPMe-Ph-NCS-HuA33 radiolabelling 
Radiolabelling of the immunoconjugate at a final concentration of 1 μM was performed 
in two different sets of conditions. 
 pH 5.5 (verification of conjugation): 
400 μL of the highest activity fraction (≈ 88 MBq) were mixed with 100 μL of 
ammonium acetate 4 M, and 42 μL of the neutralised solution (≈ 4 MBq) added 
to an immunconjugate solution (3 μL, 15 μM in ammonium acetate 0.2 M).  
 pH 7 (evaluation of the radiolabelling in the conditions required for in vivo 
experiment):  
410 μL of the highest activity fraction were adjusted to pH 7 using ammonium 
acetate (0.2 M, 400 μL) and sodium carbonate (0.1 M, 400 μL). 40 μL of this 
solution (≈5 MBq) were added to 40 μL of immunoconjugate (2 μM in ammonium 
acetate 0.2 M or PBS). In a variation of the experiment the effect of a 45 min 
delay between gallium eluate neutralisation and radiolabelling was also 
investigated.   
A similar radiolabelling procedure was also applied to the native antibody 
(≈ 1 MBq, final antibody concentration = 7.5 μM) to verify that presence of 
chelator was necessary for successful radiolabelling. 
The radiolabelling mixture was incubated for 5 min at 37 °C. Success of the 
radiolabelling was verified by iTLC using 50 mM EDTA in water as a mobile phase. The 
radiolabelling mixture was also applied to a PD10 column preconditioned with 
ammonium acetate 0.2 M (or PBS, depending on the radiolabelling mixure) to trap 
residual THPMe-Ph-NCS. The eluted fractions were analysed by iTLC and the residual 
activity trapped on the PD10 was also measured.  
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5.2.9 DFO-huA33 radiolabelling with89Zr 
89Zr-oxalate (50 μL, 57 MBq), was diluted with 1 M oxalic acid to 100 μL, buffered to 
pH 7.5 using Na2CO3 1M (106 μL) and added to 400 μL of DFO-huA33 solution in PBS 
(1.53 mg/mL, ≈ 10 μM). The radiolabelling mixture was agitated for one hour at 37 °C. 
EDTA (50 mM solution in water) was added to a final concentration of 1 mM. ITLC 
analysis of the crude radiolabelling mixture (50 mM EDTA in water as a mobile phase) 
confirmed quantitative radiolabelling. The radiolabelling mixture was then applied to 
a PD10 column preconditioned with PBS, the resulting fractions analysed by iTLC and 
the activity trapped on the column measured. The highest activity fractions were used 
to prepare doses for injections. 
5.2.10 Cell culture 
Human colorectal cancer cell line SW1222 expressing the A33 antigen was obtained 
from Sigma-Aldrich and maintained in Minimum Essential Medium (GibcoTM, 
ThermoFisher). LS174T colon adenocarcinoma cell line expressing the CEA antigen was 
donated by Prof. Barbara Pedley’ s group (UCL) and cultured in DMEM low glucose. The 
A375 melanoma cell line used as a negative control was provided by Sophia 
Karagiannis’ s group (KCL) and cultured in DMEM high glucose (4500 mg/L glucose, 
GibcoTM, ThermoFisher). Cell culture media were supplemented with 10 % foetal calf 
serum, L-glutamine (2 mM), penicillin (100 units/mL), and streptomycin (0.1 mg/mL). 
Cell cultures were maintained at 37 °C in a humidified atmosphere of 5 % CO2. A trypsin 
EDTA solution was used to passage the cells according to the formulation below: 
 0.25 % trypsin/0.53 mM EDTA in Hank’s Buffered Salt Solution without calcium 
and magnesium for experiments performed at MSKCC. 
 0.05 % trypsin, 0.02 % EDTA in PBS for experiments performed at KCL.  
LS174T cells were also passed through a 40 μm strainer (Falcon) before transferring 
them into a new flask/plate to avoid the formation of clumps. 
5.2.11 Uptake assay with pre-labelled 68Ga-THPMe-mal-Anti-CEA 
A preliminary uptake assay was performed to evaluate the specificity of the 
immunoconjugate for the CEA receptor and to optimise the conditions for pretargeting 
experiments. LS174T and A375 cells were plated 48 hours prior to the experiment in a 
24-well plate (50000 cells/well). Prior to the experiment, cell culture medium was 
replaced with fresh medium or HBSS (200 μL). 
217 
 
Cells were treated with 68Ga-THPMe-mal-Anti-CEA at two different THPMe-mal-Anti-CEA 
concentrations (1 μg/mL and 0.1 μg/mL), by addition of 6 μL of 33.5 μg/mL and 3.35 
μg/mL radiolabelled solutions, respectively. Two extra groups were added for the 
experiment in complete medium, namely the 10 μg/mL and 68Ga group. In the 10 μg/mL 
group, cells were treated with the radiolabelling mixture (1 μg/mL) in presence of a 
10-fold excess (10 μg/mL) of unlabelled immunoconjugate. In the 68Ga group, cells 
were treated with acetate buffered 68Ga, obtained by mixing equal volumes of 68Ga 
eluate and 0.2 M ammonium acetate, as a negative control. One well per cell line was 
not treated and utilised to count the cells at the end of the experiment.  
Cells were incubated at 37 °C for 1 hour, after which the supernatant was removed 
and the cells washed twice with HBSS (200 μL), lysed with 0.1 M NaOH (200 μL) and γ-
counted. Supernatant solution and washings were also collected and γ-counted. The 
percentage of the added activity that was taken up by the cells (% uptake) was 
determined for each sample, dividing the counts in the lysate by the sum of counts in 
the supernatant, washings and lysate and multiplying by 100.  
5.2.12 In vitro Pretargeting experiment 
LS174T and A375 cells were plated 48 hours prior to the experiment (50000 cells/well) 
in a 24-well plate. Six different groups were considered as described below, 
concentration refers to final immunoconjugate concentration in the well. 
 Direct radiolabelling (Pre-radiolabelled immunoconjugate,1 μg/mL, N = 3) 
 Pretargeting (1 μg/mL, N = 6) 
 Pretargeting 3x (3 μg/mL, N = 3) 
 Pretargeting w/o wash (1 μg/mL, N = 3) 
 Pretargeting with excess natural gallium (1 μg/mL, 9 μg/mL Ga(NO3)3, N = 3) 
 68Ga only (N = 3) 
Prior to the experiment, cell culture medium was refreshed (200 μL), then 6 μL of a 
33.5 μg/mL solution of THPMe-mal-Anti-CEA was added to each well designated for 1 
μg/mL pretargeting (6 μL of a 100 μg/mL THPMe-mal-Anti-CEA solution was added to 
the wells designated for 3 μg/mL pretargeting). Cells were incubated at 37 °C for 1 
hour, the medium was then changed for all the wells except the “pretargeting w/o 
wash” group.  
68Ga-THPMe-mal-Anti-CEA (immunoconjugate concentration = 33.5 μg/mL, pH= 5.5) for 
the direct radiolabelling group was prepared as described in the previous paragraph 
and analysed by HPLC. Activity for pretargeting experiments and the 68Ga-only control 
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was prepared by mixing68Ga eluate with an equal volume of ammonium acetate 0.2 M 
(pH = 5.5). 6 μL of 68Ga-THPMe-mal-Anti-CEA was added to the direct radiolabelling 
wells, 6 μL of acetate buffered 68Ga solution was added to the remaining wells (≈150 
kBq/well). For the excess natural gallium group, 5 μL of a 0.35 mg/mL solution of 
gallium nitrate in water were also added to the sample (final Ga3+ concentration 9 
μg/mL, 9:1 ratio of gallium to immunoconjugate). Cells were incubated at 37 °C for 
one hour after which the supernatant was removed and the cells washed twice with 
HBSS (200 μL), lysed with 0.1 M NaOH (200 μL) and γ-counted. Supernatant solution 
and washings were also collected and γ-counted and % uptake determined as described 
above. 
5.2.13 Immunoreactive fraction 
A saturation-binding immunoreactivity assay was performed for 68Ga-THPMe-Ph-NCS-
huA33 (5 and 10 equivalents batches) following a modified literature procedure [36]. 
10 μL of a radioimmunoconjugate solution in (0.4 ng/μL in PBS supplemented with 1 % 
bovine serum albumin, ≈ 70 kBq) were added to a suspension of 2.0 × 107 SW1222 
colorectal cancer cells in 100 μL of medium. The resulting mixture was agitated by 
pipetting and incubated for one hour on ice. Cells were then centrifuged (600 RCF for 
5 min) and the supernatant carefully removed. The cells were then washed three times 
by resuspension of the pellet in 1 mL of ice-cold PBS followed by centrifugation and 
removal of the supernatant. Radioactivity in the cell pellet, supernatant and washings 
was measured by γ-counting. After background correction of the data, the 
immunoreactive fraction was calculated by dividing the counts in the cell pellet by the 
sum of the counts in the cell pellet, media, and three washings and multiplying by 100. 
The experiment was performed in triplicate. 
5.2.14 Xenograft model 
The SW122 xenografts were established by Kimberly Edwards (Research Technician at 
MSKCC). All in vivo experiments in this chapters were performed in collaboration with 
Dr Pierre Adumeau (Dr Zeglis laboratory, Hunter College). 
Athymic nude female mice (Athymic Nude-nu, 8-10 weeks old) were obtained from 
Charles River Laboratories (Wilmington, MA). Animals were housed in ventilated cages, 
given food and water ad libitum, and were allowed to acclimatise for approximately 1 
week prior to tumour cells inoculation. SW1222 tumours were induced on the left 
shoulder by a subcutaneous injection of 5 × 106 cells in suspension in 150 μL of a 1:1 
mixture of fresh media and BD Matrigel (BD Biosciences). The xenografts were 
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monitored daily until an ideal size for imaging and biodistribution was reached (≈100-
150 mm3) in 2-3 weeks. 
5.2.15 PET imaging experiments 
Mice were randomly assigned to the different experimental groups (for each group 
N = 5). For all the experiments in this chapter administration of antibody/radiotracers 
was performed via tail vein injection on conscious mice after gentle warming with a 
heat lamp. Approximately five min prior to imaging, mice were anaesthetised by 
inhalation of 2 % isoflurane/oxygen gas mixture and positioned on the bed of a 
MicroPET Focus scanner (Concorde MicroSystem Inc.). 1 % isoflurane anaesthesia was 
maintained throughout the scan. Static scans of 10 min each were recorded at different 
time points after injections. An energy window of 350-700 keV and a coincidence 
timing window of 6 ns were used. Data were sorted into 2-dimensional histograms by 
Fourier re-binning, and transverse images were reconstructed by filtered back-
projection (FBP) into a 128 × 128 × 63 (0.72 × 0.72 ×1.3 mm) matrix. The imaging data 
were normalised to correct for non-uniformity of PET response, dead-time count 
losses, positron branching ratio, and physical decay to the time of injection. No 
attenuation, scatter, or partial-volume averaging correction was applied. Activity 
concentrations (% ID/g) were calculated from the counting rates in the reconstructed 
images by use of a system calibration factor derived from the imaging of a mouse-sized 
water-equivalent phantom containing 68Ga or 89Zr. Images were analysed using ASIPro 
VMTM software (Concorde Microsystems). Mice were sacrificed by CO2 asphyxiation. 
Details of the different experiments performed are described below.  
Imaging with 89Zr-DFO-huA33 (positive control) 
Mice were injected with 89Zr-DFO-huA33 in saline (200 μL, ≈ 7 MBq, 88 μg) and imaged 
at 25 hours after injection. At 26 hours post injection, mice were sacrificed. 
Pretargeting experiments 
Mice were injected with 100 μg of THPMe-Ph-NCS-huA33 in saline using either the 10 
eq. or the 30 eq. batch (5 mice per group). After 24 hours, mice were injected with 8-
10 MBq of 68Ga-acetate (pH 7). PET imaging of the 5 mice was performed from 50 min 
to 90 min after injection (10 min per mouse) and then repeated one hour after. Mice 





Mice were injected with 8-10 MBq of 68Ga-acetate (pH 7) and imaging performed as 
described for the pretargeting experiments, from 1 to 2 hours following administration 
of the radioactivity. Mice were culled at 3 h post injection and ex vivo biodistribution 
performed. 
68Ga followed by THPMe blood clearance 
Mice were injected with 10-11 MBq of 68Ga-acetate (pH 7). Imaging of two of the mice 
at 40 and 50 min after injection was performed. A solution of THPMe in saline (3 mg/mL) 
was prepared and pH adjusted to 7 with Na2CO3. A 400 μg/mL solution was prepared 
by dilution of the stock solution in saline. At 1 hour after gallium injection, 20 μg of 
THPMe (24 nmol, in 50 μL of saline) were also administered intravenously and all mice 
imaged from 20 to 60 min after THPMe injection. Mice were sacrificed 3 hours after the 
68Ga injection and the ex vivo biodistribution of the activity assessed. 
5.2.16 Ex vivo Biodistribution 
For all 68Ga experiments, tissues were harvested and weighed and ex vivo 
biodistribution assessed by γ-counting. The whole organ was collected in the case of 
tumour, heart, lungs, liver, spleen, stomach (unemptied) and kidneys. The femur was 
used as representative of bone, skin and fur was collected from the ears, muscle from 
the hindlimb and blood by a cardiac puncture. Only part of the small and large intestine 
(unemptied) were collected. All organs were washed in water to eliminate residual 
blood. Calibration of the γ-counter with known amounts of activity allowed 
determination of the decay-corrected CPM/MBq conversion coefficient, which was 
used to calculate % injected dose (% ID) in each organ. In the reported data, the 
residual activity in the tail (as a result of an imperfect IV injection) was subtracted 
from the total activity injected. Tail-corrected % ID were calculated and % ID/g 
obtained by dividing the tail-corrected % ID of each organ by its weight. 
5.2.17 Statistical analysis of the data 
Data obtained for in vitro and in vivo studies were analysed using GraphPad Prism, 
version 7.04 for Windows (GraphPad software). For all the statistical analysis 
comparing two groups, Student’s t-test was used. ANOVA was used to analyse results 
where more than two groups were compared. In this case, Brown-Forsythe test was 
used to verify the hypothesis of equal variances between groups and Tukey post-hoc 




In this work, the pretargeting via metal chelation hypothesis has been investigated in 
two different antigen/antibody models, targeting the carcinoembryonic antigen (CEA) 
and the transmembrane glycoprotein A33, respectively. Two different bifunctional 
derivatives of THPMe were used to allow site-specific modification (THPMe-mal-DTP, for 
the anti-CEA antibody) and non-specific conjugation (THPMe-Ph-NCS, for huA33 
antibody) to the antibody. An in vitro approach was used for the anti-CEA study, while 
the huA33 pretargeting experiments were performed in vivo. Owing to all these 
differences between the approaches, the results of the two pretargeting attempts will 
be described separately in the following sections. 
5.3.1 First attempt: THPMe-mal-Anti-CEA conjugate 
In this first set of experiments, an anti-CEA-THPMe immunoconjugate was produced by 
site-specific conjugation. A full-length anti-CEA antibody possessing 4 disulfide bonds 
was kindly provided by the laboratory of Prof. Kerry Chester (UCL) The newly 
synthesised bifunctional THPMe derivative THPMe-mal-DTP (Figure 5.4), developed as a 
collaboration between Blower/Ma (KCL) and James Baker laboratories (UCL) was 
chosen as a suitable chelator. The dibromo-/dithiophenol-maleimide platform allows 
binding of the chelator to two free cysteine residues upon disulfide bonds reduction, 
generating new cysteine bridges that can help to maintain the integrity and quaternary 
structure of the antibody [37-39]. 
 
Figure 5.4. Structure of the dithiophenolmaleimide THPMe derivative (THPMe-mal-DTP) 
used in this work. 
Immunoconjugate production and purification 
The anti-CEA antibody was transferred to borate buffer containing 5 mM EDTA to 
chelate any free metal present. HPLC analysis of the antibody (Figure 5.5) shows a 




Figure 5.5. Size-exclusion HPLC chromatogram of anti-CEA antibody. Only one peak is 
visible at 7 min 6 s, assigned to the antibody molecule. 
Conjugation to THPMe-mal-DTP was carried out upon reduction of disulfide bonds using 
tris(2-carboxyethyl)phosphine)(TCEP). The reaction was performed in duplicate and 
sampling at every step (intact antibody, antibody after TCEP treatment, antibody after 
conjugation) allowed monitoring of the reaction using SDS-PAGE as represented in 
Figure 5.6. 
 
Figure 5.6. SDS-page monitoring of the reaction between the anti-CEA antibody and the 
dithiophenolmaleimide-THPMe. Description of the lanes is as follows: A) molecular 
marker (250-10 kDa), B) intact antibody, C) antibody after exposure to TCEP (two hours), 
D) antibody after 1-hour reaction with 12 equivalents of THPMe-mal-DTP.  
As expected, even after denaturation of the sample (5 min at 75 °C, prior to gel 
loading), the intact antibody (lane B and B’) showed only one band representing the 
full-length antibody with all the chains covalently connected by disulfide bonds. 
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Conversely, after a 2-hour treatment with the reducing agent TCEP (line C and C’) the 
first band disappeared, replaced by two bands at lower molecular weight, representing 
the heavy and light side chains of the antibody, respectively. Finally, after 1 h 
incubation with 12 equivalents of the THPMe-mal-DTP at 37 °C (lane D, D’), a full-length 
antibody band is visible again, indicating successful attachment of THPMe-mal-DTP and 
correct rebridging of the side chains. The new band at an intermediate molecular 
weight suggests incorrect/partial rebridging of the side chains to obtain only half of 
the antibody (one heavy chain + one light chain). Finally, lower molecular weight bands 
are also visible indicating an incomplete conjugation/partial rebridging.  
The newly produced conjugate was left in the conjugation buffer overnight, at room 
temperature, to favour maleimide hydrolysis, to an open, unreactive form (Figure 
5.7), which increases the stability of the conjugate towards reaction with free thiols 
[38].  
 
Figure 5.7. Schematic representation of the mal-THPMe chelator after hydrolysis of the 
maleimide moiety to the more stable open form. Wavy bonds are connecting the chelator 
to the antibody. 
Purification from excess chelator/EDTA and transfer into ammonium acetate buffer 
(more suitable for radiolabelling) was then performed by ultracentrifugation. Size-
exclusion HPLC was carried out on the immunoconjugate (Figure 5.8), showing only 
one peak at 7 min 5 s, at λ = 254 nm, confirming the purity of the immunoconjugate 




Figure 5.8. HPLC analysis of THPMe-mal- Anti-CEA immunoconjugate (λ = 254 nm) 
showing a single peak at 7 min 5 s, ascribed to anti-CEA-THPMe-mal. 
Radiolabelling of the new immunoconjugate (0.5 μM in 0.1 M ammonium acetate) was 
performed at room temperature and pH 5.5 and verified using size-exclusion 
chromatography. EDTA was added to the PBS mobile phase (to a final concentration of 
2 mM), to complex any unbound gallium for quantification of radiochemical yield 
(Figure 5.9). 
 
Figure 5.9. HPLC analysis of the THPMe-mal-Anti-CEA radiolabelling mixture (0.5 μM). 
Top panel displays the radiochromatogram showing one main peak at 7 min 28 s 
assigned to the radiolabelled immunoconjugate. Bottom panel shows the UV 
chromatogram (λ = 280 nm) with a small peak at 7 min 6 s (immunoconjugate) and the 
main peak at 11 min 54 s min (EDTA). 
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The radiochromatogram showed a quantitative radiolabelling of the immunoconjugate 
in these conditions, with one main peak in the chromatogram (retention time: 7 min 
28 s) attributed to 68Ga-THPMe-mal-anti-CEA. The small side peak visible at lower 
retention time can be assigned to radioimmunoconjugate aggregates. In the UV 
chromatogram for the same radiolabelling reaction, only a small peak for the 
immunoconjugate is visible at 7 min 6 s, due to low concentration, while the main peak 
at 11 min 54 s is imputable to EDTA. On the contrary, when unchelated 68Ga was 
analysed in the same conditions (Figure 5.10) all the activity eluted at 11 min 58 s as 
[68Ga(EDTA)]. In the UV chromatogram only the EDTA peak was present. 
 
Figure 5.10. HPLC analysis of the unchelated 68Ga. Top panel shows the 
radiochromatogram with one peak at 11 min 48 s assigned to [68Ga(EDTA)]. Bottom 
panel presents the UV chromatogram (λ = 280 nm), showing one peak at 11 min 54 s 
(EDTA). 
Uptake assays with pre-radiolabelled 68Ga-THPMe-mal-Anti-CEA 
The human colon adenocarcinoma cell line LS174T, known to express the CEA antigen 
[40] and extensively used in pretargeting studies employing anti-CEA 
immunoconjugates [41], was utilised for in vitro experiments. The human melanoma 
A375 cancer cell line, which does not express the target antigen, was used as a 
negative control [42]. In preliminary uptake assays, the specific uptake of directly 
radiolabelled THPMe-mal-anti-CEA was evaluated to find suitable conditions for 
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pretargeting studies (antibody concentration, assay buffer), and to verify that the 
immunoconjugate retained affinity for its target receptor. Radiolabelling of the 
immunoconjugate was carried out at 0.22 μM (33.5 µg/mL) concentration in 0.1 M 
ammonium acetate, achieving quantitative radiochemical yield as demonstrated by 
HPLC analysis (Figure 5.11).  
 
 
Figure 5.11. HPLC radiochromatogram for the 68Ga-labelled THPMe-mal-Anti-CEA (0.22 
μM) used for uptake assays with the direct radiolabelled antibody. 
 
LS174T and A375 cells in HBSS were treated with the radiolabelled mixture (at 0.1 and 
1 µg/mL immunoconjugate concentration) and the percentage of the added activity 
that was taken up by the cells (% uptake) determined for each well. The same 
experiment was repeated in complete medium. In this case, cells were also treated 
with unchelated 68Ga as a negative control (68Ga group), and with the 1 µg/mL 
radiolabelled mixture in presence of an excess of unlabelled immunoconjugate (10 
µg/mL group), to test whether this immunoconjugate concentration was sufficient to 
saturate the target receptor. Results are reported in Figure 5.12, statistically 




Figure 5.12. Uptake of 68Ga-THPMe-mal-Anti-CEA in LS174T and A375 cell line in full 
medium (left panel) or HBSS (right panel). Values are expressed as mean ± SD (N = 3). 
In the top panel the two cell lines are compared (t-test for each immunoconjugate 
concentration), in the bottom panel the same results are displayed comparing different 
immunoconjugate concentration for the same cell line (one-way ANOVA followed by 
Tukey’s post hoc test). P values are defined as follows: * = P ≤ 0.05, **= P ≤ 0.01, *** = 
P ≤ 0.001 and **** = P ≤ 0.0001. 
Uptake of the 68Ga-THPMe-mal-Anti-CEA radioimmunoconjugate (at 0.1 and 1 μg/mL) 
was seen for LS174T cells both when using HBSS as a buffer and in complete medium. 
Non-specific uptake of 68Ga-THPMe-mal-Anti-CEA in A375 cells was low demonstrating 
specific targeting of the CEA antigen. Addition of excess unlabelled THPMe-mal-Anti-
CEA, to reach a final immunoconjugate concentration of 10 μg/mL, resulted in a 
reduction of the uptake in LS174T cells, due to partial blocking of the receptor by the 
unlabelled conjugate. However, persistence of some uptake in these conditions suggest 
that an immunoconjugate concentration of 10 μg/mL is not sufficient to completely 
saturate the receptor. Uptake of unchelated 68Ga in LS174T cells was significantly 
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lower than 68Ga-THPMe-mal-Anti-CEA uptake and, notably, did not differ from 68Ga 
uptake in A375 cells.  
The 1 μg/mL concentration in complete medium was selected for pretargeting 
experiments. Complete medium was preferred to HBSS, despite the lower cellular 
uptake percentage, since it was deemed more representative of the in vivo conditions. 
The 1 μg/mL concentration group was selected since it displayed larger difference 
between CEA positive and negative cell line compared to the 0.1 μg/mL group.  
Pretargeting experiment 
In this experiment, the % uptake for cells treated with the directly radiolabelled 
antibody (1 μg/mL) was compared with the uptake obtained in cells pretargeted with 
the unlabelled immunoconjugate (1 μg/mL antibody concentration), followed by 
replacement of medium and treatment with acetate buffered gallium-68. In order to 
obtain a robust set of data, the following groups were also considered: 
 Pretargeting w/o wash: where the medium was not refreshed between 
incubation with immunoconjugate and treatment with 68Ga. 
 Pretargeting 3x: in which the concentration of antibody in the well was 
increased to 3 μg/mL. 
 Pretargeting natural gallium: where excess natural gallium was mixed with 68Ga 
prior to addition to have a nominal 9:1 μg ratio between gallium and 
immunoconjugate. 
 68Ga only: where no immunoconjugate was used. 
The experiment was planned so that all the samples experienced the same conditions 
with the only variable being the treatment. At first, all pretargeted cells were treated 
with the relevant concentration of antibody, while the direct radiolabelling and 68Ga 
only sample were treated with the same volume/concentration of buffer. After 60 min 
incubation medium was changed for all samples except the pretargeting w/o group. 
All the cells were then incubated with activity (radiolabelled antibody for the direct 
radiolabelling group, acetate buffered 68Ga for the other groups) for further 60 min, 
then washed, lysed and the activity present in the lysate versus supernatant/washings 
quantified by γ-counting. The results (cell-bound activity expressed as percentage of 




Figure 5.13. 68Ga uptake comparing direct radiolabelling, unchelated 68Ga and different 
pretargeting groups. Uptake for LS174T (left) and A375 cells (right) are reported in the 
top panel while the bottom panel displays all the data together. Values are expressed as 
mean ± SD (n = 3, n = 6 for pretargeting groups). Different groups within each cell line, 
were compared using one-way ANOVA followed by Tukey’s multiple comparison test. 
For each of the groups the two cell lines were also compared using a t-test. P values are 
defined as follows: * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001 and **** = P ≤ 0.0001. 
These results were analysed both by comparing different groups within a single cell 
line (using one-way ANOVA) and by comparing the two cell lines for each of the groups 
(using a t-test). A significant pretargeting effect could not be seen in either case. 
LS174T and A375 cells differed significantly when comparing the two direct 
radiolabelling groups, where LS174T cells showed, as expected, higher uptake of the 
radiolabelled antibody (2.7 ± 0.1 % for LS174T cells vs 0.5 ± 0.04 for A375 cells). Higher 
68Ga uptake for LS174T cells was also visible in the pretargeting with natural gallium 
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group, where the blocking effect of natural gallium was more evident for A375 cells. 
When comparing the various groups for LS174T cells, the only significant difference 
was found between the direct radiolabelling group and the rest. To a lesser extent this 
was also seen in A375 cells, with direct radiolabelling in this case hampering 68Ga 
uptake compared to the 68Ga-only control. Interestingly, for A375 cells a significant 
suppression of the uptake was also seen for the pretargeting in the presence of natural 
gallium group. Notably, no other significant difference was found between any of the 
pretargeting groups and the 68Ga-only control for either cell line, suggesting that no 
radiolabelling took place in the medium (see Discussion). This is likely due to the low 
concentration of chelator available for binding in each well. In fact, since antibody 
concentration in the medium was 7 nM (21 nM for the pretargeting 3x group), 
concentration of the available chelator was certainly lower than 28 nM (84 nM for the 
pretargeting 3x), which is the maximum value corresponding to 1 chelator per disulfide 
bond (4 chelators per antibody) with all the immunoconjugate molecules being cell-
bound and available for binding. 68Ga radiolabelling in this concentration range is 
extremely challenging even for an outstanding Ga3+ chelator such as THPMe. 
5.3.2 Second attempt: THPMe-Ph-NCS conjugate 
In the second set of experiments, non-specific conjugation was employed with the aim 
of achieving higher chelator concentration at the target site by increasing the number 
of chelators/antibody with non-specific conjugation. The isothiocyanate derivative 
THPMe-Ph-NCS (Figure 5.14) was synthesised following literature procedures [35] and 
conjugated to the huA33 antibody available in the MSKCC and Hunter College 
laboratories (New York), where this work was performed during a research visit. 
 
Figure 5.14. Structure of the THPMe-Ph-NCS chelator used in this work [35]. 
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Immunoconjugate production and purification 
Conjugation of the THPMe-Ph-NCS to the huA33 was performed according to a modified 
literature procedure [8,30], by slowly adding a DMSO solution of the chelator to a 
solution of the antibody in PBS at pH 8.8-9.0. Two initial batches of immunoconjugate 
were produced using 5 and 10 equivalents of chelator per antibody. Different ratios 
(20, 30, 40 and 50 equivalents) were further explored in the following weeks. 
Immunoconjugate purification was performed by size-exclusion chromatography, 
followed by ultracentrifugation. Yields for each batch, as calculated by 
spectrophotometric measurements, as well as other characterisation data for the 
immunoconjugates, are reported in Table 5.3. Although attention was paid to avoid 
precipitation during the addition of the chelator to the reaction mixture, precipitation 
was observed for the 50 equivalents batch during overnight storage in the fridge. 
Samples from the 5, 10 and 30 equivalents batches underwent MALDI measurements to 
determine the average number of chelators per antibody. 
Radiolabelling 
To verify the success of the conjugation, radiolabelling of the THPMe-Ph-NCS-huA33 
conjugate was initially performed at the usual slightly acidic pH obtained by 
neutralisation with ammonium acetate buffer. Quantitative radiolabelling was 
obtained for both 5 equivalent and 10 equivalents batches at antibody concentration 
as low as 1 μM, confirming successful conjugation. Figure 5.15 shows an iTLC obtained 
for the radiolabelled immunoconjugate compared with that obtained for a mixture of 
68Ga and a native antibody.  
 
Figure 5.15. iTLC profiles of the crude radiolabelling mixture for the THPMe-Ph-NCS-
huA33conjugate (left) and the native huA33 antibody (right). For every peak, the area 
under the curve (AUC) has been calculated and reported as a percentage. 
In this mobile phase, the radiolabelled antibody stays at the baseline of the iTLC while 
any unchelated metal smears throughout the iTLC strip [43]. It is clear from Figure 
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5.15 that conjugation to THPMe-Ph-NCS is necessary for successful radiolabelling: while 
quantitative radiolabelling is observed for the immunoconjugate, the native antibody 
has only 14 % of the radioactivity associated. Purification of both mixtures on a size-
exclusion column allowed removal of excess chelator and unbound 68Ga. For the native 
antibody only 3 % of the activity eluted from the column in the void volume suggesting 
that most of the 68Ga was either non-chelated or only loosely bound to the antibody. 
On the contrary, 97.5 % of the activity was eluted in the column void volume for the 
THPMe-Ph-NCS-huA33 immunoconjugate, confirming quantitative radiolabelling. 
Radiolabelling of the immunoconjugate was also investigated in conditions that more 
closely resemble those of preclinical experiments. Neutral pH is desirable for 
intravenous (IV) injection in conscious mice, therefore the effect of eluate 
neutralisation to pH 7-7.2 on radiolabelling was evaluated. Notably, also in these 
conditions the immunoconjugate was able to bind gallium quantitatively at 1 μM for 
all tested batches (Table 5.3). In addition, to take into account the time interval 
between eluate neutralisation and injection of the mice, the effect of a 45 min delay 
between eluate neutralisation and radiolabelling of the 10 equivalent batch was 
investigated (Figure 5.16). Remarkably, also in this case radiolabelling was 
quantitative and recovery from size-exclusion column purification was > 95 %. 
 
Figure 5.16. iTLC profile and AUC for THPMe-Ph-NCS-huA33 radiolabelling (1 μM) at pH 
7, with 45 min delay between neutralisation of the 68Ga eluate and radiolabelling of the 
immunoconjugate.  
Radiolabelling of the DFO-huA33 immunoconjugate with 89Zr was carried out for use as 
a positive control for in vivo experiments. 89Zr radiolabelling was achieved in nearly 
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quantitative yield (97 % of the activity eluted from the PD10 column in the void volume) 
and purity was confirmed by iTLC analysis of the eluted fractions (Figure 5.17). 
 
Figure 5.17. iTLC profile and AUC for huA33-DFO (6.7 μM) radiolabelling with 89Zr at pH 
7.5 (fraction 2). 
Immunoreactive fraction measurements 
To verify that conjugation to the chelator did not impair the antibody ability to bind 
its target receptor, the immunoreactive fraction was determined for both the 5 and 
10 equivalent batches via a saturation-binding immunoreactivity assay [36]. The results 
are presented in Table 5.3. In this experiment, a large excess of antigen was 
employed, able to bind the totality of the added radioimmunoconjugate (100 % 
uptake). Accordingly, the observed uptake percentage reflects the immunoreactive 
fraction of the radioimmunoconjugate batch. For both the considered batches, only 
marginal detriment of the immunoreactivity was measured, with immunoreactivity 
fractions equal or superior to 90 %. Based on these results, the 10 equivalents batch 
was selected to perform preclinical experiments. Due to time constraints no 
immunoreactive fraction measurements were performed for the 30 equivalents batch. 
Quantification of chelators/antibody ratio 
Quantification of the number of chelators per antibody was performed by MALDI. 
Examples of m/z spectra of the 5, 10 and 30 equivalent batches as well as of the native 




Figure 5.18. Examples of MALDI mass spectra for the native antibody and different 
batches of immunoconjugate. The data are presented as profile m/z spectra, showing 
both [M]+ and [M]2+ species. The reported m/z values represent the average mass of the 
immunoconjugate in the sample. 
The average number of chelators/antibody (Table 5.3) was calculated from the 















Table 5.3. Summary of characterisation data for the different THPMe-Ph-NCS-huA33 
conjugates. Batches used for in vivo experiment are highlighted in pink. Immunoreactive 
fractions data are reported as average ± SD. *radiolabelling of the 50 equivalents batch 











5 eq 85.7 % quantitative 92.7 ± 0.7 0.4 
10 eq 85.9 % quantitative 89.2 ± 3.1 0.6 
20 eq 88.9 % quantitative N/A N/A 
30 eq 85.3 % quantitative N/A 1 
40 eq 87.3 % quantitative N/A N/A 
50 eq 92.4 % * N/A N/A 
235 
 
In vivo imaging and biodistribution 
Preclinical experiments were performed in nude mice bearing human SW1222 colon 
cancer xenografts. Different groups, of 5 mice each, were considered, as discussed 
below. Initially, as a positive control, 5 mice were injected with 89Zr-labelled huA33-
DFO immunoconjugate. Imaging was performed at 25 hours following 
radioimmunoconjugate administration. Examples of the PET images are shown in 
Figure 5.19. 
 
Figure 5.19. Representative PET images illustrating the biodistribution of 89Zr-DFO-
huA33 in nude mice bearing SW1222 xenografts at 25 h post injection. Coronal views 
are shown on the left, maximum intensity projections (MIP) on the right. 
As it is evident from the images, the huA33 antibody was able to selectively target the 
tumour tissue, while accumulation in other organs was minimal. As a result, high 
contrast PET images were obtained. 
The second group of mice to be imaged was the pretargeting group. Mice were 
pretreated with 100 μg of the THPMe-Ph-NCS-huA33 conjugate (10 equivalents batch) 
followed, after 24 hours, by acetate buffered 68Ga (pH ≈ 7). Injections of the activity 
were performed all at the same time (10 min range) to ensure uniformity in the Ga3+ 
speciation at the time of injection. Therefore, imaging of the mice had to be staggered 
with respect to the injection times with the first mouse scanned at 50 min after the 
injection of 68Ga and the last scanned at 90 min after injection. The scanning was then 
236 
 
repeated in the same order to investigate the effect of a longer delay between 68Ga 
injection and PET imaging on image quality and contrast. Two examples of PET scans 
at 50 min and 1 h 10 min (followed by 1 h 50 min and 2 h 10 min scans) are reported 
in Figure 5.20. Ex vivo biodistribution was performed at 3 h after gallium injection 
and is reported in Figure 5.22. Both the PET scans and the biodistribution data showed 
some accumulation of 68Ga in the tumour. However, most of the activity was still in 
the blood even at 3 h after the 68Ga injection and uptake in non-target organs, such as 
liver and bones, was also visible. 
 
Figure 5.20. PET images showing the biodistribution of 68Ga in nude mice bearing 
SW1222 xenografts, pretreated with THPMe-Ph-NCS-huA33 (10 equivalents batch) 24 
hours before 68Ga injection. For each mouse two scans of 10 min each were performed 
at ≈ 1 and 2 hours post 68Ga injection. Images are reported as coronal view (left panel) 
and MIPS (right panel). White arrows indicate location of the tumour. 
To investigate whether the uptake visible in tumours was attributable to pretargeting 
or to simple accumulation of gallium in cancer a third group of mice was injected with 
acetate buffered 68Ga, without prior injection of antibody-chelator conjugate. Imaging 
and ex vivo biodistribution were performed as in the previous group and the results 




Figure 5.21. PET images illustrating the biodistribution of 68Ga in nude mice bearing 
SW1222 xenograft at ≈ 1 and 2 h after 68Ga injection. For each mouse coronal view (left 
panel) and MIPS (right panel) are reported. White arrows indicate location of the tumour. 
 
Figure 5.22 Ex vivo 68Ga biodistribution in nude mice bearing SW1222 xenografts at 3 
hours after 68Ga injections, comparing mice pretreated with THPMe-Ph-NCS-huA33 (10 
equivalents batch) 24 hours before 68Ga injection (red), with mice that were not 
pretreated with any immunoconjugate (control group, blue). For each group N = 5, data 
are presented as mean ± SD. For each organ, comparison between the two groups was 
performed by t-test. 
As was already evident from a visual comparison of the PET images, no difference was 
found between the pretargeting and the 68Ga-only control group. A comparison 
between the two biodistributions (Figure 5.22, t-test performed for each organ) also 
revealed no significant difference in tumour 68Ga uptake for the two groups 
(10.8 ± 1.5 % ID/g in the pretargeting group vs 12.9 ± 2.5 % ID/g in the 68Ga group). The 
only significant difference among the considered organs was found for blood, whose 
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uptake was higher for the 68Ga-only group (19.1 ± 1.4 % ID/g) compared to the 
pretargeting group (14.4 ± 2.6 % ID/g). 
MALDI analysis of the immunoconjugate used (only available after the experiment) 
revealed an average of only 0.6 chelators/antibody, suggesting that a low 
concentration of the chelator at the tumour site could be the cause of the negative 
results of this first pretargeting experiment. In a second attempt at pretargeting we 
aimed at increasing the number of chelators per antibody and, accordingly, the 
concentration of chelator available for in vivo radiolabelling. MALDI analysis of the 30 
equivalents chelators/antibody batch revealed an average of 1 chelator per antibody, 
which represented only a modest increase from the 10 equivalents batch. However, 
since this was the highest ratio achievable without precipitation in the conjugation 
mixture we decided to use this new batch to carry out a second preclinical pretargeting 
experiment. Images of the PET scans and a graph showing the ex vivo biodistribution 
for the three groups considered are reported in Figure 5.23 and 5.24. 
 
Figure 5.23. PET images displaying the biodistribution of 68Ga in nude mice bearing 
SW1222 xenografts, pretreated with THPMe-Ph-NCS-huA33 (30 equivalents batch) 24 
hours before 68Ga administration. Scans performed at ≈ 1 and 2 hours after 68Ga 
injections are reported as coronal view (left panel) and MIPS (right panel). White arrows 
indicate location of the tumour. 
Once again, no significant difference was found in the tumour uptake of the 30 
equivalent pretargeting group and the gallium only control as visible from the PET 
images and from biodistribution data. ANOVA analysis of the data revealed lower 
uptake in the bones for the pretargeting 30 eq. group (6.0 ± 1.1 % ID/g) compared to 
both the gallium only group (11.4 ± 2.4 % ID/g) and the pretargeting experiment 10 eq. 




Figure 5.24. Ex vivo 68Ga biodistribution in nude mice bearing SW1222 xenografts at 3 
hours after 68Ga injections, comparing mice pretreated with THPMe-Ph-NCS-huA33 10 
equivalents batch (red), or 30 equivalents batch (green) 24 hours before 68Ga 
administration, and mice that were not pretreated with any immunoconjugate (control 
group, blue). For each group N = 5, data are presented as mean ± SD. Comparison 
among the groups was performed using one-way ANOVA for each organ. 
Owing to the failure of the pretargeting experiments, the planned isotype control 
experiments were not performed resulting in a spare group of 5 mice bearing SW1222 
xenografts. Given the relatively high accumulation of free gallium in this tumour 
(exceeding the % uptake found for the melanoma model in Chapter 4) a clearance 
experiment was performed, using THPMe as a blood clearance agent with the aim to 
increase the tumour-to-blood activity ratio. 
In this final experiment mice were injected with 68Ga followed, at one hour post 
injection of the activity, by THPMe (20 μg, 24 nmol). Mice were then imaged (from 20 
min after THPMe injection). Two of the mice were also imaged before between the first 
and second injection, in order to compare the PET images before and after THPMe-
mediated blood clearance. An example of PET images is presented below (Figure 
5.25). Ex vivo biodistribution was also performed at 3h from the 68Ga injection and 




Figure 5.25. Example PET images illustrating the biodistribution of 68Ga in a nude mouse 
bearing SW1222 xenografts before (A) and after (B) the injection of THPMe as a blood 
clearance agent. For both scans coronal view (left panel) and transverse view (right 
panel) are reported. Hot spots visible outside the mouse body in the coronal projection 
B are image artefacts due to the extremely high proportion of the activity in the bladder. 
White arrows indicate location of the tumour  
 
Figure 5.26. Ex vivo 68Ga biodistribution at 3 hours after 68Ga injections in nude mice 
bearing SW1222 xenografts, comparing mice treated with THPMe at one hour post 68Ga 
injections and the control group. For each group N = 5. Data are presented as mean ± 
SD. Comparison between the two groups was performed with a t-test for each of the 
organs. 
Both PET images and biodistribution revealed the dramatic effect of THPMe clearance, 
which notably decreased the uptake of 68Ga in every organ. A t-test performed for 
every organ revealed significantly reduced uptake in all organs aside from the large 
intestine, probably as a result of the larger variability in the % ID/g for this organ. P 




Table 5.4. Comparison between mean %ID/g and tumour/organ ratio for 68Ga and 68Ga 
+ THPMe groups. P values resulting from a t-test comparing the two groups for each 
organ are also reported. 
 
P value 
68Ga 68Ga + THP 
 Mean tumour/organ Mean tumour/organ 
Blood 5.71E-09 19.08 0.68 1.75 2.27 
Tumour 6.29E-05 12.91 1.00 3.97 1.00 
Heart 3.87E-07 5.36 2.41 0.66 5.98 
Lungs 2.01E-07 8.83 1.46 1.20 3.32 
Liver 1.43E-05 10.30 1.25 3.52 1.13 
Spleen 9.45E-06 5.21 2.48 1.63 2.44 
Stomach 0.004019 2.42 5.33 0.89 4.47 
Small intestine 0.003237 3.66 3.53 1.31 3.03 
Large intestine 0.07185 7.45 1.73 3.40 1.17 
Kidneys 0.000557 8.19 1.58 4.21 0.94 
Muscle 6.37E-07 1.76 7.36 0.25 16.09 
Bone 2.07E-05 11.43 1.13 1.81 2.19 
Skin 6.5E-07 5.99 2.15 0.86 4.62 
 
Interestingly, the clearance effect is far more noticeable for the blood than for the 
tumour. Accordingly, the tumour to blood ratio increased from 0.68 in the 68Ga-only 





5.4.1 Choice of models for pretargeting experiments 
The choice of appropriate models is of fundamental importance when designing any 
pretargeting experiment to avoid misinterpretation of the results. In this work, the 
high-affinity chemical pair was fixed and consisted of a THPMe-based chelator and 
68Ga3+, with the latter administered in an acetate buffered solution that proved to be 
effective for in vivo radiolabelling (see Chapter 4). On the other hand, other 
parameters such as the reactive chemical function of the THPMe chelator and an 
appropriate antigen/antibody pair needed to be identified. Depending on the THPMe 
chelator employed, site specific or non-specific conjugation to the antibody can be 
performed. While more control of the conjugation and on the immunoreactivity of the 
resulting immunoconjugate is gained using site specific attachment, non-specific 
conjugation allows, in principle, attachment of a higher number of chelators to the 
antibody. Both high affinity for the target receptor (undiminished immunoreactivity) 
and high availability of pretargeting sites (number of chelators/antibody) are 
important to obtain good image quality in a pretargeted experiment so any choice of 
bifunctional chelator should be a good compromise between the two. When considering 
the antigen/antibody couple, the main concerns are the high affinity of the antibody 
for the selected antigen and a slow internalisation rate of the antibody-antigen 
complex. High affinity is needed to ensure efficient binding to the antigen expressing 
tumour in vivo. Slow internalisation is important to maintain high immunoconjugate 
availability on the tumour surface, thus allowing the radiolabelled probe to bind in 
vivo. Finally, depending on the selected antigen/antibody couple, a cancer cell line 
overexpressing the desired antigen has to be chosen.  
5.4.2 First attempt: THPMe-mal-Anti-CEA conjugate 
In the first set of experiments, a site-specific conjugation was used, exploiting the 
dithiophenolmaleimide technology developed by Baker and co-workers. The 
dithiphenolmaleimide derivative of THPMe was site-specifically attached upon 
disulfide-bonds reduction to a fully human anti-CEA antibody targeting the slowly-
internalising carcinoembryonic antigen [44]. The success of the conjugation was 
verified by SDS-PAGE, which showed both full and partial rebridging of the disulfide 
bonds upon reaction with the BFC. Subsequent hydrolysis of the maleimide moiety 
(overnight incubation at room temperature and pH > 8) ensured stability against 
protein displacement by free thiols. Successful radiolabelling was obtained in the mild 
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conditions usually employed for THPMe ligands at an immunoconjugate concentration 
as low as 0.22 μM.  
The human colorectal cancer cell line LS174T, known to express the carcinoembryonic 
antigen [40], was chosen for the in vitro uptake studies using the new synthesised 
immunoconjugate. The human melanoma cell line A375, not expressing the targeted 
antigen [42], was used as a negative control. Binding of the anti-CEA antibody to its 
target antigen may be impaired following treatment with trypsin, which is likely to 
affect peripheral membrane glycoproteins such as the CEA [45]. Therefore, uptake 
assays were performed on cells plated 48 h prior to the experiment to allow them to 
fully recover from trypsin treatment. In each experiment, one well per group was used 
to count the cells, to verify that the number of cells did not differ significantly between 
control and experimental group (e.g. as a result of a different duration of the cell 
cycle for the two cell lines). The THPMe-mal-Anti-CEA conjugate retained affinity for 
the target receptor, as confirmed by uptake assays using the directly radiolabelled 
immunoconjugate. In A375 cells the uptake of 68Ga-THPMe-mal-Anti-CEA was minimal 
and similar to the % uptake measured for unchelated 68Ga, while LS174T cells showed 
significant radioimmunoconjugate accumulation at an immunoconjugate concentration 
as low as 0.1 μg/mL. Although the absolute uptake was higher when the experiment 
was performed in HBSS we decided to carry out the pretargeting experiments in 
complete medium, as these conditions were likely to be more representative of an in 
vivo situation in which other chelating agents (transferrin, amino acids, etc.) can 
compete with the immunoconjugate for 68Ga binding. 1 μg/mL was established as an 
ideal concentration of THPMe-mal-Anti-CEA conjugate to maximise uptake. Notably, a 
10-fold excess of unlabelled THPMe-mal-Anti-CEA could not completely saturate the 
target antigen (uptake still visible, although reduced, for the 10 μg/mL group). 
A reasoned choice of positive and negative controls for the pretargeting experiment 
was important to generate solid data that could attribute the success or the failure of 
the experiment solely to pretargeting and not to any other factors. The directly 
radiolabelled antibody represented the positive control, unchelated 68Ga (without prior 
addition of antibody-chelator conjugate) the negative control. A pretargeting group 
with 3 times higher immunoconjugate concentration was included (pretargeting 3x), 
to account for concentration effects. Another group, in which the medium was not 
refreshed before the addition of the activity, was also included (pretargeting w/o 
wash), to evaluate the effect of unbound immunoconjugate available for radiolabelling 
in the medium. A final group was introduced to evaluate the effect of excess gallium 
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(pretargeting natural Ga), which should impair 68Ga radiolabelling of the pretargeted 
immunoconjugate. For all these, A375 cells were evaluated alongside LS174T. 
For LS174T cells, 68Ga uptake in the pretargeting group was significantly lower than for 
the directly radiolabelled control, and no different from the 68Ga-only group, showing 
how the measured uptake is only attributable to unchelated gallium. Similarly, no 
significantly different uptake was measured for either the pretargeting w/o wash, the 
pretargeting 3x or pretargeting the natural gallium group. Had the pretargeting 
worked, a decrease in uptake should have been visible for both the w/o wash and the 
natural gallium groups, due to radiolabelling of unbound immunoconjugate or to 
natural gallium blocking of antigen-bound immunoconjugate, respectively. Finally, an 
increased uptake for the pretargeting 3x group would have suggested that some 
pretargeting was taking place, but was not measurable at the 1 μg/mL concentration. 
Overall, the results obtained for LS174T already gave a clear indication of pretargeting 
failure in the tested conditions.  
Additional confirmation of the failure was given by comparison with 68Ga uptake in the 
control cell line A375. As already seen in the preliminary experiments, no difference 
between the uptake of unchelated gallium in the two cell lines was visible. On the 
contrary, a significantly reduced uptake was seen for the directly radiolabelled 
immunoconjugate in A375 cells compared to LS174T, unsurprisingly, since in this case 
68Ga is bound to the anti-CEA antibody for which A375 cells lack the target antigen. No 
difference between % uptake in the two cell lines was visible for the pretargeting, 
pretargeting 3x and pretargeting w/o group confirming the hypothesis that in all these 
groups all the uptake is due to unchelated 68Ga. Interestingly, a significant difference 
was found between the pretargeting natural gallium groups where, unexpectedly, 
uptake in A375 cells but not in LS174T, was significantly decreased (P = 0.0062) by an 
excess of natural gallium, suggesting a saturation of 68Ga uptake in this cell line at high 
gallium concentration (similar to what was seen in Chapter 4 for 67Ga uptake studies). 
Notably, the obtained results not only proved that pretargeting did not take place in 
the experimental conditions, but also suggest that the reason of this failure is 
unsuccessful radiolabelling in the medium at the tested concentration 
(immunoconjugate concentration of 1 μg/mL, 7 nM). In fact, if the antibody could 
successfully bind 68Ga, the percentage uptake measured for the pretargeting w/o wash 
group in the A375 cell should be lower than the unchelated gallium uptake (since free 
gallium would be sequestered by the immunoconjugate present in the solution). 
Notably, even increasing the immunoconjugate concentrations three times did not 
improve the results, suggesting that a 3 μg/mL immunoconjugate concentration (21 
245 
 
nM) was still too low to achieve radiolabelling of the pretargeted THPMe-mal-Anti-CEA. 
Notably, saturation of the CEA antigen was probably not achieved at this 
concentration, since the preliminary uptake assay showed incomplete saturation even 
at 10 μg/mL of THPMe-mal-Anti-CEA. Although further increase of the immunoconjugate 
concentration could have led to a measurable pretargeting effect, this was not tested 
due to low availability of THPMe-mal-Anti-CEA. More importantly, the use of very high 
immunoconjugate concentration is undesirable and would eliminate any advantages of 
pretargeting over direct radiolabelling antibody, whose binding was already visible at 
the 30-fold lower concentration of 0.1 μg/mL. On the other hand, increasing the 
number of chelators/antibody via non-specific conjugation methods seemed a feasible 
way to increase the availability of the chelator for 68Ga binding without increasing the 
amount of immunoconjugate used. 
5.4.3 Second attempt: THPMe-Ph-NCS conjugate 
A second attempt at testing the metal chelation pretargeting hypothesis was carried 
out in collaboration with MSKCC and Hunter College during a five-week research visit. 
In this set of experiments, a fully human huA33 antibody was exploited, targeting the 
transmembrane glycoprotein A33 expressed in 95 % of colorectal carcinomas [46], 
including the colorectal cancer cell line SW1222 used in this experiment. The A33 
protein does not become internalised or shed upon binding to the antibody, and is 
therefore an ideal model for pretargeting experiments. In addition, this 
antigen/antibody/cell line triad has been extensively exploited by Lewis and Zeglis in 
preclinical pretargeting studies to validate the bioorthogonal click chemistry approach 
[30,31,43], thus representing an excellent model to test a new pretargeting strategy. 
Previous studies in the same model suggest that site-specific conjugation does not 
improve image contrast and quality [30]. Therefore, in the attempt to increase the 
number of chelators available per antibody, a non-specific conjugation was exploited 
using the THPMe isothiocyanate derivative THPMe-Ph-NCS. 
Conjugation of the selected antibody was initially performed using 5 and 10 equivalents 
of THPMe-Ph-NCS and its success was demonstrated by efficient radiolabelling of the 
purified immunoconjugates in the mild conditions typical for THPMe. In the same 
conditions, the native antibody could not specifically bind gallium, thus demonstrating 
how the THPMe chelator is responsible for 68Ga labelling. Further radiolabelling tests 
were performed in conditions more similar to those planned for the in vivo studies. In 
these experiments, the generator eluate was adjusted to a physiological pH 
(compatible with IV injection in non-anaesthetised mice). Furthermore, the 
introduction of a 45 min delay between eluate neutralisation and radiolabelling was 
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evaluated to account for the time to prepare syringes and mice prior to 68Ga injection. 
Testing these conditions was important to rule out any effect of different gallium 
speciation over pH range or time when considering the results of preclinical 
experiments. In fact, in our experience, unchelated gallium often displays a variable 
behaviour after the pH is raised above 3, presumably owing to the multitude of species 
present in these conditions (see Chapter 1). An immunoreactivity assay, performed in 
conditions of large antigen excess to ensure quantitative huA33 binding to A33 
receptor, [36], showed only a marginal impairment of the immunoreactivity, for both 
the radiolabelled immunoconjugate batches, towards SW1222 cells. Based on these 
results the 10 equivalents batch was employed for the initial in vivo experiments. 
Imaging using a 89Zr-labelled DFO-huA33 immunoconjugate confirmed the ability of the 
antibody to image SW1222 tumours with great selectivity. Imaging using a directly 
radiolabelled THPMe-hua33 derivative would have been an even stronger positive 
control for our experiment but this could not be performed for several reasons. In the 
first instance, THP chelators are very selective for gallium, as highlighted in the 
previous chapters, and a 89Zr radiolabelled derivative would have seen demetallation 
in serum over time [47]. Imaging with 67Ga, was possible in principle, but the isotope 
was not available at MSKCC at the time of the experiment. Finally, 68Ga imaging of a 
directly labelled conjugate was simply unfeasible due to the short half-life of the 
isotope. The first preclinical studies using 68Ga were therefore the pretargeting 
experiment (using the 10 equivalents batch) and the negative control that only 
employed acetate buffered gallium-68. Unfortunately, in vivo imaging and 
biodistribution did not highlight any difference between the pretargeted and 68Ga-only 
group, suggesting that the tumour uptake visible in the pretargeting group was solely 
attributable to uptake of unchelated 68Ga in the tumour. Different hypotheses were 
formulated to account for the failure of this pretargeting experiment. Similar to what 
was hypothesised for the anti-CEA antibody, the concentration of chelator may have 
been not sufficient for effective radiolabelling. Alternatively, THPMe chelator could 
have interacted with endogenous metals during the 24 hours between the 
immunoconjugate administration and the 68Ga injection, thus becoming not available 
for 68Ga radiolabelling.  
MALDI analysis of the immunoconjugate, only available after the first set of in vivo 
experiments, seemed to support the first hypothesis. In fact, only an average of 0.6 
chelators per antibody were found in the case of the 10 equivalents batch. Although 
this is an average number, and likely includes immunoconjugate molecules with few 
chelators attached, the value itself is particularly low considered the general 
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assumption that non-specific conjugation can lead to a higher number of 
chelator/antibody molecules. 
A final pretargeting attempt was conducted using an antibody reacted with 30 
equivalents of chelator (maximum amount that allowed conjugation without any 
aggregation/precipitation of the immunoconjugate). Unfortunately, also in this case 
no significant difference in the tumour uptake of 68Ga was visible. Although MALDI 
analysis of this new batch showed a modest increase in the chelator/antibody ratio (up 
to 1 chelator/antibody molecules on average), this may have been not enough to allow 
pretargeted imaging using this approach. On the other hand, some differences in 
biodistribution observed for this last group suggest that there may be other reasons 
contributing to the failure of this second attempt. In fact, a decreased uptake in bones 
was evident for this third group of animals and uptake in liver and large intestines was 
also reduced although to a lesser extent. Since all these organs are involved in 
clearance routes of free gallium (especially bone), the decreased uptake suggests that 
part of the gallium may actually bind the antibody in vivo, but this does not result in 
increased tumour uptake. No measurements of the immunoreactive fraction of the 30 
equivalents immunoconjugate batch were performed due to time constraints so it is 
not possible to know whether the immunoreactive fraction decreased compared with 
the 89 % measured for the 10 equivalents batch. In any case, it is reasonable to imagine 
that antibodies with more chelators attached will bind to their target antigen with 
lower affinity compared to those with a higher number of chelators (in fact, the MALDI 
measurements only yielded an average value, but the distribution of 
chelators/antibody is likely to be not uniform). In the presence of an excess of antibody 
with no/few chelators, those immunoconjugate molecules with several chelators are 
less likely to bind to their target antigen, but more likely to bind 68Ga, and their 
residual circulating fraction could therefore bind part of the 68Ga injected 24 h after 
antibody administration, diminishing unchelated gallium uptake in 
bones/liver/intestine without significantly altering the 68Ga tumour uptake.  
Overall, no pretargeting-related tumour uptake was observed in these in vivo 
experiments and notably, no improvement was visible when using the 30 equivalents 
compared to the 10 equivalents batch. If this were a consequence of impaired affinity 
of the immunoconjugate, that would automatically rule out the THPMe-Ph-NCS chelator 
for pretargeting purposes. If instead, this were due to an insufficient number of 
chelator molecules per antibody, this would still be an irresolvable problem, as 
conjugation of more than 1 THPMe-Ph-NCS moiety per antibody was not possible and 
resulted in precipitation of the immunoconjugate, likely due to aggregation.  
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The use of larger amount of immunoconjugate may help to increase the number of 
antibodies molecules bound to the tumour antigen. However, considering the non-
uniformity of the immunoconjugate population this may results in antibody molecules 
possessing 0-1 chelator saturating the antigen pool and leaving those immunoconjugate 
with more chelators attached (and more likely to radiolabel) in the blood stream. In 
fact, this strategy had already been exploited by Zeglis for the same antibody/antigen 
pair (using 300 μg of immunoconjugate [31]), but no improvement on the tumour 
uptake was measured. On the contrary, an increased blood-pool activity was found due 
to increase in circulating immunoconjugate molecules. 
Notably, although unsuccessful from a pretargeting point of view, these studies 
highlighted a good uptake of unchelated gallium in SW1222 tumours. This led us to use 
those mice originally allocated for isotype control to evaluate the use of THPMe as a 
blood clearance agent to increase their tumour-to-blood activity ratio as described in 
Chapter 4. The experiment was performed in the same conditions employed for the 
A375 melanoma models, in terms of delay between injections and amount of THPMe 
administered, with the only difference being that mice were injected when awake 
and, accordingly the pH of the 68Ga and THP solutions injected was 7-7.2 (instead of 
pH 5-6 employed in the A375 model). Notably, in this experiment THPMe was able to 
clear 68Ga from the blood much more efficiently than from the tumours, resulting in a 
threefold enhancement of the tumour-to-blood activity ratio (shifting its value from 
<1 to >2) as calculated from the ex vivo biodistribution data at 3 hours. PET images of 
the mice before and after THPMe treatment also showed increased image contrast and 
better tumour visualisation, despite poor quality owing to the massive accumulation 
of activity in the bladder. These results together suggest that the SW1222 colon 
carcinoma could be a good model to further investigate the use of unchelated 68Ga to 
image tumours with use of THPMe as a blood clearing agent.  
Notably, a reduced variability in 68Ga-acetate biodistribution was also observed in 
these experiments, compared to those performed for the A375 xenografts. Several 
factors were changed between the two set of experiments (generators, pH of injection, 
strain of mice, time under anaesthesia) and therefore it is difficult to ascribe this 
different behaviour to a particular cause. However, the higher pH of the 68Ga-acetate 
solution used in SW1222 experiments is likely to have played a role in this, by increasing 






In conclusion, the pretargeting by metal chelation strategy failed for both the different 
models investigated. These findings suggest that a step back should be taken and the 
feasibility of the approach re-examined. Although immunoPET is certainly the field 
that would benefit more from pretargeting, antibodies are complex molecules and 
their complexity increases upon conjugation to a chelator. Conversely, while peptide-
based imaging would not benefit from pretargeting in a clinical setting, it could 
represent an ideal system for a proof-of-concept study evaluating new pretargeting 
strategies. Peptides are more prone to chemical modification and easier to 
characterise than antibodies. Conjugation of a peptide with a chelator and subsequent 
purification will result in a single 1:1 species ruling out the presence of unconjugated 
peptide that could block the target antigen in pretargeting experiments. The 
somatostatin antagonists JR11 and LM3, developed by Fani and colleagues for the 
imaging of neuroendocrine tumours [48], possess exquisite targeting properties and do 
not internalise upon antigen binding. Conjugation of these peptide to THPMe could 
easily be performed exploiting the routes already established for the somatostatin 
agonist THPMe-TATE and other peptide derivatives. Furthermore, conjugation to three 
THPMe molecules per peptide is also possible exploiting the dendritic systems that we 
previously developed [49], thus increasing the concentration of chelator available at 
the tumour site. Somatostatin antagonists therefore represent an ideal model to test 
the feasibility of the pretargeting via metal chelation approach using THPMe and 
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6 Final remarks and future work 
In the past two decades, the use of the positron emitting radiometal 68Ga in 
radionuclide molecular imaging has seen an unprecedented blossoming, well 
documented by the continuous and rapid growth of research publications concerning 
this PET radioisotope (Figure 6.1)[1, 2].  
 
Figure 6.1. Number of papers containing gallium-68, 68Ga or Ga-68 in the title published 
each year in the 1940-2017 period (as retrieved from Web of Science, Dec 2017). 
The popularity of this radioisotope is likely to raise even more rapidly in the next 
decade, stimulated by the recent introduction of the first pharmaceutical grade 
generator and the approval of [68Ga]Ga-DOTA-TATE (NETSPOT®, approved by FDA [3]) 
and [68Ga]Ga-DOTA-TOC (SOMAKIT TOC ®, approved by EMA [4]), as imaging agents for 
the diagnosis and staging of neuroendocrine tumours. 
The main advantage of 68Ga is its ready availability from a long-lived, bench-top 
generator, reducing production costs and technical complexity compared to cyclotron-
produced isotopes. In addition, generator-based production of gallium-68 opens the 
possibility, unique among PET radiometals, of one-step, kit-based radiolabelling 
procedures. This opportunity could boost even more the clinical utility of 68Ga making 
it the workhorse of PET imaging, in the same way in which 99mTc is the workhorse of 
SPECT. On the other hand, 68Ga radiolabelling still present some unresolved issues, 
such as the presence of metal contaminants in the generator eluate (at concentrations 
higher than that 68Ga3+ itself) and the, likely related, inability 68Ga radiotracers to 
achieve high specific activity in the radiolabelling.  
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Clinical use of 68Ga is mainly based on receptor imaging with radiolabelled peptides, 
whose pharmacokinetics is compatible with its short half-life. Unsurprisingly, research 
in this field has been mainly focusing on the development of new peptide-based 68Ga 
tracers for the imaging of cancer, although other applications, such as imaging of 
infection and inflammation, are also being investigated [5]. Other important areas of 
research include the development of (i) better quality generators and purification 
systems, to decrease presence of metal contaminants in the 68Ga eluate, (ii) improved 
chelators for Ga(III), moving away from the old “one (chelator) fits all (metals)” 
paradigm. 
Our group has developed a tris(hydroxypyridinone) chelator THPMe, able to complex 
68Ga3+ rapidly in extremely mild conditions. Notably, neither eluate pre-processing nor 
radiotracer purification are required for THPMe radiolabelling to achieve quantitative 
radiochemical purity, thus making this chelator ideal for kit-type 68Ga radiolabelling. 
The bioconjugate derivative THPMe-PSMA has successfully completed a first in human 
investigation and is now undergoing a multi-centre clinical trial for the imaging of 
prostate cancer [6].  
The extreme facility of 68Ga labelling displayed by THPMe stimulated further 
investigation on this chelator to understand the reasons behind its outstanding affinity 
for gallium and to explore potential new approaches to 68Ga imaging arising from THPMe 
properties. Development of novel THP-based chelators with different chemical 
properties, but with preserved or even improved affinity for 68Ga is also important, to 
create a library of THP chelators that could be used for different applications. In this 
work, we aimed at answering, at least partially, these questions through a 
multidisciplinary project that spanned from synthetic chemistry, through 
radiochemistry, to in vitro and in vivo experiments. 
In the first part of this work, a new tris(hydroxypyridinone) chelator THPH was 
developed, by replacing the classical N1-Me pyridinone units with new N1-H precursors. 
Notably, this small chemical change resulted in the need for different synthetic 
strategies compared to THPMe synthesis. THPH was found able to bind 68Ga 
quantitatively in the same extremely mild conditions employed for THPMe, forming a 
1:1 = Ga:THPH species. A thorough side-by-side characterisation of the two chelators 
(and resulting metal complexes) allowed us to highlight chemical differences between 
the two ligands, and also to shed some light on their effectiveness in binding 68Ga. For 
both chelators, ligand affinity for Ga(III) was found superior to the affinity for Fe(III), 
as shown in spectrophotometric titrations. Although the measured preference for 
Ga(III) may be only be descriptive of a short-term situation, owing to a slow attainment 
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of thermodynamic equilibrium for these complexes, this still holds true in 68Ga 
radiolabelling experiments, where short reaction time is essential. Indeed, 
competition experiments in a radiolabelling setting showed how the presence of excess 
iron only marginally affects 68Ga radiolabelling for both ligands. Reasons for this 
preference are likely to be found in the tripodal structure of these chelators, which 
may impose geometric constraints for metal coordination that fits Ga(III) better than 
Fe(III). In fact, no preference whatsoever was observed for the bidentate 
hydroxypyridinone chelator deferiprone. Notably, THPH was found to be even more 
selective than THPMe for Ga(III), and showed significantly lower affinity for Fe(III).  
Future continuation of this project should aim at extending the library of THP 
compounds and their bifunctional derivatives. In this regard, the benzylated 
tris(hydroxypyranone) BnTHPO, developed as a synthetic intermediate en route to 
THPH, holds great promise as a versatile platform for the synthesis of a library of 
tris(hydroxypyridinone) chelators with tunable properties and metal preferences. 
Notably, synthesis of more water-soluble derivatives is also to be sought, to enable 
structural characterisation of the resulting gallium complex, expanding our knowledge 
on the Ga(III) coordination environment for THP ligands. Development of bifunctional 
derivatives for THPH and other THP chelators will enable conjugation to peptides and 
other relevant biomolecules. Importantly, given the remarkably mild condition for 68Ga 
radiolabelling of THP chelators, they could also be attached to small proteins (such as 
the scFv fusion proteins), whose pharmacokinetics is compatible with the short half-
life of the radiometal. 
In a second part of this work, we tried to explore new possibilities for 68Ga imaging, 
relying on the ability of THPMe to bind Ga(III) in extremely mild conditions. In the first 
instance, we investigated the use of THPMe as a blood clearance agent, in the context 
of cancer imaging with gallium salts. The strategy of exploiting the tumour localising 
properties of gallium was widely used in the past with 67Ga-citrate, but failed to be 
translated to 68Ga imaging, owing to the mismatch between the short half-life of this 
isotope and the slow blood clearance of unchelated gallium. Therefore, we 
investigated the use of THPMe as a 68Ga blood clearance agent, to be administered after 
the injection of the radiometal, with the aim of enhancing tumour-to-blood ratio and, 
accordingly, image contrast at short time points. The conditions for 68Ga in vivo 
chelation were studied first in normal animals, showing that 24 nmol of THPMe are able 
to effectively bind previously administered 68Ga, when injected up to one hour after 
the radiometal. The [68Ga(THPMe)] complex was quickly excreted renally, resulting in 
an accelerated blood clearance of the radiometal and in lower accumulation in bones 
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and other organs. However, the high variability observed in 68Ga biodistribution 
(probably due to subtle variation in generator eluate, pH, elution time etc.), often 
confounded the clearance effect, whose significance was only evident when large 
sample sizes were considered. The clearance properties of THPMe were also 
investigated in xenografts bearing mice, in cancer models that were found able to 
accumulate 68Ga in tumour when injected with 68Ga-acetate. The experiment was 
originally performed in an A375 melanoma model, but lead to inconclusive results, 
owing to an unexpectedly fast clearance of the radiometal and poor accumulation into 
tumours and other organs. Notably, when a similar experiment was performed in a 
colon cancer model (SW1222 xenografts) a three-fold increase in the tumour-to-blood 
ratio was observed for mice treated with THPMe one hour after 68Ga injection, highlight 
the potential of THPMe as a blood clearance agent in this model. Importantly, high 
variability in 68Ga biodistribution was observed throughout the whole project and 
seems intrinsically linked to the use of unchelated/loosely chelated forms of gallium, 
highlighting the complexity of gallium speciation in living organisms. Variability could 
possibly be reduced in future experiments, by administering gallium in a form that is 
more stable (e.g. citrate complex, transferrin complex, or [Ga(OH)4]
-), but still able 
to both deliver the radiometal to the tumour and to cede it to THPMe in the blood 
clearance step. Different species of transferrins (human, mouse etc.) could also be 
investigated with this purpose. 
A final section of this work was also inspired by the ability of THPMe to coordinate 68Ga 
in vivo. In this case, a new pretargeting strategy was explored, referred to as 
pretargeting via metal chelation, based on THP and Ga(III) as a high affinity chemical 
pair able to bind in vivo. Compared to other pretargeting strategies, this approach 
would have the advantage of almost eliminating any preparative radiochemistry, thus 
greatly simplifying its clinical translation. In this work, two different derivatives of 
THPMe, namely THPMe-Mal-DTP and THPMe-Ph-NCS, were attached to the non-
internalising antibodies anti-CEA and huA33, respectively. The ability of these 
immunoconjugates to undergo pretargeted 68Ga uptake was investigated in vitro (using 
the THPMe-mal-anti-CEA derivative), or in vivo (using the THPMe-Ph-NCS-huA33 
immunconjugate) in cancer models expressing the relevant target antigens. 
Unfortunately, neither of these attempts succeeded, possibly due to a low availability 
of the THPMe chelating moiety at the antigen site (owing to the low number of 
chelators/antibody and/or to the presence of non-conjugated antibody). Increasing 
the number of chelators per antibody represents a possible solution to this technical 
limitation. However, this was found not feasible for THP-Ph-NCS with precipitation of 
the immunoconjugate visible when 50 equivalents of chelator were used for the 
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conjugation procedure. Other bifunctional THPMe derivatives could in principle be 
tested to achieve higher chelator/antibody ratio, but we suggest that first a step back 
is taken and the pretargeting hypothesis explored in a simpler peptide-based model. 
In addition, a more fundamental problem can be recognised for our pretargeting 
approach: the interaction between the two components of the high affinity chemical 
pair (in our case 68Ga3+ and THPMe) should be bio-orthogonal to avoid interference with 
biological processes. Despite the high affinity of THPMe for 68Ga3+, its complexation is 
certainly not bio-orthogonal. In fact, 68Ga3+ can interact with transferrin and, in this 
or other forms, it can accumulate in several organs, including tumours. THPMe itself, 
despite its preference for Ga(III) over Fe(III), can still interact with iron or other metals 
in the time between immunoconjugate and 68Ga injection. Overall, these 
considerations do not exclude the possibility of pretargeting by metal chelation, but 
suggest that the use of a different, truly bio-orthogonal radiometal/chelator couple 
should be preferred. 
In conclusion, this work shows how the potential for 68Ga imaging of cancer is vast and 
expanding. In this context, outstanding Ga(III) chelators such as the 
tris(hydroxypyridinone) ligands here investigated, not only provide useful tools for the 
development of novel receptor-targeting 68Ga tracers, but also open new opportunities 
in 68Ga imaging, exploiting their ability to bind gallium in extremely mild conditions. 
Although the first attempts in this direction were only partially successful, they 
contribute to our knowledge of the THP/Ga(III) system and pave the way to further 
investigation with improved THP chelators. The development of the THPH ligand 
described in this work represents the first step in the creation of a library of THP 
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PET images of mice injected with THPMe at 5 minutes after 68Ga injection 
 
Figure S 1. PET images (sagittal view) for healthy mice injected with 0 µg (A) or 20 µg 








PET images of mice injected with THPMe at 90 minutes after 68Ga injection 
 
Figure S 2. PET images (sagittal view) for healthy mice injected with 0 µg (A) or 20 µg 
(B) of THPMe 90 minutes after injection of 68Ga. 
 
